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Chemotherapy is a common and effective method to treat many forms of cancer.
However, treatment of cancer with chemotherapy has severe side effects which often
limit the doses of therapy administered. Because some cancer chemotherapeutics target
proliferating cells and tissues, all dividing cells, whether normal or tumor, are affected.
Cell culture studies have demonstrated that UCN-01 is able to reversibly and selectively
arrest normal dividing cells; tumor cells lines do not undergo this temporary arrest.
Following UCN-01 treatment, normal cells displayed a 50-fold increase in IC50 for
camptothecin; tumor cells showed no such increased tolerance.
We have examined the response of the proliferating tissues of the mouse to UCN01 treatment, using the small bowel epithelium as a model system. Our results indicate
that UCN-01 treatment can cause a cell cycle arrest in the gut epithelium, beginning 24
hours following UCN-01 administration, with cell proliferation remaining suppressed for
one week. Two weeks post-UCN-01 treatment the rate of proliferation returns to normal
levels. 5-FU administered during this period demonstrates that UCN-01 is able to
provide protection to normal cells of the mouse within a narrow window of efficacy,
from three to five days post-UCN-01. UCN-01 pretreated mice displayed improved
survival, weight status and blood markers following 5-FU compared to control mice,
indicating that UCN-01 can protect normal dividing tissues.
The mechanism by which UCN-01 arrests normal cells in vivo was also
examined. We have demonstrated that UCN-01 treatment in mice causes an increase in
the G1 phase cell cycle proteins cdk4 and cyclin D, as well as the inhibitor p27.
Phosphorylated Rb was also elevated in the arrested cells. These results are a departure
from cell culture studies, in which inhibition of G1 phase cyclin dependent kinases led to
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hyposphosphorylation of Rb. Future investigation will be required to understand the
mechanism of UCN-01 action. This is important information, especially for
identification of alternate compounds which could provide the protection afforded by
UCN-01.
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Introduction
The nondiscriminatory action of most chemotherapeutic agents still in use today is the
major limiting factor in their successful use. Most cytotoxic agents affect cells, which are
actively dividing, including both the tumor and the normal dividing cells of the body
(gastro-intestinal epithelium, hematopoietic cells and hair follicles). The toxic effects on
these normal tissues limit the doses of chemotherapy that can be administered, and this
limitation can even lead to more resistant (multidrug resistant, MDR) tumors.

To better direct the toxicity of treatment towards the cancer and away from the host,
investigators have tried one of two methods; the first is directed therapy specific for a
particular neoplasm. Gleevec used in the treatment of chronic myelogenous leukemia
(CML) is a successful example. CML is caused by a chromosomal translocation which
gives rise to a chimeric mRNA of the breakpoint cluster region of chromosome 22 (BCR)
and the c-ABL tyrosine kinase gene from chromosome 9 (de Klein et al., 1982). The
resulting BCR-ABL kinase has increased tyrosine kinase activity and the ability to
transform cells (Konopka et al., 1984; Lugo et al., 1990), and has been identified as the
sole leukemogenic event in animal models (Daley et al., 1990; Heisterkamp et al., 1990).
A screen for inhibitors of this kinase identified Gleevec as the most specific, and in
clnical studies it was shown to be very effective in treating CML patients (Druker et al.,
1996). For newly diagnosed CML patients treated with Gleevec, the overall survival at 5
years was 89% (Druker et al., 2006). The specific nature of the kinase inhibition and the
decreased side effects in comparison to previous standard of care (IFN-α treatment)
demonstrates the power of targeted therapy.
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An alternative method seeks not to target the tumor, but rather to deflect the toxicity of
chemotherapeutic agents away from the normal cells of the host. This approach will be
the focus of this study. The idea of protecting normal cells from the toxicity of
anticancer chemotherapeutics appeared more than 35 years ago. The majority of the
protective studies employ a two step approach: cells are reversibly arrested at one of
several cell cycle checkpoints, and then are subsequently exposed to cytotoxic agents
which preferentially act upon dividing cells. The temporary arrest of the pretreated cells
affords a measure of protection against agents, which take advantage of the processes of
cell division, largely DNA synthesis and mitosis. The arrest can be caused by a variety of
actions, including inhibition of protein synthesis, growth factor deprivation, and direct or
indirect inhibition of specific cell cycle enzymatic processes. Other measures use
modulation of growth factors to prevent the apoptotic signaling cascade following
cytotoxic treatment or to stimulate cell proliferation prior to the cytotoxic insult. The
latter method increases the overall population of affected epithelial tissues to allow the
host to better tolerate the loss of some of these cells when treated with a
chemotherapeutic drug. The following is a chronological summary of various methods
used by several different laboratories over a 40 year period, all attempting to protect
normal cells against toxic affects of chemotherapy in vitro and in animal studies.

General Inhibition of macromolecules (i.e. DNA, RNA, protein)
The first studies reported some success in protecting cells from cytotoxic agents by
inhibiting either protein or DNA synthesis prior to treatment. One inhibitor used is
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cycloheximide (CHX), a drug of bacterial origin which prevents protein synthesis by
blocking the movement of transfer RNA (tRNA) molecules along the ribosome (Obrig et
al., 1971). Two studies in rats demonstrated that simultaneous or initial treatment with
CHX protected bone marrow and intestinal crypt cells from nitrogen mustard (HN2)
toxicity (Ben-Ishay and Farber, 1975; Weissberg et al., 1978). The rationale behind this
protection is that dividing cells require protein synthesis to proceed through the cell
cycle. After treatment with CHX, the cells undergo an arrest in the G2 phase of the cell
cycle (Verbin and Farber, 1967); later application of a toxic agent against either DNA
synthesis or mitosis will fail if the cells are held outside of these target phases of the cell
cycle. Just as important as this cell cycle effect is that a differential protecting effect
must exist such that normal cells are protected and tumor cells are not. As a tumor cell
by definition harbors one or more cell cycle defects, it is hoped that this difference can be
exploited to better protect normal cells. Using the CHX model, it has been demonstrated
that normal cells are susceptible to cell cycle arrest following the loss of protein
synthesis, while transformed cells can replicate independently of protein synthesis
(Campisi et al., 1982; Medrano and Pardee, 1980). This differential was demonstrated as
protective in human myeloid progenitor cells (Slapak et al., 1985). Normal
granulocyte/macrophage progenitors (CFU-GM), malignant progenitor cells from CML
patients, and two leukemia cells lines HL-60 and KG-1 were pretreated with CHX and
then exposed to the antimetabolite cytosine arabinoside (ara-C). The survival of normal
CFU-GM cells were significantly increased by CHX pretreatment, while the malignant
progenitors and cell lines were afforded no such protection. However, it appears that
some malignant cells are able to take advantage of the CHX cell cycle arrest and
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protection from subsequent cytotoxic insult. Studies on the human osteosarcoma cell line
KSu demonstrated that CHX pretreatment afforded a degree of protection against
vincristine, colchicine, and Δ12-prostagladin J2 (Sakai et al., 1989). Thus it appears that
CHX protection may not be specific for normal cells, and given its toxicity may not be
clinically relevant.

A similar protective strategy was utilized to afford protection to baby hamster kidney
cells (BHK) but not their polyoma virus-transformed (Py-BHK) variant line (Pardee and
James, 1975). It had previously been shown that caffeine was able to reversibly arrest
cells in G1 (Walters et al., 1974). The exact nature of caffeine-mediated arrest is still
unclear, but inhibition of either cyclin D/cdk4 (Hashimoto et al., 2004) or cyclin E/cdk2
(Qi et al., 2002) or both, leading to hypophosphorylated Rb and subsequent G1 arrest.
The authors showed that the arrest due to caffeine was similar to that seen following
growth factor (serum) deprivation, and that streptovitacin A (SVA) also caused a
reversible G1 arrest in the untransformed BHK cells. The Py-BHK cells were not
affected by any of the cell cycle arresting compounds (caffeine, SVA or serum
deprivation). Treating/arresting the BHK cells with SVA or caffeine significantly
increased their survival when subsequently treated with ara-C or hydroxyurea (HU). The
Py-BHK cells had no such protective effect and were efficiently killed by both agents. A
more recent study demonstrated this differential between the immortalized MCF-10A
cells and the tumor cell line MCF-7 (Blagosklonny et al., 2000a). Withdrawal of
epidermal growth factor (EGF) from MCF-10A cells caused them to undergo a G1/G0
arrest; similar treatment of MCF-7 cells did not affect the cell cycle profile. Growth
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arrest in the MCF-10A cells prevented subsequent toxicity from the microtubule
polymerizing effects of paclitaxel, while the tumorigenic MCF-7 cells were not protected.
The same results were observed when each cell line was treated with the EGF receptor
inhibitor AG1478; MCF-10A cells underwent a G1/G0 arrest, while MCF-7 cells were
unaffected by low the same levels of AG1478. The fungal metabolite anguidine has been
shown to protect normal cells from chemotherapeutics (Teodori et al., 1981). Anguidine
is another inhibitor of protein synthesis, and is thought to promote the disassembly of
polyribosomes (Liao et al., 1976). Pretreatment of Chinese hamster ovary cells (CHO)
with anguidine arrested the cells and provided protection against ara-C, adriamycin, HU
and fluorouracil (5-FU). It was also demonstrated that anguidine can preferentially
induce cytostasis and protection in normal but not transformed cells (Hromas et al.,
1983). Normal WI-38 cells treated with a low concentration of anguidine exhibited a G1
arrest, while the SV40 variant WI-38 VA13 cells were had no cell cycle perturbation.
Following anguidine, the normal cells were protected against the growth inhibitory
effects of ara-C and adriamycin, while the VA13 cells were potently inhibited. However,
as with CHX, not all tumor cells may evade the cell cycle arresting effect of anguidine.
For example, the human andenocarcinoma cell line LoVo was treated with increasing
concentrations of anguidine (1µg/ml – 50 µg/ml) and underwent an arrest in the S phase
of the cell cycle at all concentrations (Dosik et al., 1978). Anguidine may also not be a
reversible inhibitor, further limiting any clinical utility (Liao et al., 1976). In this study,
treatment of HeLa cells with 1mM anguidine caused degradation of polyribosomes,
preventing initiation of protein chain synthesis and cell death.
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Growth arrest has been successfully used in vivo as a protective measure prior to high
dose chemotherapy (Raffaghello et al., 2008). Based on studies which showed a
protective effect of serum deprivation in primary glial cells but not four glioma lines from
oxidative (H2O2) damage, mice were starved for 48 to 60 hours and then treated with high
dose etoposide. While only 8 of the 23 mice treated with etoposide alone survived, 16
out of 17 undergoing short-term starvation (STS) survived. Unfortunately, the STS
protocol seems to protect injected tumors as well. Mice inoculated with the
neuroblastoma line NXS2 were treated with high dose etoposide, with one group
undergoing STS prior to treatment. While the STS group initially had improved survival
(7/8 alive at 36 days) compared to etoposide alone (3/6 dead by day 5), long term
survival was worse for the STS group. All STS/etoposide mice succumbed to tumor
burden by day 53, while the 3 remaining etoposide-only mice lived for 83, 131, and 140
days. Thus, like some other measures of protection, it appears that STS may be nonspecific and protect tumors in addition to normal cells.

Cell cycle arrest as a protective measure has also been induced by inhibiting protein
synthesis using the histidine analogue L-histidinol. L-Histidinol reversibly arrests the
growth of cells in G0 by inhibiting both protein and ribosomal RNA synthesis
(Warrington et al., 1977). BALB/3T3 cells incubated with L-histidinol went into a
G1/G0 arrest, and this arrest was reversible after up to 3 days of L-histidinol exposure
(Warrington et al., 1977). This arrest was duplicated in the normal CHO variant LR73,
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while transformed TR3 line continued to proliferate (Warrington and Fang, 1982b).
Subsequent treatment with ara-C had no effect on the normal arrest LR73 cells, while the
TR3 line was potently growth-inhibited. A similar study using cocultivated normal
human foreskin fibroblasts (HFF) and transformed HeLa cells produced in identical result
(Warrington, 1978). It was demonstrated that pretreatment of HFF cells with L-histidinol
and theophylline produced a G1/G0 arrest, while HeLa cells continued to grow and
divide. Subsequent exposure to HU or ara-C was toxic to the dividing HeLa cells, while
the HFF cells survived. HeLa cells form distinct colonies in culture and can be
distinguished morphologically from HFF cells. The two lines were cultured together and
the experiment repeated. L-Histidinol and theophylline followed by ara-C or HU allowed
the selective eradication of HeLa cells. The protective effect of L-histidinol was also
established in murine spleen cells. 1 mM L-histidinol provided a reversible G1 arrest for
up to 72 hours, and upon removal the cells did not enter into S phase until 96 hours
(Warrington and Fang, 1982a). While arrested, the cells were protected from the toxicity
of both ara-C and 5-FU. The same group found that mice inoculated with L-1210
leukemia and then treated with L-histidinol had spared normal bone marrow cells and had
enhanced antitumor effects of both ara-C and 5-FU (Warrington and Fang, 1985;
Warrington et al., 1984). Mice (both naïve and those with implanted L1210 tumors)
were injected with 5 mg of L-histidinol (~ 167 mg/kg) or PBS control, followed by either
15 or 30 mg of 5-FU (450 or 900 mg/kg) or 25 mg (130 mg/kg) ara-C. All PBS mice
receiving 5-FU died by day 13, while all mice pretreated with L-histidinol survived at
least three months. In addition, clonogenic assays of bone marrow cells of mice
sacrificed 24 hours after 5-FU/ara-C treatment demonstrated a protection factor of up to
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21,00 for the L-histindol pretreated mice versus PBS pretreated (ratio of relative cell
survival of L-histidinol pretreated to PBS pretreated). Additionally, the combination
seemed to enhance to ability of 5-FU and ara-C kill the implanted tumor cells (by
clonogenic assay), and was able to increase the survival of tumor bearing mice by 50%.
Another group was able to demonstrate protection of normal cells in mice when Lhistidinol was given as a 24-hour infusion following 5-FU, perhaps demonstrating that the
G1 arrest may not be the sole source of protection (Edelstein and Heilbrun, 1988). In
these experiments, mice were treated for with a 50 mg infusion of L-histidinol (or saline
control) for 24 hours prior to receiving 10 mg 5-FU. The pretreated group had a 30%
survival rate versus 0% for the saline control group. However, if the same 50 mg
infusion began immediately following 5-FU injection, the survival rate increased to 100%
(saline controls remained at 0% survival). Because the arresting affect of L-histidinol
was not present when 5-FU was administered in this experiment, it cannot completely
account for the increase in survival.

Unfortunately, not all L-histidinol treatments have been effective in exploiting the
differences between normal and tumor cells. A panel of murine cells including the
normal A31 line and three transformed derivatives (BP-A31, M-A31 and SV-A31)
exhibited the expected protective effect of L-histidinol against ara-C toxicity in the
normal A31 cells (Warrington and Muzyka, 1983). A 24-hour incubation in 1-3 mM Lhistidinol prior to 48 hours of 05. – 1.0 µg/ml ara-C significantly improved the survival
of the A31 cells. However, all three transformants were also afforded varying degrees of
protection by L-histidinol pretreatment, all demonstrating improved survival to 48 hours
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of ara-C alone. It was further shown in the murine breast tumor model CD8F1 that Lhistidinol can increase the tolerance of mice for 5-FU (Stolfi et al., 1987). 7 mg of Lhistidinol given prior to 130 mg/kg of 5-FU resulted in a significant increase in white
blood cell (WBC) counts, body weight, and survival compared to mice receiving saline
prior to 5-FU treatment. Pretreatment with 7 mg of L-histidinol also increased the LD50
of a single dose of 5-FU from 283 mg/kg to 504 mg/kg. However, the tumors were also
afforded a measure of resistance to 5-FU, and the therapeutic result of L-histidinol plus 5FU were not superior to 5-FU alone at the lower, unprotected dose. First passage
transplants of spontaneous CD8F1 breast tumors were implanted into mice receiving
either 5-FU alone or L-histidinol followed by 5-FU. The mice receiving 5-FU alone had
a maximal tolerated dose of 100 mg/kg/week, while the mice pretreated with L-histidinol
had an increased tolerance, up to 150 mg/kg/week. However, the weights of the
implanted tumors in the 5-FU group (601 +/- 96 mg) were not significantly different from
those in the 5-FU plus L-histodinol group (807 +/- 227 mg). A more encouraging study
exploits the antibiotic minocycline to protect the murine small intestine from 5-FUinduced mucositis (Huang et al., 2009). The mice receiving minocycline concurrently
with 5-FU (30 mg/kg/day for 5 days for each drug) demonstrated decreased weight loss,
lower diarrhea levels, and improved villus measurements compared to the PBS plus 5-FU
(30 mg/kg/day X 5) control mice. It was demonstrated that minocycline was able to
repress apoptosis in the small bowel crypts by inhibiting the upregulation of PARP-1
activity induced by 5-FU. It does not appear that minocycline is exerting protection by
modulating or arresting the epithelial tissues, as villi from mice sacrificed after the 5-day
course of treatment were approximately the same lengths as control mice. It was also
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shown that the minocycline pretreatment did not protect implanted CT-26 colon cancer
xenografts from 5-FU toxicity; by three weeks, the tumors in mice pretreated with
minocycline were significantly smaller compared to the tumors in mice receiving PBS
prior to 5-FU. The mechanism for the improved tumor response is currently unknown,
but the differential response between normal and tumor cells to minocycline treatment is
encouraging. Other studies have shown an anti-angiogenic effect of minocycline, which
may explain the synergistic result seen when combined with 5-FU (Frazier et al., 2003;
Saikali and Singh, 2003). Similar results were observed in mice treated with the
benzamidine derivative CR3294 three days prior to 5-FU treatment (Letari et al., 2009).
By inhibiting cytokine release in the gut epithelium, CR3294 increased by 3-fold the
number of mice not experiencing diarrhea and increased the surviving crypts per crosssection by 2.8 fold compared to PBS controls. CR3294 did not affect the growth of
tumor xenografts (HT29 and MDA-MB231 cells) nor the efficacy of 5-FU to treat these
tumors.

Modulation of growth factors
Other studies have attempted to differentiate normal cells from tumor cells to afford
protection against toxicity have utilized substances that occur normally in cells. The
polypeptide growth factor transforming growth factor β (TFG-β) is a potent inhibitor of
epithelial cell proliferation as well as an immune suppressor and hematopoietic regulator
(Massague et al., 1987; Roberts et al., 1985; Sing et al., 1988). To evaluate the possible
protective effect of TFG-β, mice were treated with 5 µg/day TFG-β for 5 days and
sacrificed; hematopoietic progenitor cells were decreased by more than 50% compared to
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control mice, indicating an arrest in the marrow. The same course of TFG-β was then
given prior to a single injection of 150 mg/kg 5-FU. Unfortunately, hematopoietic
progenitor cells were lower in the TGF-β group at the hyperproliferative phase (9 days
after 5-FU treatment) compared to 5-FU alone; by 16 days, the number of blood
precursors in the two groups were not significantly different. A similar study produced a
different result, demonstrating that hematologic recovery following 150 mg/kg 5-FU was
accelerated in mice treated given TFG-β (two doses of 2.5 µg daily for days -4 to 0),
peaking at day 11 as opposed to day 16 after 5-FU (Grzegorzewski et al., 1994). While
TFG-β did not increase survival in mice receiving a single high dose (340 mg/kg) 5-FU,
it was protective against a subsequent dose of 5-FU. For this experiment, mice were
treated with 150 mg/kg at day zero. On days 9-13, mice were then treated with either
twice-daily 2.5 µg TGF-β or saline control. A second dose of 300 mg/kg 5-FU was then
given on day 13. Survival in mice given TFG-β was 90%, while the control mice
survival was less than 40%. Interestingly, mice treated with TFG-β and doxorubicin
(DXR) were also protected. As before, mice were treated from days -4 to 0 with twicedaily 2.5 µg TGF-β or saline control, and then given a single dose of 14 mg/kg DXR. All
of the control mice had died by day 15, while 80% of the TGF-β mice survived beyond
day 30. This result was interesting, in that cell cycle arrest must not be the only
protective effect of TGF-β; DXR can damage DNA in noncycling cells. Cell culture
studies using the CCL64 cell line (non-tumorigenic mink epithelial cells) demonstrated
the protective effect of TFG-β in vitro against vinblastine, vincristine, etoposide, taxol,
ara-C, methotrexate (MTX) and 5-FU (McCormack et al., 1997). Cells were incubated
with 15 pM TFG-β or control media for 24 hours, and the cytotoxic agent was added for
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an additional 48 hours. In all cases, the IC50 for each drug was increased (by CFU assay)
by incubation with TFG-β versus control; the increase for each drug (in µg/ml) was: 0.04
to 25 for ara-C; 0.05 to 50 for MTX; 0.5 to 1.0 for 5-FU; 0.15 to 0.45 for etoposide;
0.002 to 0.1 for taxol; and 0.0002 to 0.02 for vincristine. TFG-β was also protective in a
hamster model of oral mucositis (Sonis et al., 1997). Topical application of TFG-β to the
oral mucosa prior to 5-FU treatment reduced cell proliferation (measured by PCNA IHC)
and reduced weight loss, incidence of oral mucositis, and increased survival. Protection
was also afforded to the small intestine by TFG-β treatment prior to irradiation (Booth et
al., 2000). A single dose of TFG-β increased the surviving number of crypts by 3-4 fold,
and a continuous infusion resulted in a 12-fold increase. While the results using TFG-β
are promising, it remains unclear as to what the exact mechanism of protection is. The
protection against toxicity that is not cell cycle specific (IR and DXR) is difficult to
explain, and the likelihood that the protection could be extended to tumors seems
substantial. Growth factors have also been used to stimulate proliferation of tissues
susceptible to chemotherapeutic agents to enhance recovery following treatment.
Granulocyte colony stimulating factor (G-CSF) had been shown to increase the
proliferative index of many blood cell lineages, including granulocytes, erythrocytes, and
monocytes (Pospisil et al., 1995). Rats given G-CSF 2 hours after 5-FU significantly
increased the production of erythrocytes in the recovery period, indicating improved
hematopoiesis in the G-CSF pretreated mice (Weiterova et al., 2000).

Cytostatic agents
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A more cell cycle-specific protection modality employs the kinase inhibitor
staurosporine. As kinases are an important factor in the regulation of the cell cycle (and
one which can be lost in many tumors), modulation of kinases could result in a
differential effect in the two populations of normal versus tumor cells (Hartwell and
Kastan, 1994; Zhou and Elledge, 2000). Indeed, it was demonstrated that three
nontransformed mammalian cells (HSF-43, HSF-55 and HFL-1) were prevented from
entering S phase by very low (1 ng/ml) levels of staurosporine (Crissman et al., 1991). In
contrast, three transformed cell lines (FT210 mouse mammary carcinoma, tumorigenic
WCHE/5 Chinese hamster cells and HL-60 human leukemia cells) were unaffected at low
levels (1-10 ng/ml) of staurosporine. At high levels of staurosporine (50-75 ng/ml) the
transformed cells were instead arrested at the G2 phase. Similar findings were exhibited
in comparing normal human lymphocytes with the lymphocytic leukemia MOLT-4 cell
line treated with staurosporine (Bruno et al., 1992). Normal lymphocytes treated with
low (5-10 ng/ml) staurosporine accumulated in G1; high staurosporine levels (50-100
ng/ml) resulted in both a G1 and G2 block. However, the MOLT-4 cells accumulated
only at G2 for all doses of staurosporine (5-100 ng/ml). The specificity of staurosporinemediated arrest for normal cells was also shown in a panel of breast epithelial cells (Chen
et al., 2000). Four breast tumor cell lines (MDA-MB436, MDA-MB157, MCF-7 and
T47D), the immortalized breast epithelial MCF-10A line, and two normal breast
epithelial cells (76N and 81N) were treated with staurosporine and three specific cyclin
dependent kinase (cdk) inhibitors: olomoucine, roscovitine and flavopiridol. While the
three cdk inhibitors caused a dose-dependent growth inhibition in all cells, staurosporine
was able to distinguish the two normal cell lines from the transformed ones. At 2nM,
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greater than 50% inhibition was seen in both 76N and 81N cells, while no drug-mediated
effect was observed in any of the transformed lines. Further exploration with two
variants of the 76N line, 76NE6 (degraded p53) and 76NE7 (degraded Rb), demonstrated
a p53-independent, Rb-dependent arrest at both 0.5 and 10 nM staurosporine (see
Mechanism below). Induction of G1 arrest by 0.5 nM staurosporine was protective of the
81N cells against the toxicity of doxorubicin (0.125 µM) and camptothecin (0.5µM);
MDA-MB157 and MDA-MD436 cells realized no protective benefit from staurosporine
pretreatment. The staurosporine pretreatment increased the MTD for camptothecin in the
normal cells by two orders of magnitude. This protective effect was also realized when
normal proliferating lymphocytes were treated with staurosporine prior to camptothecin.
While staurosporine seems to select only normal cells for arrest and subsequent
protection, its additional effects on normal cells are likely to prevent it from being used
clinically (Way et al., 2000). Staurosporine has been shown to initiate differentiation of
epidermal cells (Sako et al., 1988), and may function as a tumor promoter in mouse skin
(Fujiki et al., 1989). Staurosporine may also prevent platelet aggregation, which could
impair wound healing (Secrist et al., 1990; Takano, 1994). The adverse effects of
staurosporine spurred the development of analogs such as UCN-01 (see below).

Low dose cytotoxic agents
An alternative to using a cytostatic drug to arrest cells as a protective measure is to
actually use chemotherapeutic agents to cause an initial, low level of damage to the cells.
This initial event would not be so great as to cause cell death, but instead activate a cell
cycle checkpoint, thus arresting the cells while the damage is repaired. During this arrest,
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a second, greater insult would theoretically not affect the arrested cells with functioning
checkpoints; tumor cells with defective checkpoints should continue to grow and divide,
leaving them susceptible to the second cytotoxic agent. One such study uses a low level
of a DNA damaging agent to cause a cell cycle arrest in cells with functioning
checkpoints; subsequent treatment with microtubule-active drugs is ineffective in these
arrested cells, while checkpoint-deficient cells continue to cycle and are sensitive to the
secondary treatment (Blagosklonny et al., 2000b). Low doses of DXR (50-100 ng/ml)
for 16 hours caused a G2 arrest in HCT116 cells with wild-type p53. Subsequent
paclitaxel treatment (100 ng/ml for hours 17-48) of these cells was ineffective in causing
significant cell death, unlike mock-pretreated controls. MTT assay after 48 hours
demonstrated that the paclitaxel-only group had a survival rate of 30%, the cells treated
with DXR prior to paclitaxel had an improved survival rate of 70%. HCT116 clones
deficient in either p21 or p53 were also not protected by the low dose DXR pretreatment,
suggesting that a p53-dependent induction of p21 is required to realize the G2 arrest and
protection of primary DXR. Indeed, adenovirus-mediated expression of p21 in the p21 /- cells was protective against the paclitaxel treatment, similar to DXR pretreatment.

Specific cytoprotective agents
Other agents have been reported to have cytoprotective effects for patients undergoing
anticancer therapy. Amifostine (WR-2721) is an organic thiophosphate which has been
shown to protect against hematologic toxicity and some cumulative organ damage in
patients receiving radiotherapy as well as some chemotherapeutic agents (Castiglione et
al., 1999; Kemp et al., 1996). Amifostine has selective efficacy in normal cells versus
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tumor cells due to its activation; it is converted to the active WR-1065 by membranebound alkaline phosphatases, which are more active in normal cells versus neoplasms
(Culy and Spencer, 2001). The active metabolite then acts as a free radical scavenger and
can facilitate detoxification of cytotoxic agents (Pierelli et al., 1998). The clinical
experience with amifostine as a protective agent provides an unclear picture of its
efficacy. A small phase II trial on 10 patients with advanced esophageal cancer
employed 500 mg amifostine administered subcutaneously prior to 25 fractions of 45 Gy
radiation treatment, plus carboplatin and 5-FU (Jatoi et al., 2004). It was unclear if
amifostine was protective in this setting, as it did not allow a dose escalation and seemed
to carry its own toxicities (nausea, hypotension and vomiting). However, amifostine was
effective in protecting salivary glands. A meta-analysis of 14 separate trials (total 1451
patients) indicates that amifostine is protective against mucositis when combined with
radiotherapy compared to radiation treatment alone (Sasse et al., 2006). A phase I trial
for small cell lung cancer incorporated amifostine into a regimen with etoposide,
radiation and cisplatin. It was determined that the MTD of fractionated radiation in the
group receiving amifostine could be increased from 45 Gy to 60 Gy (Garces et al., 2007).
However, the authors point out that the fractions in this group were decreased from 1.5
Gy to 1.2 Gy, which may also have improved tolerance of the higher total dose of
radiation. A phase II trial for advanced esophageal cancer enrolled 54 patients to be
treated with a combination of carboplatin, 5-GU, paclitaxel and radiation (Jatoi et al.,
2007). Amifostine was given to 19 patients to evaluate its protective ability in this setting.
No significant protection was observed among patients receiving amifostine, and one
patient death was attributed to amifostine administration (acute hypotension immediately
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following 500 mg subcutaneous amifostine) and its use was discontinued. Overall,
amifostine seems to be able to protect salivary glands and some epithelial cell
populations against mucosotis, and does not adversely affect the efficacy of tumor
treatment. The efficacy of amifostine is still being investigated in two ongoing studies
(NCT00409331 and NCT00167908).

Another protective agent used to prevent mucositis following chemotherapy is
palifermin/kertiocyte growth factor (KGF). Recombinant KGF is administered to
patients prior to a regimen of chemotherapy. Palifermin binds the keratinocyte growth
factor receptor (KGFR); KGFR is found in the epithelial cells of the gastrointestinal tract
as well as the liver, pancreas and lung (Spencer et al., 2005). Pretreatment with
palifermin activates the KGFR leading to differentiation and maturation of epithelial cells
and subsequent thickening of epithelium of the gastrointestinal tract. This increase
diminishes the DNA damage and apoptosis seen in these cells (McDonnell and Lenz,
2007). A phase III trial of non-Hodgkins lymphoma patients receiving total body
irradiation utilized palifermin (or placebo control) for three days prior to radiation
treatment and for three days following treatment (Spielberger et al., 2004). Patients
receiving palifermin had significantly reduced high grade oral mucositis, and the duration
of mucositis was shortened (median day 6 versus day 9 for placebo). A phase II study in
head and neck squamous cell carcinoma patients also evaluated the protective ability of
palifermin in a regimen of radiation, cisplatin and 5-FU (Brizel et al., 2008). The
duration of high grade mucositis was shorter in the patients receiving palifermin (median
6.5 weeks versus 8.1 weeks for placebo), but the difference was not statistically
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significant. A much larger phase III study evaluating palifermin protection in head and
neck cancer patients (NCT00626639) is currently underway.

Unfortunately one common theme among the protective measures reported in the
literature is the absence of any change in the progression of cancer or time to death of the
patients receiving these measures. While the decreased side effects experienced by some
patients certainly enhance quality of life during and after treatment, the lack of
meaningful improvement in therapeutic outcome relegates these methods to only an
adjunct role in therapy. It is hoped that our work will lead to a protective scheme that is
more than simply supportive. To this end, the work described in the future chapters of
this thesis demonstrates how treatment of normal cells with UCN-01 can afford
protection against the toxic affects of chemotherapy. To appreciate the role of UCN-01
as protector of normal cells, it is crucial to examine the journey that UCN-01 has taken as
a chemotherapeutic agent in cultured cells and in animal models to its current use in
clinical trials. These studies has helped pave the way to the novel use of this agent which
I have pursued in my dissertation work, namely use of UCN-01 to protect normal cells
against the toxic affects of chemotherapy.

UCN-01
The understanding of mechanisms of cellular proliferation, malignant transformation,
differentiation and apoptosis has produced a wide array of potential targets to control
these events. One such element is the serine/threonine kinase family protein kinase C
(PKC), which was shown to be crucial in tumor-promoting process of plant-derived
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phorbol esters (Castagna et al., 1982). It has been demonstrated that in cell lines
transformed with p21RAS that PKC is required for cell survival; inhibition of PKC drove
transformed variants of NIH/3T3 and Balb cell lines to apoptosis, while no effect was
seen in the parental lines (Xia et al., 2007). The search for possible inhibitors of PKC
lead to the discovery of staurosporine (ST) from the bacterium Streptomyces sp. (Omura
et al., 1977). Staurosporine was found to be a potent PKC inhibitor (IC50 of 2.7 nM), and
was also very toxic to HeLa cells, with an IC50 of 4 pM for a 72-hour exposure (Tamaoki
et al., 1986). Staurosporine can drive most mammalian cells types into apoptosis via
mitochondrial caspase activation, although the exact mechanism of its action is unknown
(Bertrand et al., 1994; Jacobson and Evan, 1994; Takahashi et al., 1997). In addition to
its toxicity, ST has also been noted for its promiscuity of target molecules, including
protein tyrosine kinases (Meggio et al., 1995; Ruegg and Burgess, 1989). The inhibitory
potential of ST against some of these targets is summarized in Table 1.

UCN-01 (7-hydroxystaurosporine) is an indolocarbazole compound originally isolated
from a culture broth of Streptomyces sp. as a selective protein kinase C (PKC) inhibitor
(Takahashi et al., 1987). UCN-01 was found to be more specific than staurosporine
inhibition of PKC (Table 1); it was also shown to be an effective inhibitor of cAMPdependent protein kinase (PKA) and v-src tyrosine kinase (Takahashi et al., 1989;
Takahashi et al., 1990). These studies demonstrated that UCN-01 is a more selective
inhibitor of PKC than staurosporine, affecting the α, β, and γ isozymes most potently; no
effect on the atypical PKC ζ was measured (Seynaeve et al., 1994). Subsequent studies
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Table 1: IC50 values for UCN-01 and Staurosporine
Kinase
PKC
PKC-α

UCN-01
4.1 nM
29 nM

Staurosporine
2.7 nM
58 nM

PKC-β

34 nM

65 nM

PKC-γ

30 nM

49 nM

PKC-δ

590 nM

330 nM

PKC-ε

530 nM

160 nM

PKC-ζ

> 30 µM

> 30 µM

PKA
MAPK

42 nM
910 nM

8.2 nM
20 nM

Chk1

8-10 nM

4 nM

Chk2
Cdk 1

500 nM
31 nM

3.7 nM
3-9 nM

Cdk 2

30 nM

7 nM

Cdk 4

32 nM

10 mM

p60v-src tyrosine
kinase

45 nM

6.4 nM
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Reference
(Tamaoki, 1991)
(Seynaeve et al.,
1994)
(Seynaeve et al.,
1994)
(Seynaeve et al.,
1994)
(Seynaeve et al.,
1994)
(Seynaeve et al.,
1994)
(Seynaeve et al.,
1994)
(Meijer, 1995)
(Meijer, 1995;
Tamaoki, 1991)
(Busby et al., 2000;
Luo et al., 2001)
(Yu et al., 2002)
(Gadbois et al.,
1992; Kawakami et
al., 1996)
(Gadbois et al.,
1992; Kawakami et
al., 1996)
(Gadbois et al.,
1992; Kawakami et
al., 1996)
(Meijer, 1995;
Tamaoki, 1991)

indicate that UCN-01 is a somewhat promiscuous kinase inhibitor, with at least 23
demonstrated targets (Komander et al., 2003).

The effects of UCN-01 in cultured cells fall into one of two broad categories (cell cycle
arrest and apoptosis), and vary with cell type, drug concentration, and interaction with
other agents. As a single agent, UCN-01 has been shown to either arrest cells in the G1
phase of the cell cycle or to drive cells into apoptosis. In concert with cytotoxic drugs or
radiation, UCN-01 can abrogate S or G2 cell cycle arrest, preventing damage repair, also
causing apoptosis. While the effects of UCN-01 generally fall into one of these areas, the
mechanism(s) underlying these responses are not entirely clear. The studies on UCN-01
will be detailed below.

UCN-01 and cell cycle arrest (Table 2)
An early study on UCN-01 demonstrated a spectrum of growth inhibition on a panel of
five breast cancer cell lines (Seynaeve et al., 1993). Differential sensitivity among the
lines was noted, with MDA-MB468 being most resistant and MCF-7 most susceptible to
growth inhibition. The IC50 values for UCN-01 determined by MTT assay were as
follows (all in nM): H85787 22+/- 3, MCF-7 30 +/- 1, SK-BR-3 45 +/- 4, MDA-MB453
68 +/- 3, MDA-MB468 100 +/- 30. A G1 to S block (DNA histogram, no quantification
available) was seen following 150nM UCN-01 treatment in MDA-MB468 cells,
demonstrated by propidium iodide flow cytometry. This block was accompanied by a
decrease in overall cellular protein phosphorylation. Decreased phosphorylation was
demonstrated by autoradiography of whole cell lysate separated by SDS-PAGE following

21

Table 2: UCN-01 and Cell Cycle Arrest in Cultured Cells
Cell line(s)

Drug/Dose

H85787 (breast
tumor)
MCF-7 (breast
tumor)
Sk-Br-3 (breast
tumor)
MDA-MB453
(breast tumor)
MDA-MB468
(breast tumor)

A431
(epidermoid
carcinoma)
A431
(epidermoid
carcinoma)
A431
(epidermoid
carcinoma)
A431
(epidermoid
carcinoma)
A431
(epidermoid
carcinoma)
Ma-31 (Rb+
lung cancer)
N417 (Rb- lung
cancer)
H209 (Rb mut
lung cancer)
Ma-31 (Rb+
lung cancer)
N417 (Rb- lung
cancer)
H209 (Rb mut
lung cancer)

Effect/Result

Reference

22 nM UCN-01

Experimental
data
MTT Assay

IC50

30 nM UCN-01

MTT Assay

IC50

45 nM UCN-01

MTT Assay

IC50

68 nM UCN-01

MTT Assay

IC50

100 nM UCN01

MTT Assay

IC50

PI flow, 32P
protein labeling

G1 block,
↓ protein
phosphorylation
G1 block

Seynaeve et al.,
1993
Seynaeve et al.,
1993
Seynaeve et al.,
1993
Seynaeve et al.,
1993
Seynaeve et al.,
1993

150 nM UCN01
50 nM UCN-01

PI flow

Akinaga et al.,
1993

0.26 µM UCN01

PI flow

G1 block (50%
→ 70%)

Akinaga et al.,
1994

1.56 µM UCN01

PI flow

G1 block (50%
→ 60%)

Akinaga et al.,
1994

5.8 nM
staurosporine

PI flow

G1 block (50%
→ 75%)

Akinaga et al.,
1994

58 nM
staurosporine

PI flow

G2 block (16%
→ 60%)

Akinaga et al.,
1994

2.197 µM
UCN-01
737 nM UCN01
181 nM UCN01
602 nM
staurosporine
54 nM
staurosporine
29 nM
staurosporine

MTT Assay

IC50, ↓
phospho-Rb
IC50

Shimizu et al.,
1996
Shimizu et al.,
1996
Shimizu et al.,
1996
Shimizu et al.,
1996
Shimizu et al.,
1996
Shimizu et al.,
1996

MTT Assay
MTT Assay

IC50

MTT Assay

IC50

MTT Assay

IC50

MTT Assay
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IC50, ↑
phospho-Rb

Table 2 continued
A549 (NSCLC) 100 nM UCN01
A431
260 nM UCN(epidermoid
01
carcinoma)

PI flow, anti-Rb
western
PI flow,
western,
histone H1
kinase assay

A431
(epidermoid
carcinoma)
A431
(epidermoid
carcinoma)
WiDr (Rb+
colon
carcinoma)

1.56 µM UCN01

HCT116 (Rb+
colon
carcinoma)

100, 300 nM
UCN-01

WI-38 (Rb+
lung fibroblast)

100, 300 nM
UCN-01

Saos-2 (Rbosteosarcoma)

100, 300 nM
UCN-01

WI-38 VA13
(SV40 xform)

100, 300 nM
UCN-01

A549 (Rb+
NSCLC)

100 nM UCN01

PI flow, anticyclin B
western
PI flow, anticyclin B
western
PI flow,
western,
histone H1
kinase assay
PI flow,
western,
histone H1
kinase assay
PI flow,
western,
histone H1
kinase assay
PI flow,
western,
histone H1
kinase assay
PI flow,
western,
histone H1
kinase assay
PI flow,
western

Calu1 (Rb+
NSCLC)

100 nM UCN01

PI flow,
western

H596 (Rb mut
NSCLC)
5637 (Rbbladder cancer)
RB5 (Rb+ 5637

100 nM UCN01
100 nM UCN01
100 nM UCN-

PI flow,
western
PI flow,
western
PI flow,

58 nM
staurosporine
100, 300 nM
UCN-01
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G1 block, ↓
phospho-Rb
G1 block
(37.7% →
61.6%); ↓
phospho-Rb,
cdk2 activity; ↑
p21, p27
G1 block, no
change in
cyclin B
G2 block, ↑
cyclin B

Kawakami et
al., 1996
Akiyama et al.,
1997

G1 block (Rb
dependent),
↓ cdk2 activity,
↑ p21
G1 block
(Rb dependent),
↓ cdk2 activity,
↑ p21
G1 block
(Rb dependent),
↓ cdk2 activity,
↑ p21
Apoptosis,
↓ cdk2 activity,

Akiyama et al.,
1999b

Apoptosis,
↓ cdk2 activity,
↑ p21

Akiyama et al.,
1999b

G1 block (73%
→ 86%), ↑p21,
↓ phospho-RB
G1 block (52%
→ 72%), ↑p21,
↓ phospho-RB
No G1 change,
↑p21
No G1 change

Mack et al.,
1999

G1 block (70%

Akiyama et al.,
1999a
Akiyama et al.,
1999a

Akiyama et al.,
1999b
Akiyama et al.,
1999b
Akiyama et al.,
1999b

Mack et al.,
1999
Mack et al.,
1999
Mack et al.,
1999
Mack et al.,

Table 2 continued
subline)
DU-145 (Rb
mut prostate
cancer)
DU1.1 (Rb+
DU-145
subline)
76N (normal
human
mammary
epithlelium)
81N (normal
human
mammary
epithlelium)
76NE6 (E6
transformed
76N)
76NE7 (E7
transformed
76N)
SBC-3 (small
cell lung
cancer)

01

western

100 nM UCN01

PI flow,
western

100 nM UCN01

PI flow,
western

80 nM UCN-01

PI flow,
western, HH1
kinase assay

80 nM UCN-01

PI flow,
western, HH1
kinase assay

80 nM UCN-01

PI flow,
western, HH1
kinase assay
PI flow,
western, HH1
kinase assay
PI flow,
western, kinase
assay (HH1 and
Rb)

80 nM UCN-01
200 nM UCN01

SBC-3/UCN
(UCN-01
resistant SBC-3
subline)
HaCaT
(HNSCC)

200 nM UCN01

HN12
(HNSCC)

100 nM UCN01

PI flow,
western, kinase
assay (HH1 and
Rb)

HN30 (HNSCC
p53 mut)

100 nM UCN01

PI flow,
western, kinase
assay (HH1 and

100 nM UCN01

PI flow,
western, kinase
assay (HH1 and
Rb)
PI flow,
western, kinase
assay (HH1 and
Rb)
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→ 90%), ↓
phospho-RB
No G1 change
G1 block (42%
→ 66%), ↓
phospho-RB
G1 block (↑
11%), ↓ p53,
pRb, cdk4,
cdk2 kinase
G1 block (↑
15%), ↓ p53,
pRb, cdk4,
cdk2 kinase
Increased G1
phase (+20%),
↓ pRb, cdk4
Increased S
phase (+10%),
no protein Δ
G1 block (36%
→ 56%), ↓
pRb, cdk2,
cdk2 kinase, ↑
p21 bound
cdk2, IRF-I
No G1 block,
no Δ in cell
cycle proteins
or IRF-I
G1 block (35%
→ 52%), ↑ p21
& p27, ↓ cdk4,
↓ cdk2 & cdk4
kinase activity
G1 block (35%
→ 52%), ↑ p21
& p27, ↓ cdk4,
↓ cdk2 & cdk4
kinase activity
G1 block (35%
→ 52%), ↑ p21
& p27, ↓ cdk4,

1999
Mack et al.,
1999
Mack et al.,
1999
(Chen et al.,
1999)

(Chen et al.,
1999)

(Chen et al.,
1999)
(Chen et al.,
1999)
(Usuda et al.,
2000)

(Usuda et al.,
2000)
(Patel et al.,
2002)

(Patel et al.,
2002)

(Patel et al.,
2002)

Table 2 continued
HCT116 (colon
carcinoma)
HCCT p53-/-

Rb)
100 nM UCN01
100 nM UCN01
100 nM UCN01
100 nM UCN01

PI flow, kinase
assay, western
PI flow, kinase
assay, western
PI flow, kinase
assay, western
PI flow, kinase
assay

HSC-3 (oral
squamous cell
carcinoma)
LMF4 (oral
squamous cell
carcinoma)

300 nM UCN01

PI & Annexin
V flow, western

300 nM UCN01

PI & Annexin
V flow, western

PrEC (normal
prostate
epithelium)
DU145
(prostate
cancer)
PC3/M
(prostate
cancer)
SK-GT5
(gastric cancer)
CHO (Chinese
hamster ovary)
K562
(myelogenous
leukaemia)

20 – 400 nM
UCN-01

HCCT p21 -/HaCaT

↓ cdk2 & cdk4
kinase activity
G1 block, ↑
p21,
↑ p21
No G1 effect

(Facchinetti et
al., 2004)
(Facchinetti et
al., 2004)
(Facchinetti et
al., 2004)
(Facchinetti et
al., 2004)

MTT assay,
western

G1 block, ↑
ERK protein,
kinase activity
G1 block (53%
→ 64%), ↑p21,
↓ cdk2
G1 block (27%
→ 63%), ↑p53,
p21, ↓cdk2,
ppRb
Growth arrest,
↑p21, ↓cyc D

(Blagosklonny
et al., 2001)

20 – 400 nM
UCN-01

MTT assay,
western

Growth arrest,
↑p21, ↓cyc D

(Blagosklonny
et al., 2001)

20 – 400 nM
UCN-01

PI flow,
western

G1 arrest,
↑p21, ↓cyc D

(Blagosklonny
et al., 2001)

1 µM UCN-01

Western

50 nM UCN-01

Western

50 nM UCN-01

PI flow,
western

↓ E2F1
↑ p21, p27
↑ Rb, ↓ ppRb,
↑ Sp1
G1 block (32%
→ 65%), ↑Rb,
↓ ppRb, ↑ Sp1

(Hsueh et al.,
2001)
(Penuelas et al.,
2003)
(Penuelas et al.,
2003)
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(Otsubo et al.,
2007)
(Otsubo et al.,
2007)

32

P-orthophosphate labeling for 90 minutes. Treatment of A431 human epidermoid

carninoma cells with 0.05 µM UCN-01 also caused a G1 arrest as shown by propidium
iodide flow cytometry (DNA histogram, no quantification available) (Akinaga et al.,
1993). Further work with these cells showed that UCN-01 and staurosporine have
different effects on cell cycle distribution, depending on concentration (Akinaga et al.,
1994). At both 50% (0.26 µM) and 80% (1.56 µM) inhibitory levels, UCN-01
consistently caused a G1 accumulation. Propidium iodide flow cytometric analysis
demonstrated an increase in the G1 fraction (from 50%) to 70% at 0.26 µM UCN-01, and
to 60% at 1.56 µM. Staurosporine treatment resulted in a G1 arrest (75%) at the lower
effective dose (0.0058 µM), but shifted to a G2/M (G2 increased from 18% to 60%)
accumulation at the 80% inhibitory level (0.058 µM). It was also noted that UCN-01 did
not alter the rate of DNA synthesis in these cells or the progression through mitosis; only
the G1 to S phase transition was delayed. The different effects of UCN-01 and
staurosporine may be due to a divergence of their effects on the retinoblastoma (Rb)
protein (Shimizu et al., 1996). A panel of lung cancer cell lines (Ma-31 with wild-type
Rb, N417 with null Rb, and H209 with mutant Rb) was treated with both agents and IC50
values for each drug on each cell line were determined by MTT assay: values for UCN01 for Ma-31, N417 and H209 are 2197, 737 and 181 nM respectively. For
staurosporine, the IC50 values for Ma-31, N417 and H209 are 602, 54 and 29 nM,
respectively. Treatment with each drug at IC50 levels showed a decrease in the levels of
Rb for Ma-31 and H209 cells. However, in the wild-type Rb line (Ma-31), staurosporine
increased the ratio of hyper- to hypophosphorylated Rb, while UCN-01 decreased this
ratio. Hypophosphorylated Rb can bind to E2F transcription factors, sequestering it away
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from genes required for cell growth and division. A similar effect was seen in another
lung cancer cell line, A549 (Courage et al., 1996; Kawakami et al., 1996). Cyclin
dependent kinases cdk2, cdk4 and cdk6 were immunopurified from the cells and
incubated in vitro with UCN-01; subsequent kinase assays on purified Rb demonstrated
dose-dependent inhibition of Rb phosphorylation. In growing A549 cells, 100 nM UCN01 caused a G1 arrest (DNA histogram, no quantification cited) and a decrease in hyperphosphorylated Rb. A G1 arrest induced in A431 cells also showed an increase in
dephosphorylated Rb (Akiyama et al., 1997). In addition, the levels of cyclin A and
cyclin D1 were reduced, as was the activity of cdk2 and the levels of its active, threonine
160-phosphorylated form. The cell cycle inhibitors p21 and p27 were also increased in
UCN-01 treated cells. A431 cells synchronized at M phase with nocodazole and then
treated with either UCN-01 or staurosporine showed a G1 or G2/M block, respectively
(Akiyama et al., 1999a). While staurosporine inhibited a reduction in cyclin B, UCN-01
had no effect on cyclin B levels.

The ability of UCN-01 to produce a cell cycle arrest may be determined in part by the Rb
status of the cell being treated. A study comparing Rb-proficient cell lines (colon
carcinoma WiDr, HCT116 and lung fibroblast WI-38) to an Rb-defective line (Saos-2
osteosarcoma) and an SV40-transformed line (WI-38 VA13) found that functional Rb led
to a UCN-01-mediated G1 arrest (DNA histogram, no quantification available) at both
100 and 300 nM, whereas lack of Rb resulted in apoptosis at both doses (Akiyama et al.,
1999b). The G1 arrest was accompanied by a drop in the kinase activity of cdk2 and the
levels of active (Thr-160 phosphorylated) cdk2 in all five cell lines. Levels of p27 were
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increased all cell lines except Saos-2 (p27 null), but p21 levels were not altered in any of
these lines following UCN-01 treatment. A similar finding was reported in non-small
cell lung cancer (NSCLC) lines; wild-type Rb expressing lines A549 and Calu1 were
arrested in G1 (increase in G1 from 73% to 86% in A549, and from 52% to 72% in H596,
both at 100nM UCN-01) after UCN-01 treatment, while no arrest was observed in the
Rb-null line H596 (Mack et al., 1999).

Unlike the previous cited work (Akiyama et al.,

1999b ), UCN-01 (100 nM) caused an increase in p21 in all three cell lines, regardless of
Rb status. (Hypophosphorylation of Rb was also noted in the wild-type lines, in both p53
wild-type (A549) and mutant (H596) cell lines. The role of Rb in the UCN-01-induced
G1 arrest was further examined using isogenic cell lines: the bladder cancer cell line 5637
(Rb-null), prostate cancer cell line DU-145 (Rb-mutant) and their Rb-expressing sublines
(RB5 and DU1.1, respectively). In both pairs, Rb hypophosphorylation and G1 were
arrest were seen in UCN-01 treated sublines, whereas the parental lines had no arrest.
The dispensability of p53 and requirement for Rb were confirmed in mammary epithelial
cells as well (Chen et al., 1999). Normal mammary epithelial cell lines (76N and 81N)
underwent a G1 arrest at low levels of UCN-01 (increase in G1 population of 11% in 76N
and 15% in 81N, both at 80nM). Two breast cancer cell lines (p53-null and Rb-inactive
MDA-MB157 and p53/Rb-null MDA-MB436) did not undergo this G1 arrest following
low doses (20-80 nM) of UCN-01. Two variants of the normal 76N line were also tested:
76NE6 cells, which lack p53, and 76NE7 cells, which are p53 deficient. At 20nM UCN01, 76NE6 cells were growth-arrested and accumulated in G1, similarly to the 76N cells.
The 76NE7 cells did not, suggesting the requirement of Rb for the UCN-01 mediated
arrest. In the UCN-01 sensitive cells, UCN-01 induced arrest was accompanied by
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decreases in cdk2 and cdk4, as well as cdk2-associated kinase activity. As in the
previous studies, Rb phosphorylation decreased concomitant with arrest, as were levels of
cyclin D. However, no changes were observed in the levels of p21 and p27 in these cells,
unlike in the previous reports. However, the authors demonstrated that the binding of
p27 was altered following the UCN-01-mediated decrease in cdk4. As cdk4 levels
decreased, the freed p27 was able to bind and inhibit cdk2. Similar to the Mack et al.
study (Mack et al., 1999), the small cell lung cancer line SBC-3 and the UCN-01 resistant
subline SBC-3/UCN were examined after UCN-01 treatment (Usuda et al., 2000). In the
responsive SBC-3 cells, 0.2 µM UCN-01 caused a G1 accumulation (36% G1 increased
to 56%), loss of phosphorylated Rb, decreased cdk2 activity, and increases in p21 and
p21 binding to cdk2. The arrest resistant SBC-3/UCN cells demonstrated no arrest at up
to 1 µM UCN-01, and none of the underlying cell cycle protein changes seen in the SBC3 cells were recapitulated. As in other reports, p53 did not appear to play a role in the
cell cycle arrest due to UCN-01. Because p21 seems to be a crucial player in the growth
inhibition observed, the authors looked for regulators of p21 other than p53. One
possibility is interferon regulatory factor I (IRF-I), which can bind to the promoter of p21
and cause transactivation of the gene (Coccia et al., 1999). The authors found that the
UCN-01 responsive SBC-3 cells, IRF-I was basally expressed, and UCN-01 increased
this expression in a dose-dependent manner. In the resistant SBC-3/UCN cells, IRF-I
was not seen in the untreated samples, and very little was induced, even after 1µM UCN01 treatment.
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Three head and neck squamous cell carcinoma (HSNCC) cell lines treated with UCN-01
displayed many of the same cell cycle alterations reported above (Patel et al., 2002).
HaCaT, HN12, and HN30 cells were growth-arrested and accumulated in G1 following
UCN-01 treatment, with an IC50 as low as 17nM. The inhibitors p21 and p27 increased,
and cyclin D levels and cdk2- and cdk4-associated kinase activities were diminished. A
subsequent study demonstrated the same G1 arrest in HaCaT cells, but with only an
increase in the inhibitor p21, but not p27 (Facchinetti et al., 2004). To explore this
difference further, the authors utilized the colon carcinoma cell line HCT116 and two
isogenic sublines, one p21-/- and the other p53-/-. UCN-01 treatment (100 nM for 12
hours) increased p21 expression regardless of p53 status, and only p21 expressing cells
underwent the UCN-01 mediated G1 arrest. Promoter deletion studies demonstrated that
only the Ras-activation domain was required for increased levels of p21, and that the p53
activation site was dispensable. UCN-01 modulation of PKC, PDK1 and AKT was also
ruled out as affecting the p21 levels in the cells. As the Ras activation domain was
required for p21 induction, the authors investigated pathways downstream of Ras. The
mitogen-activated protein kinase (MAPK) pathway is a cascade of
kinase/phosphorylation interactions in which activated, upstream kinases phosphorylate
and activate subsequent kinases leading to activation of several transcription factors. In
the canonical pathway, Ras activates Raf, the MAPK kinase kinase (MAPKKK), which
then activates MEK (MAPKK), which then activates the ERK1 and ERK2 via
phosphorylation (Figure 1). HCT116 cells treated with UCN-01 displayed increased
ERK kinase activity at doses that induced p21 accumulation, and the activation of ERK
temporally preceded the increase in p21. Inhibition of MEK (via PD98059 or UO126)
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Figure 1: Proliferative pathways affected by UCN-01,
resulting in cell cycle arrest. Green indicates activities
enhanced by UCN-01, red designates inhibition by UCN-01.
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prevented the p21 promoter activation following UCN-01 treatment, and no p21
accumulation or p21 increase was seen. Finally, p21 induced by UCN-01 was almost
exclusively located in the nucleus. While the exact nature by which UCN-01, a kinase
inhibitor, is able to activate a proliferative pathway such as MAPK is unknown, it is not
without precedent. Other antiproliferative drugs have been shown to activate the MAPK
pathway, such as cisplatin (Wang et al., 2000) and paclitaxel (Bacus et al., 2001). It
might also be possible that UCN-01 activates a stress response which can in turn activate
the MAPK pathway (Benhar et al., 2002).

The inhibitor p21 has been implicated in other cell lines as well. A panel of 8 oral
squamous cell carcinoma (OSCC) cell lines treated with UCN-01 demonstrated growth
inhibition and G1 phase increase in both primary and metastatic cells (Otsubo et al.,
2007). The levels of p21 were increased, and the levels cdk2 and Rb phosphorylation
were diminished. As in previous reports, levels of p27 were not affected. Induction of
p21 and decreased cyclin D were also correlated with a G1 arrest in both normal prostate
epithelial cells (PrEC) and prostate cancer cell lines DU145, PC3 and PC3M
(Blagosklonny et al., 2001). UCN-01 was unable to inhibit the growth of LNCaP cells,
and was able to abrogate a G1 arrest caused by phorbol ester (a PCK activator). These
disparate effects may tie in with the previous study concerning the actions of UCN-01 on
the MAPK pathway (Facchinetti et al., 2004). PKC can activate the MAPK pathway,
which in turn can lead to increased levels of cyclin D and the inhibitor p21 (Dent et al.,
1998; Sherr, 1996). The balance of proliferative response to growth arrest appears to be
specific for each cell type, and may shape the response to UCN-01.
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While many descriptions of mechanism of UCN-01 cell cycle arrest have focused on Rb
phosphorylation and the cell cycle proteins implicated in that process, it has also been
reported that UCN-01 can affect E2F-mediated transcription of G1 and S phase genes by
directly affecting E2F protein levels (Hsueh et al., 2001). In the gastric cancer cell line
SK-GT5, 1µM UCN-01 treatment produced a 99% drop in the levels of E2F-1. It was
further shown that the decrease was due to ubiquitin/proteasome–mediated proteolysis.
However, the cell cycle proteins p21, p27, and cyclin B were not diminished by the
UCN-01-mediated proteolytic process responsible for degrading E2F; the levels of p21
and p27 increased after UNC-01 treatment, and cyclin B was unchanged. The authors
also note that inhibition of E2F degradation (using proteasome inhibitor LnLL) was not
able to prevent the UCN-01-mediated G1 arrest in these cells. E2F repression has been
shown to inhibit cell cycle progression by other agents, such as retinoic acid and IFN-α
(Iwase et al., 1997; Zhu et al., 1997). In bronchial epithelium, retinoic acid mediates
degradation of cyclin D through the ubiquitin/proteasome pathway (Langenfeld et al.,
1997), similar to the results seen in A341 cells treated with UCN-01 (Akiyama et al.,
1997). Whether or not the drop is cyclin D is dependent upon increased degradation
through the unbiquitin/proteasome pathway is still under investigation.

The ability of UCN-01 to modulate the transcription and stability of Rb has also been
demonstrated in cultured cells (Penuelas et al., 2003). Low levels of UCN-01 (30-50nM)
were shown to cause cell cycle arrest in CHO, K562 and HeLa cells, and led to increased
levels of Rb; 50 nM UCN-01 caused an increase in the G1 population from 35% to 65%
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in K562 cells. This increase in Rb was attributed to both increased Rb mRNA levels and
decreased degradation of Rb. The authors also noted an increase in the transcription
factor Sp1 at these low concentrations of UCN-01. Sp1 has been shown to interact with
Rb to enhance the transcription of Sp1, and Rb can activate transcription of p21 through
Sp1 (Decesse et al., 2001; Noe et al., 1998). It is possible in this cell line that increased
levels of Rb could both diminish the transcription of E2F-dependent genes (such as
cyclins D and E) as well as increase levels of p21, leading to cell cycle arrest in G1.

UCN-01 has also been demonstrated to inhibit endothelial cell growth (Kruger et al.,
1998). UCN-01 prevented outgrowth from rat aortic explant cultures, and inhibited
hypoxia-inducible factor (HIF-1) dependent transcription, and could possibly be used to
prevent angiogenesis.

In summary, these studies have demonstrated that UCN-01 can cause growth inhibition in
many cell lines, and that the arrest is due to a block in the G1 phase of the cell cycle (see
Table 2). The cell cycle proteins involved in G1 and the transition to S phase are the
most commonly indicated as the actors in this arrest. Rb seems to be required in most
cells, and hypophosphorylated Rb is a hallmark of the arrest and could putatively be
sequestering the E2F transcription factor, preventing cell cycle progression. The levels
and activities of the G1 cyclin dependent kinases, and the levels of the cyclins D, E, and
A, and the inhibitors p21 and p27 have all been implicated, although the effects of UCN01 on any specific protein vary among published reports and seem to be cell type
specific. It also appears that p53 is not required for this process, and that the MAPK
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pathway may also be involved. However, very few studies have been done on normal
cell lines, and the mutations and abnormalities necessary in tumor cells can obscure any
evaluation of cell cycle processes. More importantly, none of these studies have
examined the actions of UCN-01 in vivo, which are likely to be different than those in
any immortalized cell culture line.

UCN-01 and apoptosis (Table 3)
In addition to inhibiting growth, UCN-01 has also been implicated as an inducer of
apoptosis in various cancer cell lines. Exposure of four T lymphoblast cell lines (Jurkat,
Molt-3, Molt-4, and Hut-78) to UCN-01 for 24 hours led to decreased cell viability,
G2/M phase cells, and total protein phosphorylation. The sub-G1 (apoptotic) cell
population increased, beginning 3 hours after UCN-01 treatment (Wang et al., 1995).
Interestingly, the histone H-1 kinase activities of cdk1 and cdk2 immunoprecipitated
from Jurkat cells showed a dose-dependent increase with UCN-01 treatment; the authors
identified the lack of inhibitory phosphorylation at threonine 15 by the Wee1 kinase as
the cause (Figure 2). Exposure of purified cdk1 and cdk2 to UCN-01 in vitro led to the
expected decrease in phosphorylation of histone H1. This study highlights the possibility
that a kinase inhibitor such as UCN-01 can impair the kinase ability of an upstream cell
cycle inhibitor, thus potentiating downstream kinases, even if UCN-01 itself is able to
inhibit the later enzymes when isolated in vitro. A panel of eight ovarian carcinoma cells
lines, both p53-proficient (OVCAR 429, 433, 3, and 420) and p53 mutant (SKOV 3,
SKOV 3 R, and OVCAR 432), exposed to UCN-01 for 24 hours displayed increased
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Figure 2: Apoptotic pathways affected by UCN-01. Green
indicates activities enhanced by UCN-01, red designates
inhibition by UCN-01.
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Table 3: UCN-01 and Apoptosis in Cultured Cells
Cell line

UCN-01
dose
100-300 nM

Experimental
Data
MTT assay, 32P
labeling, PI
flow, HH1
kinase assay,
western

OVCAR 429
(ovarian cancer,
p53 wt)

100 nM

MTT assay,
EtBr flow

SKOV 3
(ovarian cancer,
p53 null)

100 nM

MTT assay,
EtBr flow

SKOV SN3
(ovarian cancer,
p53 trans)
HL60
(myeloblastic
leukemia)

100 nM

MTT assay,
EtBr flow

0.1 – 10 µM

DNA
fragmentation,
HH1 kinase

10 µM

Western, 32P
labeling

K562
(myeloblastic
leukemia)

0.1 – 10 µM

DNA
fragmentation,
HH1 kinase

HT29 (colon
carcinoma)

0.1 – 10 µM

DNA
fragmentation,
HH1 kinase

A549 (NSCLC)

400 nM

PI flow,
TUNEL assay,
HH1 kinase,
western

Jurkat (Tlymphoblast)
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Cellular
Reference
effects
Growth
(Wang et al., 1995)
inhibition, ↓
G2 (18% →
10%),
apoptosis, ↑
cdk1 & cdk2
activity, ↓
Wee1 activity
Growth
(Husain et al.,
inhibition
1997)
(30% survival),
↑ G1 (42% →
59%), ↓ G2
(19% → 10%),
apoptosis
↓ G1 (50.7%
(Husain et al.,
1997)
→ 24.1%), ↑
G2 (5.7% →
34%)
↑ G1 (75% →
(Husain et al.,
1997)
88%),
apoptosis
↑ DNA
(Shao et al., 1997b)
fragmentation,
apoptosis,
↓cdk1 activity
(Shao et al., 1997a)
↑PKCα,
↑ppPKCα
↑ DNA
(Shao et al., 1997b)
fragmentation,
apoptosis,
↓cdk1 activity
↑ DNA
(Shao et al., 1997b)
fragmentation,
apoptosis,
↓cdk1 activity
↑ apoptosis
(Sugiyama et al.,
1999)
(60%), ↓ G1
(43% → 22%),

Table 3 continued
A549/UCN
(UCN-01
resistant A549
subline)

400 nM

PI flow,
TUNEL assay,
HH1 kinase,
western

LS513 (colon
carcinoma)

100 nM – 1
µM

Condensed
nuclei, western

SW48 (colon
carcinoma)

100 nM – 1
µM

Condensed
nuclei, western

WiDr (colon
carcinoma)

100 nM – 1
µM

Condensed
nuclei, western

HT29 (colon
carcinoma)

100 nM – 1
µM

Condensed
nuclei, western

Cos-7 (monkey
kidney)
HT1080
(human
fibrosarcoma)

0.3 – 1 µM

western

0.3 – 1 µM

GSK-3 kinase,
western,Casp-3
assay

NL-17 (mouse
colon
carcinoma)
293T

0.3 – 1 µM

GSK-3 kinase,
western

1 µM

GSK-3 kinase,
Casp-3 assay

SH-EP
(neuroblastoma,

50 – 500 nM

MTT assay,
TUNEL,
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no Δ in cdk2
activity
no ↑ apoptosis,
↑G1 (43% →
67%), ↓cdk2
activity, ↓p21,
↓p27, ↓ppRb
↑ apoptosis
(50%), ↑PARP
cleavage,
↓bcl-xL, no
NF-κB Δ
↑ apoptosis
(45%), ↑PARP
cleavage,
↓bcl-xL, no
NF-κB Δ
no apoptosis,
no PARP
cleavage,
↑bcl-xL,
↑NF-κB Δ
no apoptosis,
no PARP
cleavage,
↑bcl-xL,
↑NF-κB Δ
↓ppAkt
↓ppAkt,
↑caspase-3
activity,
↓PDK1
activity
↓ppAkt,
↓PDK1
activity
↓Akt activity,
↑caspase-3
activity,
↓PDK1
activity
Apoptosis,
↑ active

(Sugiyama et al.,
1999)

(Bhonde et al.,
2005)

(Bhonde et al.,
2005)

(Bhonde et al.,
2005)

(Bhonde et al.,
2005)

(Sato et al., 2002)
(Sato et al., 2002)

(Sato et al., 2002)

(Sato et al., 2002)

(Shankar et al.,
2004)

Table 3 continued
Bcl-2 null, p53
wt)

western, PI
flow

SH-SY5Y
50 – 500 nM
(neuroblastoma,
Bcl-2 wt, p53
wt)
SK-N-MC
50 – 500 nM
(neuroblastoma)

TUNEL

TUNEL,
western

caspase-3, ↑G1
(36% → 50%),
↓ppAkt,
↓ppGSK-3
Apoptosis

(Shankar et al.,
2004)

MSN
(neuroblastoma,
BCL-2 null)

50 – 500 nM

TUNEL,
western

IMR32
(neuroblastoma,
Bcl-2 wt, p53
wt)
SK-N-SH
(neuroblastoma,
Bcl-2 +/-, p53
wt)
HN6 (HNSCC)

50 – 500 nM

TUNEL

Apoptosis,
↑ active
caspase-3,
↓ppAkt,
↓ppGSK-3
Apoptosis,
↑ active
caspase-3,
↑cleaved
PARP,
↓ppAkt,
↓ppGSK-3
Apoptosis

50 – 500 nM

TUNEL

Apoptosis

(Shankar et al.,
2004)

100 nM

HN12
(HNSCC)
HN13
(HNSCC)
HN19
(HNSCC)
HN26
(HNSCC)

100 nM

western,
GSK-3 kinase
western

↓ppAkt,
↓Akt activity
↓ppAkt

100 nM

western

↓ppAkt

100 nM

western

↓ppAkt

100 nM

western

↓ppAkt

(Amornphimoltham
et al., 2004)
(Amornphimoltham
et al., 2004)
(Amornphimoltham
et al., 2004)
(Amornphimoltham
et al., 2004)
(Amornphimoltham
et al., 2004)
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(Shankar et al.,
2004)

(Shankar et al.,
2004)

(Shankar et al.,
2004)

apoptosis regardless of p53 status (Husain et al., 1997). However, the cell cycle response
in these cells appears to depend on p53; wild-type p53 cells demonstrated a G1 arrest,
while p53-null cells accumulated in G2. Apoptosis after UCN-01 exposure was also seen
in two myeloblastic leukemia cell lines (HL60 and K562) and one colon carcinoma line
(HT29), all p53-null (Shao et al., 1997c). The result was remarkable in that these lines
have historically been resistant to apoptosis. DNA fragmentation in these cells was
preceded by increased activity of cyclin B/cdk1. Inhibition of either caspases (via ZVAD-FMK) or serine proteases (by DCI) protected these cells from apoptosis. In a
subsequent study, the same group identified modulation of PKCα to coincide with
apoptosis in the HL60 cells (Shao et al., 1997a). The authors demonstrated that UCN-01
did not directly affect PKCα; instead, the drug increased autophosphorylation of
PKCα, leading to its activation, approximately 3 hours after UCN-01 treatment, at which
time apoptosis also became apparent. As in the previous study, caspase inhibition with
Z-VAD-FMK protected the cells from apoptosis; the activity of PKCα was also inhibited.
The involvement of PKCα is further supported by an analysis of a UCN-01 resistant cell
line, A549/UCN, in which levels of PKCα were greatly diminished (Courage et al.,
1997). When cultured without UCN-01 for six months, the cells regained their sensitivity
to UCN-01 and also expression of PKCα.

Further exploration of the A549 line and UCN-01-driven apoptosis-resistant A549/UCN
subline helped to uncover a mechanism which determines the cellular response to UCN01 (Sugiyama et al., 1999). After exposure to 0.4µM UCN-01, 62% of A549 cells were
driven into apoptosis, while the resistant A549/UCN cells had no increase following

40

treatment; instead, 67% of these cells accumulated in G1 (compared to 22% in A549
cells). Similar to the arresting effects detailed in the previous section, the A549/UCN
cells exhibited a dose dependent increase in p21 and p27, and decreases in cyclin A,
phosphorylated Rb, and active cdk2. Cdk2 kinase activity was reduced as well. None of
these changes were observed in the parental A549 cells. Finally, expression of the antiapoptotic bcl-2 protein was seen in A5549/UCN cells, both in UCN-01-treated cells and
untreated controls. No bcl-2 expression was seen in A549 cells (Figure 2). Levels of the
anti-apoptotic bcl-xL were diminished in both lines after UCN-01 treatment. Bcl-xL was
also demonstrated as an actor in the apoptotic response of four colon carcninoma cell
lines (Bhonde et al., 2005). The cell lines LS513 and SW48, which undergo apoptosis
following UCN-01 treatment also had a dose-dependent decrease in bcl-xL expression.
However, the UCN-01-resistant WiDr and HT29 lines, which are resistant to apoptosis at
levels of UCN-01 up to 1.0µM, had not such modulation; levels of bcl-xL were constant
regardless of treatment. PARP cleavage mimicked the bcl-xL and apoptotic responses,
with increasing cleavage in the LS513 and SW48 cells, and no cleavage seen in the
resistant WiDr and HT29 lines. While the repression of bcl-xL by UCN-01 in the
sensitive cells lines is a factor in the increased apoptosis observed, the authors also
demonstrate that cell cycle arrest may be just as important to the survival of the resistant
lines. LS513 clones transduced with a bcl-xL retrovirus were resistant to UCN-01mediated apoptosis, unlike the mock-infected controls. The bcl-xL overexpressing clones
also entered a G1 arrest following UCN-01 treatment (from 45% G1 to over 60%); the
mock-infected control cells had no change in the G1 population due to UCN-01
treatment. Thus, while UCN-01 can mediate apoptotic factors such as bcl-xL and thus
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possibly enhance the toxic effects of other agents, this ability may be preempted by a
UCN-01-mediated cell cycle arrest. The mechanism of bcl-xL transcriptional control by
UCN-01 is still under investigation.

Apoptosis caused by UCN-01 was also shown in an ex vivo model of leukemia. Cells
harvested from chronic lymphocytic leukemia (CLL) patients treated with 0.4µM UCN01 for 4 days demonstrated a 50% loss in viability, correlated with induction of apoptosis
(Byrd et al., 2001). No changes in the anti-apoptotic bcl-2 protein or the pro-apoptotic
bax protein were observed following UCN-01 treatment. A dose dependent decrease in
p53 was observed, but a subsequent study on mouse splenocytes with wild-type or null
p53 showed no requirement for p53 to induce apoptosis. The mechanism by which
UCN-01 is able to induce apoptosis in these cells is uncertain, but the ability to do so
without p53 present holds some promise for treating CLL patients who have become
resistant to other modes of therapy such as chlorambucil and fludarabine, which require
p53 to cause cell death (Mentz et al., 1996).

While the PDK1-Akt survival pathway (Figure 2) was previously excluded as a possible
mechanism in the G1 arresting effect of UCN-01 by Komander et al., it may be involved
in the apoptotic response. Cos-7, HT1080 and NL-17 cells treated with 1 µM UCN-01
exhibited a dose-dependent reduction in phosphorylated (active) Akt; the kinase activity
(GSK-3 peptide substrate) of Akt was also reduced, and caspase-3 activity and PARP
cleavage (markers of apoptosis) were increased (Sato et al., 2002). The lack of
phosphorylation was shown not to be caused by direct inhibition of PI3K or Akt, but
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rather by inhibition of the upstream kinase PDK1. The inhibition of PDK1 and induction
of apoptosis were also demonstrated in vivo using implanted NL-17 and PC-3 cells
(discussed below). Alteration of the Akt pathway by UCN-01 was also demonstrated in
six neuroblastoma cell lines, SH-EP, SH-SY5Y, SK-N-MC, MSN, IMR32, ANS SK-NSH (Shankar et al., 2004). Cells treated with 0.05µM UCN-01 were positive for
apoptosis (TUNEL staining) and had active (cleaved) caspase-3 and cleaved PARP.
Furthermore, UCN-01 diminished the levels of active (phosphorylated) Akt. Acting as a
prosurvival protein, Akt can phosphorylate (and thus deactivate) the proapoptotic kinases
GSK3β and Bad, and can also modulate p53 (Khwaja, 1999; Pap and Cooper, 1998).
Indeed, four hours after UCN-01 exposure, when phospho-Akt was diminished, GSK3β
phosphorylation was also reduced, allowing GSK3β to remain in its active, proapoptotic
state. Blockade of Akt activity was also demonstrated in HNSCC cells
(Amornphimoltham et al., 2004). Both Akt and GSK3β phosphorylation were inhibited
upon UCN-01 exposure in these cells, although these cells underwent growth inhibition
rather than apoptosis.

Analysis of the apoptotic mechanism following UCN-01 treatment in human colon
carcinoma HT-29 cells uncovered some features seen previously (Chan et al., 2003).
0.1µM UCN-01 resulted in 50% cell death within 48 hours. Caspase-3 activity was
induced, and the levels of anti-apoptotic bcl-xL were diminished. Transfection with
exogenous bcl-xL was able to rescue the cells from UCN-01, as apoptosis was reduced
and caspase-3 was not activated; PARP was also not cleaved in these cells. The MAPK
pathway was also implicated in this study, although not the canonical growth factor
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cascade shown to play a role in arrest in the study by Facchinetti et al. Instead, the p38
MAPK pathway was implicated. This signaling pathway responds to cellular stress and
increases in inflammatory response, and leads to cytokine production and apoptosis. HT29 cells which were treated with 0.1µM UCN-01 exhibited increased p38 expression;
exogenous bcl-xL experiment prevented this increase, as well as apoptosis.

Several cells lines, all derived from tumors, have shown varying vulnerability to UCN01-mediated apoptosis (see Table 3). As in the studies examining the G1 cell cycle
arrest, many players have been implicated, and no clear mechanism of apoptotic
induction yet exists. While the purpose of the project detailed here is to exploit the
temporary arrest of normal cells following UCN-01 treatment to prevent apoptosis, the
pathways described above are important in that they illustrate both the pluripotency of
UCN-01 and may help guide the selection of tumors which would be appropriate to treat
under the protection protocol. The fate of a particular cell type following UCN-01
treatment seems to depend on the balance of various cell control pathways, and it appears
that the difference between cell death and cell arrest could hinge on PKC, the original
target for which UCN-01 was developed. In a tumor cell, UCN-01 is able to activate
PKC, likely due to constitutively active receptor tyrosine kinase signaling. The activation
of PKC can then trigger apoptosis both through bcl-2 inhibition and lack of GSK3β
repression (Figure 2). In normal cells, UCN-01 can inhibit PKC, leading to decreased
NF-κB signaling and cell cycle arrest. Cancers with mutated stress responses and lacking
pro-apoptotic machinery may be resistant to growth inhibition, which would leave them
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susceptible to other cytotoxic agents after UCN-01 exposure, while normal cells would
be protected in a state of temporary cell cycle arrest.

UCN-01 and G2/M checkpoint abrogation (Table 4A-4D)
While UCN-01 can clearly trigger G1 checkpoint stimulation (causing a G1 arrest) or
drive some cells into apoptosis, the compound has also been exploited for its ability to
prevent the G2/M phase cell cycle checkpoint from arresting cells and allowing for DNA
damage repair to proceed (Eastman, 2004). Following damage from either
chemotherapeutic drugs or radiation, some tumor cells enter a G2 arrest. Following
cytotoxic treatment with UCN-01 can abrogate this checkpoint, forcing cells with damage
to enter mitosis. These crippled cells will then undergo apoptosis, thus enhancing the
damage done to the tumor. As with the studies focusing on apoptosis due to UCN-01
alone, this project does not seek to take advantage of the G2 checkpoint abrogation. It is
our aim to arrest normal cells in the G1 phase of the cell cycle, thus preventing damage
from agents which target actively dividing cells, not to enhance toxicity to tumor cells.
However, as the mechanisms and targets of UCN-01 seem both numerous and not
entirely clear, it is important to be cognizant of any and all actors in these processes.
Below is a summary of the current knowledge of the ability of UCN-01 to abrogate the
G2/M checkpoint arresting machinery. The tables 4A – 4D summarize the different
mechanisms of UCN-01 when used in combination therapy.

The major pathway thought to be affected by UCN-01 in this paradigm is that of
cdk1/cyclin B complex in G2. When active, cdk1 is unphosphorylated at both Thr14 and

45

Table 4A: UCN-01 in S/G2 arrest abrogation when used with a second agent/IR

Cell Line
CA46 (lymphoma)

Damaging Agent
IR

HCT116/E6 (colon
carcinoma, p53 null)
HCT116 (p53 wt)
MCF-7/ADR (breast
cancer, p53 null)
MCF-7 (breast
cancer, p53 wt)
A431 (human
epithelial
carcinoma, p53 mut)
PSN-1 (human
pancreatic
adenocarcinoma,
p53 mut)
HCT-116 (p53 wt)

Camptothecin

Effect(s) Observed
G2 arrest
abrogation, ↑cdk1
activity (loss of
ppThr14 & ppTyr15)
Apoptosis resistance
Apoptosis, G2 arrest
abrogation
PCNA→DNA, S
arrest abrogation,
apoptosis
↓cyclin A levels &
cdk2 kinase activity,
S arrest abrogation,
↑ cdk1 activity,
apoptosis
Apoptosis

MCF-7 (p53 wt)
MCF-7/E6 (p53-)

Cisplatin
Cisplatin

CHO (hamster
ovary, p21 & p53
null)
HT29 (colon
carcinoma, p53 mut)

Cisplatin

Camptothecin
Camptothecin

Apoptosis resistance
Apoptosis

(Shao et al., 1997b)
(Shao et al., 1997b)

Camptothecin

Apoptosis resistance

(Shao et al., 1997b)

Mitomycin C

G2 arrest
abrogation,
apoptosis
G2 arrest
abrogation,
apoptosis

(Sugiyama et al.,
2000)

Mitomycin C

Apoptosis resistance

MCF-7 (p53 wt)

Mitomycin C

Apoptosis resistance

WiDr (colon
carcinoma, p53 null)
WiDr/BM (colon
carcinoma, p53 +)
MDA-MB231
(breast cancer, p53
mut)

Mitomycin C

Apoptosis

Mitomycin C

Apoptosis resistance

SN38

S/G2 arrest
abrogation,
apoptosis

(Sugiyama et al.,
2000)
(Sugiyama et al.,
2000)
(Sugiyama et al.,
2000)
(Sugiyama et al.,
2000)
(Kohn et al., 2002)

Camptothecin

Mitomycin C
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Reference
(Wang et al., 1996)

(Wang et al., 1996)
(Wang et al., 1996)
(Bunch and
Eastman, 1997)
(Shao et al., 1997b)

(Shao et al., 1997b)

(Sugiyama et al.,
2000)

Table 4A continued
MCF-10a (breast
epithelium, p53 wt)

SN38

HCT116 (p53 wt)

IR

HCT116 (p53 null
subline)

IR

HCT116 (p53 wt)

SN38

MCF-7 (p53 wt)

SN38

CAKI-1 (renal
carcinoma, p53 wt)
U87MG (glioma,
p53 wt)
SUM102 (breast
cancer, p53 wt)
A549 (lung
carcinoma, p53 wt)
A549/E6 (p53 null)

SN38

LXSN (lung
carcinoma, p53 wt)
A549 (p53 wt)

IR

Calu (lung
carcinoma, p53 wt)

IR

HT29 (colon
carcinoma, p53 mut)

IR

SW480 (colon
carcinoma, p53 mut)

IR

SW260 (colon
carcinoma, p53 mut)

IR

S/KS (rectal
carcinoma, p53 mut)

IR

Apoptosis
resistance, ↓ cyclins
A&B
G2 arrest
abrogation, Chk2
inhibition
G2 arrest
abrogation, Chk2
inhibition
G2 arrest
abrogation, ↓p21,
↑cyclin B
G2 arrest
abrogation, ↓p21,
↑cyclin B
UCN-01 unable to
block G2 arrest
UCN-01 unable to
block G2 arrest
UCN-01 unable to
block G2 arrest
No UCN-01enhanced toxicity
G2 arrest
abrogation,
apoptosis
No UCN-01enhanced toxicity
G2 block
abrogation, no
increased toxicity
G2 arrest
abrogation,
apoptosis
G2 arrest
abrogation,
apoptosis
G2 arrest
abrogation,
apoptosis
G2 arrest
abrogation, no
increased toxicity
G2 arrest
abrogation, no

SN38
SN38
IR
IR

IR
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(Kohn et al., 2002)
(Yu et al., 2002)
(Yu et al., 2002)
(Levesque et al.,
2008)
(Levesque et al.,
2008)
(Levesque et al.,
2008)
(Levesque et al.,
2008)
(Levesque et al.,
2008)
(Xiao et al., 2002)
(Xiao et al., 2002)
(Xiao et al., 2002)
(Mack et al., 2004)
(Mack et al., 2004)
(Playle et al., 2002)
(Playle et al., 2002)
(Playle et al., 2002)
(Playle et al., 2002)

Table 4A continued

increased toxicity
G2 arrest
abrogation, no
increased toxicity
G2 arrest abrogation

S/KS (rectal
carcinoma, p53 mut)

IR

CHO

Cisplatin

HT29
MDA-MB231,
T47D (breast
cancer)
MDA-MB231, GI
101A
A341, PSN-1,
HCT116, MCF-7
U87MG

Camptothecin
Cisplatin

S arrest abrogation
S/G2 arrest
abrogation

Camptothecin

Temozolomide

184B5, 184B5/E6
HCT116

Adriamycin
SN-38

A549, PC-3

Perifosine

Apoptosis, S/G2
arrest abrogation
Apoptosis, S/G2
arrest abrogation
G2 arrest
abrogation, Chk1
inhibition
G2 arrest abrogation
S/G2 arrest
abrogation
S arrest abrogation

MCF10a

SN38

HT29

Ara-C

Mitomycin C

S arrest abrogation,
↓p21
Apoptosis, ↑cdk1,
chk1 inhibition, G2
arrest abrogation
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(Playle et al., 2002)
(Bunch and
Eastman, 1996)
(Shao et al., 1997a)
(Lee et al., 1999)
(Jones et al., 2000)
(Sugiyama et al.,
2000)
(Hirose et al., 2001)
(Luo et al., 2001)
(Tse and Schwartz,
2004)
(Dasmahapatra et
al., 2004)
(Levesque et al.,
2005)
(Shao et al., 2004)

Table 4B: UCN-01 and apoptosis in concert with a second agent
Cell Line(s)
SKOV-3, OVCAR3, -420, -429, -432
SK-GT5

Damaging Agent
CDDP

MCF-7, T47D,
HS578T, BT549,
MDA-N, MDAMB231, MDA435

Camptothecin

U937

Ara-C

NCI-H322M,
MDA-MB435, NCIH23, HT29, MCF-7
MCF-7, MCF7/ADR
U937, HL-60

Mitomycin C,
cisplatin, 5-FU,
topotecan,
fludarabine
Danazol,
mifepristone
Fludarabine

ML-1

Gemcitabine

MDA-MD231,
MCF-7, T47D,
DU145, LNCaP
U937

PD98059

Lymphocytes
(normal and CLL)
A431

UV light, 4-HC

K562, LAMA84

UO126, PD184352

ML-1

Fludarabine

RPMI8226, NCIH929, U266 MM

PD184352

5-FU

17-AAG

FdUrd
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Effect(s) Observed
Apoptosis (p53
dependent)
Apoptosis, TS
suppression
Apoptosis, growth
inhibition (p53
independent),
inverse correlation
with bcl-2, bcl-xL
Apoptosis, caspase
activation,
mitochondrial
damage
Apoptosis (p53
dependent), growth
inhibition

Reference
(Husain et al., 1997)

Apoptosis (ER/PR
dependent)
Apoptosis (sequence
dependent)
Apoptosis, no cell
cycle progression
Apoptosis, MAPK
inhibition, ↑Bax

(Yokoyama et al.,
2000)
(Harvey et al.,
2001)
(Shi et al., 2001)

Apoptosis, ↓Akt,
↓MAPK
Apoptosis, DNA
repair inhibition
Apoptosis,
inhibition of TS and
DNA repair
Apoptosis, ↓Mcl-1,
↓ cyclin D,
↓Bcr/Abl, Jnk
activation
Apoptosis, cdk2 and
cdc25a reactivation
Apoptosis,
inhibition of UCN01 MEK activation

(Jia et al., 2003)

(Hsueh et al., 1998)
(Nieves-Neira and
Pommier, 1999)

(Tang et al., 2000)

(Monks et al., 2000)

(McKinstry et al.,
2002)

(Yamauchi et al.,
2002)
(Grem et al., 2002)
(Yu et al., 2002)

(Sampath et al.,
2002)
(Dai et al., 2002)

Table 4B continued
A549, Calu1, H596

Cisplatin

U937, HL-60
U266, MM.1S,
MM.1R
HMEC, HMEC/E6,
MDA-MB231

Ara-C
Bay 11-7082

HT29

Ara-C

HCT116

SN-38

A549, PC-3

Perifosine

U937, HL-60, Raji,
Jurkat

L744832

U937

Rapamycin

MCF10A

SN38

CD138+

L744832

TE2, TE12, H322,
H460, H513, H211
U266, RPMI8226

Valproic acid

MDA-MB231, GI
101A
A341, PSN-1,
HCT116, MCF-7

Camptothecin

HCT116

Camptothecin

Apoptosis, ↓cyclin
A and cyclin B
Apoptosis, ↓Bcl-2
Apoptosis, IκB,
NFκB disruption
Apoptosis,
normal/tumor
differential, p53
dependence
Apoptosis, ↑cdk1,
chk1 inhibition, G2
arrest abrogation
Apoptosis, S/G2
arrest abrogation,
p53 independence
Apoptosis, S arrest
abrogation, Akt
activation
Apoptosis, MEK
inactivation, Jnk
activation
Apoptosis,
↓MEK/ERK, ↓Bcl2, ↓cyclin D
Apoptosis, S arrest
abrogation, ↓p21
Apoptosis, Jnk
activation, Akt
inactivation
Apoptosis, NFκB
suppression
Apoptosis, Bim
dependence
Apoptosis, S/G2
arrest abrogation
Apoptosis, S/G2
arrest abrogation,
p53 dependence
Apoptosis, DNA ds
breaks, ↑γH2AX,
↓p21

Topotecan

PD184352

Mitomycin C
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(Mack et al., 2003)
(Wang et al., 2003)
(Dai et al., 2004)
(Redkar et al., 2004)

(Shao et al., 2004)
(Tse and Schwartz,
2004)
(Dasmahapatra et
al., 2004)
(Dai et al., 2005)
(Hahn et al., 2005)

(Levesque et al.,
2005)
(Pei et al., 2005)
(Yeow et al., 2006)
(Pei et al., 2007)
(Jones et al., 2000)
(Sugiyama et al.,
2000)
(Furuta et al.,
2006)`

Table 4C: Cell lines demonstrating growth arrest when treated with UCN-01 and a
second agent
Cell Line(s)
A431

Secondary Agent
Mitomycin C

Effect(s) Observed
G1/S arrest

A-172, T-98G

BCNU and cisplatin

n/a

MCF-7, T47D,
HS578T, BT549,
MDA-N, MDAMB231, MDAMB435
HMEC, HE6,
MDA-MB231
NCI-H322M,
MDA-MB435, NCIH23, HT29, MCF-7

Camptothecin

p53 independence,
inverse correlation
to bcl-2, bcl-xL

Camptothecin

DNA ds breaks, p53
dependence
p53 dependence

MCF-7

Mitomycin C,
cisplatin, 5-FU,
topotecan,
fludarabine
Tamoxifen

MDA-MB231,
MCF-7, HCT116,
HEPG2

PD184352,
AZD6244, FTI277,
R115777

↓Rb
phosphorylation
Bax/Bak
dependence, ERK
activity
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Reference
(Akinaga et al.,
1993)
(Pollack et al.,
1996)
(Nieves-Neira and
Pommier, 1999)

(Jones et al., 2000)
(Monks et al., 2000)

(Koh et al., 2003)
(Hamed et al., 2008)

Table 4D: Studies demonstrating p53 dependence/independence for actions of UCN-01
and a second agent
Cell Line(s)
HMEC, HE6,
MDA-MB231
NCI-H322M,
MDA-MB435, NCIH23, HT29, MCF-7
SKOV-3, OVCAR3, -420, -429, -432
A341, PSN-1,
HCT116, MCF-7

Secondary Agent
Camptothecin

Effect(s) Observed
DNA ds breaks, p53
dependence
p53 dependence

Mitomycin C,
cisplatin, 5-FU,
topotecan,
fludarabine
CDDP

Apoptosis (p53
dependent)
Apoptosis, S/G2
arrest abrogation,
p53 dependence
Apoptosis,
normal/tumor
differential, p53
dependence

Mitomycin C

HMEC, HMEC/E6,
MDA-MB231

Topotecan

MCF-7, T47D,
HS578T, BT549,
MDA-N, MDAMB231, MDA435

Camptothecin

HCT116

SN-38

Apoptosis, growth
inhibition (p53
independent),
inverse correlation
with bcl-2, bcl-xL
Apoptosis, S/G2
arrest abrogation,
p53 independence
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Reference
(Jones et al., 2000)
(Monks et al., 2000)

(Husain et al., 1997)
(Sugiyama et al.,
2000)
(Redkar et al., 2004)

(Nieves-Neira and
Pommier, 1999)

(Tse and Schwartz,
2004)

Tyr15 (Ohi and Gould, 1999). However, upon DNA damage, cdk1 is phosphorylated at
both these sites and is inactivated. The phosphorylation status of cdk1 is determined by
the interplay of the Wee1 kinase and the Cdc25C phosphatase. The ATM kinase,
activated by DNA damage, can phosphorylate and activate the checkpoint kinases Chk1
and Chk2 (Weinert, 1997). These kinases are able to phosphorylate Cdc25C, allowing
binding to 14-3-3 proteins and sequestering it in the cytoplasm. The expulsion of
Cdc25C from the nucleus prevents removal of the inhibitory phosphates on cdk1, leaving
it inactive and the cell arrested in G2. By inhibition of ATM, Chk1, Chk2 and other
signaling molecules, UCN-01 is able to blunt this arrest. The specific actions of UCN-01
in the G2/M transition will be reviewed here (Figure 3).

Most of the studies reviewed in this section first require induction of the G2 checkpoint
prior to evaluating the ability of UCN-01 to then allow the cells to pass it. The focus will
be on studies which examine the mechanism of UCN-01 action; other studies which
concentrate on the enhanced ability to kill cells via this abrogation will be mentioned as
appropriate.

The initial study on UCN-01 in this context was done using human lymphoma CA46
cells (Wang et al., 1996). Following γ irradiation (6.3 Gy), the cells were arrested at the
G2/M phase of the cell cycle. UCN-01 was able to inhibit the resultant G2 arrest in a
dose- dependant manner. 30 nM of UCN-01 had little effect, but 100 nM allowed the
progression of some cells into G1, and 300 nM completely abolished the G2 arrest (DNA
histogram, no number cited). UCN-01 was able to activate the cyclin B/cdk1 complex
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Figure 3: Pathways implicated in the abrogation of S/G2 phase
arrest by UCN-01. Green indicates activities enhanced by
UCN-01, red indicates inhibition by UCN-01.
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3.5-fold in irradiated cells over the level seen with radiation alone; this activation of the
cyclin B/cdk1 kinase complex was shown to be due to the absence of the inhibitory
phosphorylations on cdk1 at Thr14 and Tyr15 (Figure 3). In the same study, it was also
discovered that p53 may play a role in the ability of UCN-01 to abrogate the G2 arrest.
MCF-7 cells with functional p53 and treated with cisplatin (2.5-15 µM) followed by 100
nM UCN-01 were much more resistant to cell death than MCF-7/E6 cells with defective
p53 subjected to the same treatment. At 10 nM cisplatin, control MCF-7 cells had a 10%
survival rate, while the MCF-7/E6 survived at less than 0.01%.

An alternate mechanism was demonstrated in Chinese hamster ovary (CHO) cells (Bunch
and Eastman, 1997). Cisplatin treatment induces an S phase arrest in these cells; UCN01 speeds the cells through S into G2 and then into apoptosis. The S phase arrest was
caused by sequestration of proliferating cell nuclear antigen (PCNA) away from the DNA
(Figure 3). PCNA is required for DNA replication, so its removal can effectively block S
phase progression. This process usually proceeds by the binding of PCNA to p21, which
in turn has been induced by p53 (Figure 3). In this setting another mechanism must be
responsible, as both p53 and p21 are absent in CHO cells. Nevertheless, UCN-01
treatment after cisplatin was able to return PCNA to the DNA fraction of these cells, and
the S phase arrest was circumvented. However, the mechanism by which PCNA is
sequestered away from the DNA and then returned via UCN-01 is unclear.

Potentiation of UCN-01 cell killing in the absence of p53 was also demonstrated
following camptothecin treatment (Shao et al., 1997b). HT29 colon carcinoma cells (p53
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mutant) entered into an S phase arrest after camptothecin treatment. This alteration was
marked by both increased levels of cyclin A and cyclin A/cdk2 kinase activity. UCN-01
prevented both these increases, and also increased cdk1 kinase activity. In the same
study, UCN-01 potentiated the cell killing ability of camptothecin in HT29 cells,
reducing the amount needed to kill 50% of the cells by over 6-fold. UCN-01 also
potentiated the toxicity of camptothecin in HCT116/E6 and MCF-7/ADR cells, both of
which are defective for p53 function (Shao et al., 1997b). This enhancement was greatly
diminished in the p53 wild-type HCT116 and MCF-7 cells. A similar finding was
reported when using UCN-01 to nullify the G2 arrest and therefore increase the
cytotoxicity of mitomycin c (MMC) (Sugiyama et al., 2000). UCN-01 significantly
potentiated MMC in the p53 mutant cell lines A431 (human epithelial carcinoma) and
PSN-1 (human pancreatic adenocarcinoma), but showed no such effect in p53 wild-type
HCT116 or MCF-7 cells. The same differential effect was observed when using p53defective WiDr cells and a wild-type p53-transfected derivative line, WiDr/BM
(Sugiyama et al., 2000). The effect of p53 on UCN-01 checkpoint abrogation was also
demonstrated using two breast epithelial cell lines, the p53 mutant tumor cell line MDAMB231 and p53 wild-type MCF10a line (Kohn et al., 2002). Treatment with the
topoisomerase inhibitor SN38 generated a G2 arrest in both lines; subsequent UCN-01
treatment was able to block the arrest in the p53 mutant MDA-MB231 line, but not in the
MFF10A human mammary epithelial cell line (see Figure 3). The resistance of MCF10A
cells correlated with diminished expression of both cyclins A and B.
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Not all studies have shown that UCN-01 acts primarily by inhibiting Chk1, or that p53 is
important in this response. Exposure of HCT116 cells and a p53 null subline to ionizing
radiation (IR) lead to a G2 arrest; secondary UCN-01 was able to blunt this arrest,
regardless of p53 status (Yu et al., 2002). IR induced p53 upregulation and stabilization
as well as increased activity of Chk2; Chk1 activity was not altered (Figure 3). UCN-01
was able to prevent this increase in p53 levels in the wild-type cells, and also blocked
phosphorylation of the stabilizing serine-20 site, a target of Chk2 (Dumaz et al., 2001).
This report seems to be in conflict with the previous body of work, indicating that the p53
pathway may have differing sensitivity to UCN-01 in terms of cell lines and
concentrations. Also in conflict was the finding that UCN-01 can inhibit Chk2 in vitro.
The vulnerability of p53 wild-type cells to this mechanism was demonstrated again, not
only in the HCT116 cells, but also in MCF-7 cells (Levesque et al., 2008). After SN38
treatment, these cells went into a G2 arrest, concomitant with repression of cyclin B and
enhancement of p21 expression. UCN-01 was able to block these responses, and the cells
entered mitosis and apoptosed. However, three other p53 wild-type lines, CAKI-1,
U87MG, and SUM102 demonstrated the same response to SN38, and UCN-01 was
ineffective in reversing this response (Levesque et al., 2008). One possible factor in the
p53-related UCN-01 sensitivity/resistance may be the MDM2 assistant protein, MDMX
(Jin et al., 2006). MDMX is a recruiting factor for MDM2, the E3 ubiquitin ligase
responsible for p53 degradation. Active Chk1 phosphorylates MDMX, which enhances
binding to the 14-3-3 proteins and sequesters it away from the nucleus. 293T cells
stimulated to activate the DNA repair pathway via UV treatment demonstrated exactly
this response, and subsequent UCN-01 exposure was able to repress all these effects.
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One issue with many of these studies is that the expression and activity of the proteins
noted is often correlated with the arrest and UCN-01-mediated release, but are not shown
to be necessary or sufficient. In fact, a recent study using short hairpin RNA (shRNA) to
block Chk1, Chk2 or both in MDA-MB231 cells seems to indicate that neither is required
for the G2 arrest after SN38 treatment, pointing to the possibility that an alternate kinase
is instead acting to produce the arrest (Zhang et al., 2008). Modulation of Cdc25A was
seen in the absence of both kinases, and the alternate checkpoint kinase MAPKAPK2
(MK2) was ruled out as the effector as well in MDA-MB231 cells. To date, no clear
mechanism for the DNA-damage arrest and its abrogation via UCN-01 exists.

Further uncertainty about the involvement and importance of p53 in UCN-01 potentiation
of cell killing comes from studies utilizing UCN-01 to enhance cell death following
ionizing radiation (Xiao et al., 2002). The human lung carcinoma cell lines A549 and
LXSN are p53 wild-type. Upon irradiation, these cells accumulated in both G1 and G2
phases of the cell cycle. However, a p53-disrupted E6 A549 subline exhibited only a G2
arrest following the same treatment. Application of UCN-01 six hours later resulted in a
significant reduction in survival of the E6 cells; the p53-competent A549 and LXSN cells
were not similarly sensitized, indicating that functional p53 may protect cells from the
UCN-01 enhanced mortality. However, a subsequent study on A549 and the p53 wildtype Calu1 cell lines blurs this distinction (Mack et al., 2004). Ionizing radiation
treatment resulted in the cell cycle arrest seen previously, and in both cell lines UCN-01
was able to abrogate the G2 arrest. As before, A549 cells were resistant to UCN-01
enhanced decrease in cell survival when given following irradiation. However, Calu1
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cells were sensitive to this treatment protocol, despite expressing functional p53. The
enigmatic reaction to irradiation plus UCN-01 treatment was likewise observed in a panel
of five colorectal tumor cell lines with mutant p53 (Playle et al., 2002). Exposure to 5
Gy of radiation resulted in a G2 arrest in all five lines (HT29, SW480, SW260, S/KS, and
S/RG/C2); successive UCN-01 was able to blunt this response in all cell types. However,
analysis of cell survival following this treatment demonstrated a significant decrease in
survival in only the HT29 and SW480 lines when treated with UCN-01 compared to
radiation alone. An in vivo study of p53 wild-type RIF-1 tumors in mice demonstrated a
significant reduction in tumor growth when UCN-01 was given prior to 20 Gy of
radiation compared to either treatment alone (Khan et al., 2009). These studies indicate
that p53 may partially modulate the activity of UCN-01, but the drug may have distinct
actions which do not involve p53.

The ability of UCN-01 to move cells through the G2 phase of the cell cycle seems to lie
at least in part upon the activation or maintenance of active cdk1. Murine FT210 cells,
which have a temperature sensitive cdk1, were placed into G2 arrest using γ irradiation
(Yu et al., 1998). Successive treatment with 0.3µM UCN-01 was able to abrogate the G2
arrest at the permissive temperature. However, at the non-permissive temperature for
cdk1 activity in these cells, UCN-01 could no longer abrogate G2 arrest. UCN-01 was
still able to abrogate the G2 arrest in the parental cell line (FM3A), ruling out temperature
as a complicating factor. UCN-01 treatment also resulted in the inactivation of the Wee1
kinase in FM3A cells, thus preventing it from adding inhibitory phosphate groups onto
cdk1. The inactivation of Wee1 does not appear to be due to direct inhibition by UCN-01
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(in vitro incubations showed Wee1 to be quite resistant to UCN-01 inhibition) but rather
via a feedback loop. Cdk1/cyclin B can phosphorylate Wee1, thus targeting it for
ubiquitination by cdc34 and proteasomal degradation (Michael and Newport, 1998). The
increased activity of cdk1 could thus result in decreased Wee1. Finally, UCN-01 also
prevented the phosphorylation/deactivation of the Cdc25C phosphatase (Yu et al., 1998).
These two activities are likely to increase the activity of cdk1 and thus push cells into
mitosis. One possible upstream regulator of Cdc25C is the human checkpoint kinase,
either Chk1 or Chk2. In vitro studies have shown direct inhibition of Chk1 by UCN-01,
with an IC50 of 11nM (Busby et al., 2000). K562 erythroblastoid leukemia cells enter a
G2 arrest following γ irradiation; subsequent UCN-01 treatment reduced the
phosphorylation of Cdc25C, and completely relieved the G2 block. However, Chk2 was
shown to be highly resistant to UCN-01, suggesting to action of UCN-01 is most likely
through Chk1 inhibition. More evidence for the modulation of Cdc25C via Chk1 was
obtained from HeLa cells arrested in G2 following γ irradiation (Graves et al., 2000). In
the absence of UCN-01, the prevailing status of Cdc25C was serine-216 phosphorylated
and 14-3-3 bound (Figure 3). Addition of UCN-01 reduced the phosphorylation at
serine-216 and caused Cdc25C to detach from 14-3-3; cdk1 activation and mitotic entry
soon followed. One other item noted in this study was the inability of UCN-01 to induce
freed Cdc25C (released from 14-3-3) to reenter the nucleus; the majority of the now
serine-216 dephosphorylated, monomeric Cdc25C was still cytoplasmic. How this
cytosolic phosphatase could activate the nuclear cdk1 is unclear. The role of Cdc25C is
unclear in the breast tumor line MDA-MB231 as well (Kohn et al., 2002). While UCN01 can block a G2 arrest in these cells, the levels of active Cdc25C seem to depend on the

60

dose of UCN-01 used. While a high concentration of UCN-01 (500 nM) rapidly
increased the levels of active Cdc25C, low UCN-01 (15 nM) produced very little active
Cdc25C, even though this dose was sufficient to drive the arrested (p53 mutant) cells into
mitosis.

While the reports concerning the ability of UCN-01 to cause a cell cycle arrest implicate
many pathways and protein effects, the abrogation of a G2/M arrest following a damage
response seems to be less complicated. Most of the experimental evidence indicates an
increase in cdk1 kinase activity concomitant with cell cycle progression through mitosis.
This increase can be due to inhibition of chk1 and/or chk2, leading to cdc25 phosphatase
activity to remove the inhibitory phosphorylations on cdk1. In addition, UCN-01 can
diminish p53, leading to deceased levels of 14-3-3 proteins (thus keeping cdc25 in the
nucleus and able to activate cdk1) and also lower levels of p21, in turn also increasing
cdk1 activity. While some of the pathways leading to G1 arrest may also be activated by
UCN-01, the prior DNA-damaging stimulus may make those pathways unimportant.
Damaged cells arrested in G2 and then forced through mitosis will most likely die, so
activation of a G1 checkpoint may be of little consequence. In addition, the loss or
mutation of p53 in many of the cell lines examined may further prevent cdk1 inhibition,
thus abrogating the G2 arrest. The literature concerning UCN-01 synergism with or
potentiation of secondary agents is quite extensive, but also outside the focus of this
project. While many studies have been discussed here to gauge the various possible
mechanisms of UCN-01 actions, other reports focus mainly upon its effects (usually
inhibition of proliferation or enhanced apoptosis). Summarized in Tables 4A-D are
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studies concerning UCN-01 in combination with either IR or other agents, grouped into
four categories of effects and mechanisms: S/G2 arrest abrogation, growth inhibition,
apoptosis, and p53 dependence/independence.

UCN-01 in vivo (Table 5)
While the volume of work examining UCN-01 in cell culture systems is quite extensive,
the in vivo effects and mechanisms of UCN-01 action are poorly understood, as few in
vivo studies have been done using UCN-01. As with the in vitro work, UCN-01 was
originally used to prevent or retard the growth of implanted tumors in mice. The first
such study demonstrated a functional difference between UCN-01 and staurosporine.
Using three human tumor lines (A431, HT1080 and HL-60) and two murine tumor lines
(K-BAL and M-MSV-BALB), it was found that while UCN-01 was much less potent at
inhibiting growth in culture than staurosporine (IC50 for 72 hours of UCN-01 treatment
was 9.2 – 87.4 fold less potent than staurosporine), it was effective at slowing the growth
of all five lines when implanted into mice, while staurosporine had no effect (Akinaga et
al., 1991). The tumors were implanted into the flanks of nude mice (human tumors) or
antigen-matched syngeneic mice (murine tumors), and were treated daily for 5 days with
UCN-01 or staurosporine. UCN-01 prevented tumor growth at doses between 5 and 7.5
mg/kg; equivalent doses of staurosporine had no effect on these tumors. The
combination of MMC and UCN-01 was synergistic in killing implanted A431 cells, and
this was confirmed as a viable treatment option in two other solid tumor models (Co-3
and murine sarcoma 180) as well as the P388 murine leukemia model (Akinaga et al.,
1993). A constant infusion of UCN-01 of 1 mg/kg/day for one week was also effective in
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Table 5: In vivo studies using UCN-01 in tumor-bearing animals
Tumor
A431
HT1080
HL-60
K-BALB
M-MSV-BALB
A431

Co-3

Murine
sarcoma 180
P388

U-87

PAN-3-JCK

CRL 1420

Drug Regimen
5 mg/kg (ip)
/day X 5
7 mg/kg (ip)/
day X 5
7 mg/kg
(ip)/day X 5
7.5 mg/kg
(ip)/day X 5
7.5 mg/kg
(ip)/day X 5
4 mg/kg
mitomycin c +
14.5 mg/kg
UCN-01 (iv)
4 mg/kg
mitomycin c +
14.5 mg/kg
UCN-01 (iv)
6 mg/kg
mitomycin c +
14.5 mg/kg
UCN-01 (iv)
4 mg/kg
mitomycin c +
14.5 mg/kg
UCN-01 (iv)
1 mg/kg/day
UCN-01 X 7
days (ip)
5 mg/kg/day
UCN-01 X 5
days (ip)

Tumor Effect
60% growth
inhibition
83% growth
inhibition
39% growth
inhibition
73% growth
inhibition
79% growth
inhibition
83% growth
inhibition

Mechanism
n/a

80% growth
inhibition

n/a

(Akinaga et al.,
1993)

89% growth
inhibition

n/a

(Akinaga et al.,
1993)

Lifespan
increased 105%

n/a

(Akinaga et al.,
1993)

50% decreased
tumor volume,
57% survival at
60 days (vs.
0.7% control)
Tumor weight
T/C = 36.3%

n/a

(Pollack et al.,
1996)

G1 arrest
(37%→61%),
↑p21, ↓cdk2
activity
G1 arrest
(67%), ↑p21,
↓cdk2 activity

(Abe et al.,
2001)

G1 arrest
(43%→61%),
↑p21, ↓cdk2
activity

(Abe et al.,
2001)

10 mg/kg/day
UCN-01 X 5
days (ip)

Tumor weight
T/C = 16.8%

5 mg/kg/day
UCN-01 X 5
days (ip)

Tumor weight
T/C = 32.3%
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n/a
n/a
n/a
n/a
n/a

Reference
(Akinaga et al.,
1991)
(Akinaga et al.,
1991)
(Akinaga et al.,
1991)
(Akinaga et al.,
1991)
(Akinaga et al.,
1991)
(Akinaga et al.,
1993)

Table 5 continued

MX-1

Br-10

MCF-7

MX-1

HN12

MDA-MB231

MCF-7

MDA-MB231

10 mg/kg/day
UCN-01 X 5
days (ip)
5 mg/kg/day
UCN-01 X 5
days (ip)
10 mg/kg/day
UCN-01 X 5
days (ip)
7.5 mg/kg/day
UCN-01 X 5
days/week X 2
weeks (ip)
7.5 mg/kg/day
UCN-01 X 5
days/week X 2
weeks (ip)
7.5 mg/kg/day
UCN-01 X 5
days/week X 2
weeks (ip)
7.5 mg/kg/day
UCN-01 X 5
days (ip)

0.2 mg/kg
UCN-01 X 3 +
25 mg/kg
PD184352 X 3
0.1 mg/kg
UCN-01 X 3 +
25 mg/kg
PD184352 X 3
0.2 mg/kg/day
UCN-01 X 2
days + 100
mg/kg/day
R115,777 X2
0.2 mg/kg/day
UCN-01 X 2
days + 25
mg/kg/day
PD184352 X2

Tumor weight
T/C = 16.2%
Tumor weight
T/C = 89.9%
Tumor weight
T/C = 66.1%

G1 arrest
(52%), ↑p21,
↓cdk2 activity
↓cdk2 activity,
No Δ in p21 or
cell cycle
↓cdk2 activity,
↑p21, no Δ in
cell cycle

(Abe et al.,
2001)

Tumor weight
T/C = 27.0%

↑p21, pRb dephosphorylation

(Koh et al.,
2002)

Tumor weight
T/C = 25.0%

↑p21, pRb dephosphorylation

(Koh et al.,
2002)

Tumor weight
T/C = 65.9%

↑p21, no Δ in
pRb
phosphorylation

(Koh et al.,
2002)

Tumor weight
T/C = 0.3%

(Patel et al.,
2002)

Tumor weight
T/C = 32%

Apoptosis
(TUNEL),
↑p27,
↓cyclin D
Apoptosis,
↓ angiogenesis

Tumor weight
T/C = 34%

Apoptosis,
↓ angiogenesis

(Hamed et al.,
2008; Hawkins
et al., 2005)

3-fold decrease
in tumor
volume vs.
controls

↓Ki-67 levels,
decreased ex
vivo plating
efficiency of
excised tumors

(Hamed et al.,
2008)

4-fold decrease
in tumor
volume vs.
comtrols
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(Hamed et al.,
2008; Hawkins
et al., 2005)

Table 5 continued
NL-17
5 & 10 mg/kg
UCN-01 (ip)
PC-3
6, 9, 13 mg/kg
UCN-01 (ip)

No tumor effect
noted
No tumor effect
noted
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↓PDK1 activity
↓PDK1 activity

(Sato et al.,
2002)
(Sato et al.,
2002)

reducing the tumor volume of implanted (subcutaneous) U-87 malignant glioma tumors
(Pollack et al., 1996). 28 days after the UCN-01 treatment, no mice had evidence of
tumor re-growth, and postmortem analysis was unable to identify any tumor cells. In the
same study, intracranial gliomas were treated with 2 mg/kg/day for one week. By day 60,
only one of fourteen control mice had survived, whereas four out of seven UCN-01treated mice survived until day 90.

The in vivo mechanism by which UCN-01 can inhibit tumor growth was examined using
two implanted pancreatic cancer lines (PAN-3-JCK and CRL 1420) and the breast cancer
line MX-1 (Abe et al., 2001). The two pancreatic lines were potently inhibited by 5
mg/kg UCN-01, while MX-1 was unaffected. The pancreatic lines had increased levels
of p21 and decreased cdk2 activities. The cells were arrested in G1, and an increase in
apoptosis was noted as well. The levels of p27 were not affected by UCN-01.
Interestingly, the resistant MX-1 line was demonstrated to have a baseline cdk2 activity
more than 6 fold higher that the two responsive lines, leading to the conclusion that the
balance between kinases and their acitvator/inhibitors plays a key role in determining
response to UCN-01. A later study examining implanted MX-1 cells as well as two other
breast carcinomas (MCF-7 and Br-10) had similar findings (Koh et al., 2002). 7.5
mg/mkg UCN-01 was effective in inhibting the in vivo growth of the Br-10 and MCF-7
lines, but MX-1 was again resistant. At this dose, p21 was induced in all three tumors,
but only the responsive ones exhibited decreased Rb phosphoryation; MX-1 showed little
change in Rb. UCN-01 also demonstrated antitumor activity against HN12 (HNSCC)
implanted in mice (Patel et al., 2002). 7.5 mg/kg/day for five days in these xenografts
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models abolished tumor growth. Analysis of tumor tissue following UCN-01
demonstrated increased apoptosis versus vehicle-treated tumors as measured by TUNEL
assay. In addition, p27 levels were elevated and cyclin D levels diminished in the UCN01 treated tumors. Unlike the in vitro studies on HNSCC lines, no changes in p21 were
observed after UCN-01 injection.

A different study demonstrated the efficacy of the combination of UCN-01 and a second
inhibitor, PD184352 (and inhibitor of MEK1 and MEK2), in implanted MDA-MB231
and MCF-7 tumors (Hawkins et al., 2005). Treatment with either agent alone for two
days had minimal effect on the implanted tumors, but the combination of 25 mg/kg
PD184352 and 0.2 mg/kg UCN-01 greatly reduced the growth of MDA-MB231 tumors
and completely eradicated MFC- tumor growth. Reduced growth potential correlated
with an increase in apoptosis at both 5 and 30 days post-treatment. This study is in
agreement with a similar report using PD184352 with UCN-01 to treat both implanted
MDA-MB231 and MCF-7 tumors (Hamed et al., 2008). The combination treatment
significantly retarded tumor growth compared to either agent alone. In addition, Ki-67
immunoreactivity was completely abolished and CD31 reduced, indicating growth arrest
and reduced angiongenesis. Further experimentation with radiation and the drug
combination revealed that while radiation during the drug treatment course encompassed
no increase in cytotoxicity, irradiating the tumors 24 hours after the cessation of drug
treat significantly increased cell death within the tumors, indicating a sequencedependent radiosensitization effect.
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The Akt-PDK1 survival pathway, which has been previously implicated in some cell
lines as a possible modulator of UCN-01 activity, has also been shown to be affected by
UCN-01 in vivo (Sato et al., 2002). Mice transplanted with either the murine colon
carcinoma line NL-17 or the human prostate PC-3 line were treated with 6-13.5 mg/kg
UCN-01 i.p. for one or four hours. After tumor harvest, the authors found both decreased
levels of PDK1 and PDK1 kinase activity. However, conflicting reports about the
potential effects of UCN-01 on this pathway make the importance of this finding
questionable. The ultimate effects of UCN-01 on tumors were not further explored, and
the factor(s) that determine whether tumors apoptose, undergo growth arrest or remain
unaffected is not currently understood. The studies here are summarized below in Table
5.

UCN-01 in the clinic (Table 6)
UCN-01 has been utilized in clinical trials, initially as a single agent to attempt cause
apoptosis in refractory tumors and/or arrest tumor growth. Much more frequently, UCN01 has been used in combination with cytotoxic drugs, either simultaneously or
subsequently, to abrogate the G2 checkpoint response in damaged cells and force them
into mitotic catastrophe or apoptosis. The trials using UCN-01 alone to suppress tumors
and/or cause tumor-specific apoptosis were an attempt to translate previous studies (see
above) into meaningful clinical outcomes. The Phase I trials using UCN-01 as a single
agent will be discussed first; Phase I trials combining UCN-01 with other agents will be
detailed next, followed by the Phase II trials.
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Table 6: Clinical Trials of UCN-01
Study Reference

Study Design

Dosing Schedule

(Sausville et al.,
2001)

Multiple dose, phase
I trial in cancer
patients
Multiple dose, phase
I trial in cancer
patients

Single 72 hour
infusion of 5.4 – 53
mg/M2
1-5 cycles of 1-3
hour infusion of 3 –
95 mg/M2 given
every 28 days
5-FU: weekly 24
hour infusion, 250 –
2600 mg/M2

(Dees et al., 2005)

(Kortmansky et al.,
2005)

(Lara et al., 2005)

(Perez et al., 2006)

(Edelman et al.,
2007)

(Hotte et al., 2006)

Multiple dose
combination phase I
trial in cancer
patients

UCN-01: 72/36
hour infusion of
135/67.5 mg/M2
every 28 days
Cisplatin: 1 hour
infusion 20 – 75
mg/M2

Multiple dose
combination phase I
trial in cancer
patients

UCN-01: 72 hour
infusion of 45
mg/M2/day
Cisplatin: 20-30
mg/M2 22 hours
prior to

Multiple dose
combination phase I
trial in cancer
patients

UCN-01: 34-45
mg/M2/day over 72
hours
Carboplatin: 2-5
AUC for 1 hour
prior to

Multiple dose
combination phase I
trial in cancer
patients

UCN-01: 50/25 –
90/45 mg/M2/day
over 72 hours
Topotecan: 0.75 – 1
mg/M2/day X 5 days

Multiple dose
combination phase I
trial in cancer
patients

UCN-01: 70/35 –
90/45 mg/M2 over 3
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Status
(enrolled)
Completed
(n=47)
Completed
(n=24)
Completed
(n=35)

Early Closure
(n=10)

Completed
(n=7)

Completed
(n=23)

Completed
(n=33)

Table 6 continued
(Jimeno et al., 2008)

(Kummar et al.,
2009)

(Sampath et al.,
2006)

Multiple dose
combination phase I
trial in cancer
patients

Multiple dose
combination phase I
trial in cancer
patients
Multiple dose
combination phase I
trial in cancer
patients

(Rini et al., 2004)

Single dose phase II
trial in renal cell
carcinoma patients

(Welch et al., 2007)

Single dose
combination phase
II trial in ovarian
cancer patients

NCI-04-C-0173

hour infusion every
21 days
Irinotecan: 60 – 90
mg/M2 on days 1&8

Completed
(n=16)

UCN-01: 50/25 –
90/45 mg/M2 for 3
hour infusion every
21 days
Prednisone: 60
mg/M2/day X 5 days

Completed
(n=15)

UCN-01: 17 – 34
mg/M2/day for 72
hours on days 3-5
Ara-C: 1 – 1.5
g/M2/day for 4 days

Completed
(n=13)

UCN-01: 45
mg/M2/day for 3
days
90 mg/M2/day for 3
days initial; 45
mg/M2/day
subsequent cycles of
21 days
Topotecan: 1
mg/M2/day days 1-5
UCN-01: 70/35
mg/M2/day for days
1-3, each cycle 21
days
UCN-01 72 hour
infusion every 28
days

Phase II trial in
lymphoma patients
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Completed
(n=21)

Completed
(n=29)

Ongoing

Phase I trials using UCN-01 as a single agent
In a phase I trial utilizing UCN-01 as a single agent, 47 patients with refractory tumors
(10 renal cell carcinoma, 8 NSCLC, 7 non-Hodgkin’s lymphoma, 4 colorectal, 4
melanoma, 3 leiomyosarcoma, 2 prostate, 2 head & neck, 2 Hodgkin’s, and five
unspecified) were given 1.8 – 53 mg/M2/d UCN-01 over a 72 hour period; the rationale
was based on an in vitro study (Seynaeve et al., 1993) in which the breast cancer cell line
MDA-MB-468 required exposure of 72 hours to become irreversibly growth arrested
(Sausville et al., 2001). The initial treatment plan had called for the doses of UCN-01 to
be re-administered every 2 weeks. However, patients receiving the three lowest doses
(1.8, 3.6 and 6 mg/M2/d) exhibited extremely long drug half-lives, ranging from 4471176 hours. This unexpected result was determined to be caused by extremely tight
binding to the human serum protein α1-acidic glycoprotein (hAGP); this binding
decreases both the clearance of UCN-01 and unbound fraction of UCN-01 in plasma
(Sausville et al., 1998).
This complication caused the treatment schedule to be amended from every two weeks to
every four weeks for the higher doses (12-53 mg M2/d). The subsequent doses were also
given over a 36-hour period instead of the initial 72 hours. UCN-01 was generally well
tolerated, with no dose limiting toxicity (DLT) until 34 mg/M2/d, and only one of eight
patients treated at the 45 mg/M2/d dose experienced DLT. Patients receiving 53 mg/M2/d
experienced both hyperglycemia and pulmonary toxicity, and this dose was not
recommended for further study. All patients experienced at least transient
hyperglycemia, which was attributed to peripheral tissue insulin resistance. Insulin
treatment resolved most cases of hyperglycemia. It is believed that UCN-01 inhibits
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glucose transport activity by inhibiting the phosphorylation of Akt at threonine 308,
leading to the hyperglycemia observed in the patients (Kondapaka et al., 2004). The
response to treatment was small; 25 had disease progression within 2 months of
treatment, 19 had stable disease, and one melanoma patient displayed a partial response
for 6 months. One interesting patient had recurrent large-cell lymphoma and was treated
with UCN-01 and adenopathy following radiation treatment. The patient displayed no
disease progression after 38 months of UCN-01 treatment at a dose of 24 mg/M2/d.

Another phase I trial utilizing UCN-01 as a single agent enrolled 24 patients with
refractory solid tumors (9 colorectal, 4 prostate, 3 cervical, 2 kidney, 2 breast, and one
each of gastric, lung, leiomyosarcome, and unknown primary adenocarcinoma) (Dees et
al., 2005). Patients were given UCN-01 as a 1-3 hour infusion from 3-95 mg/M2.
Hypotension was the DLT at the 95 mg/M2 dose. As in the previous study, mild to
moderate hyperglycemia was seen in many patients, 14 out of 22 receiving ≥ 12 mg/M2.
No treatment responses were seen in this study. 21 patients displayed tumor progression
following 1-5 courses of UCN-01 treatment, 2 were removed from the study for toxicity
concerns, and one patient had stable disease for one year.

Phase I trials of UCN-01 used in combination therapy
The use of UCN-01 in combination with a cytotoxic drug appeared more frequently than
the single agent trials. These studies all attempted to use UCN-01 to abrogate the G2
DNA-damage checkpoint response following an initial treatment with a cytotoxic drug.
The rationale for this method is that inhibition of the arrest/repair pathways
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(predominantly by inhibition of chk1) would prevent the tumor cells from undergoing
cell cycle arrest in response to an initial toxic repairing damage and force damaged cells
through mitosis and ultimately cell death.

A phase I trial of UCN-01 combined with fluorouracil was conducted on 35 patients, 21
of which were diagnosed with metastatic colon cancer (Kortmansky et al., 2005). The
treatment plan followed called for weekly doses of fluorouracil (250 – 2600 mg/M2);
UCN-01 was given once every four weeks, immediately after cessation of fluourouracil
administration. UCN-01 was given at 135 mg/M2 for the initial dose, and 67.5 mg/M2 for
subsequent doses. The treatment plan was set up to mimic the synergism seen in the in
vitro study by Hsueh, et al., in which gastric cancer cells treated first with fluorouracil
followed by UCN-01 demonstrated apoptosis in 46% of the cells, versus 4% for
fluorouracil alone and 17% for UCN-01 followed by fluorouracil (Hsueh et al., 1998).
The in vivo treatment regimen was tolerated well by most patients, with one DLT at 560
mg/M2 fluorouracil, one at 845 mg/M2, and one at 1900 mg/M2. No DLT was observed
at the highest fluorouracil doses, 2527 and 2600 mg/M2. Of 32 patients assessable for
response to the treatment regimen, no positive response to the treatment was observed,
although 8 patients had stable disease. UCN-01 did not affect the pharmacokinetics of 5FU (completely cleared within the first hour of UCN-01 administration), and the
concentration of 5-FU had no effect on the plasma concentrations of UCN-01. The
authors felt that the treatment was safe, and planned a Phase II trial using 2600 mg/M2 5FU in combination with UCN-01.
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Another phase I trial combined cisplatin with UCN-01 treatment on ten patients with
advanced, malignant solid tumors (2 NSCLC, 2 soft tissue sarcoma, and one each on
esophageal, head & neck, pancreatic, melanoma, gastric, and unknown primary
adenocarcinoma cancer patients) (Lara et al., 2005). Previous in vitro work examining
the actions of UCN-01 plus cisplatin against glioma and NSCLC cells had indicated
synergism between these two agents when UCN-01 was used secondarily (Mack et al.,
2003; Pollack et al., 1996). The dose escalation scheme for the clinical study called for
cisplatin to be administered at five dose levels from 20-75 mg/M2; cisplatin was to be
given over a 2 hour infusion, followed 22 hours later by 45 mg/M2 UCN-01. The first
dose level (20 mg/M2 cisplatin) exhibited one DLT of grade 3 hypoxia; the other five
patients in this cohort had no adverse events. At the next dose (30 mg/M2 cisplatin), one
patient experienced grade 5 sepsis along with respiratory failure, and another presented
with grade 3 atrial fibrillation. Grade 3 hypoxia, dysphagia, renal failure and
hyponatremia were also observed at this dose, and the trial was ended due to toxicity.
The authors were optimistic that alternative platinum agents could be used, but concluded
that the UCN-01/cisplatin combination was too toxic for use in patients.

A second trial treating seven patients (5 melanoma, one bladder carcinoma, and one
thyroid carcinoma) using UCN-01 with cisplatin also found this limiting toxicity; using
the treatment regimen above, with the exception of a one-hour cisplatin infusion (rather
than two), the first two patients receiving 20 mg/M2 cisplatin followed by 45 mg/M2/d
UCN-01 experienced grade 3 and 4 limiting toxicities, including subarachnoid
hemorrhage, cardiac ischemia, hypoxia and hyperglycemia (Perez et al., 2006).
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However, it was found that decreasing the UCN-01 administration from 45 to 34
mg/M2/d allowed the remaining five patients to tolerate either 20 mg/M2 or 30 mg/M2
cisplatin with no DLT. An interesting aspect of this study was data collected on biopsies
stained for geminin via IHC. Geminin is a protein expressed only in S and G2 phases of
the cell cycle, and is believed to function as a preventer of DNA re-duplication
(Tachibana et al., 2005). This group had previously demonstrated in vitro that cells
undergoing DNA damage and subsequent G2 arrest stain positive for geminin using the
active metabolite of irinotecan, SN38 (Eastman et al., 2002). In patient biopsies, geminin
was increased following cisplatin administration, and then markedly decreased after
subsequent UCN-01 treatment, indicating that UCN-01 is inhibiting the G2 damage
checkpoint and allowing progression through mitosis. Of the seven patients, four only
received one cycle of therapy and were not evaluated for impact on disease progression;
the three remaining patients received two cycles of treatment, and all had progressive
disease. The authors are currently continuing this area of study with a new trial, using a
revised 3-hour infusion of UCN-01; results of this study are as of yet unavailable.

The platinum agent carboplatin has also been evaluated clinically in combination with
UCN-01 (Edelman et al., 2007). This Phase I trial included patients with the following
cancers: NSCLC (10), small cell lung (3), bladder (2), head & neck (2), and one each on
adrenotcortical carcinoma, esophagus, gastric, adenoid cystic, pancreatic, and unknown
primary carcinoma. Carboplatin was administered from an area under the curve (AUC,
mg/mL min) of 2.5-5 over a one-hour infusion, followed by UCN-01 from 50-90 mg/M2
given over three hours. Each treatment cycle was 21 days long, and up to six cycles were
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allowed per patient. The second and all subsequent UCN-01 doses were 50% of the
initial dose. 23 patients were enrolled in the study, and no DLT toxicity was observed; 6
patients were treated at the highest dose level (carboplatin AUC 5, UCN-01 90 mg/M2).
No tumor response was observed, but seven patients did exhibit stable disease. Two of
the small cell lung cancer patients, whose tumors were chemotherapy-refractory, were in
this category, and the authors suggest further exploration of combination therapy for
small cell lung cancer. It was also noted that the active metabolites of irinotecan were
decreased upon UCN-01 administration. As these products are inhibited by the
cytochrome P450 CYP3A4, it was unexpected that UCN-01 somehow presumably
inhibited the CYP3A4 pathway. The specifics of UCN-01 and its effects on irinotecan
metabolism are poorly understood.

UCN-01 was used in one phase I trial in combination with topotecan; this trial was
somewhat different that the others, in that UCN-01 treatment preceded the administration
of the cytotoxic drug (Hotte et al., 2006). Preclinical data indicated that UCN-01 and the
topoisomerase inhibitor synergistically killed tumor cells, and that the order of
administration of the two drugs was unimportant for this result (Monks et al., 2000; Tse
and Schwartz, 2004). 33 patients were enrolled with the following malignancies: 20
ovarian neoplasm, one ovarian epithelial cancer, three colorectal cancer, two peritoneal
neoplasm, two salivary gland cancer, and one each of cervical carcinoma, endometrial
cancer, renal pelvic cancer, cervical squamous cells carcinoma, and one unspecified solid
tumor. Topotecan and UCN-01 were administered to 33 patients on a 21-day cycle: on
day one, UCN-01 was given over 3 hours, followed by a 30 minute topotecan infusion.
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Topotecan only was then given on days 2-5. Three dose levels were given, with no dose
escalation. Dose 1 utilized 70 mg/M2 UCN-01 for the first dose, 35 mg/M2 for
subsequent doses, and 0.75 mg/M2 topotecan. Dose 2 used the same UCN-01 amounts
with 1.0 mg/M2 topotecan. The third dose group received a primary dose of UCN-01 of
90 mg/M2 and then 45 mg/M2 subsequently plus 1.0 mg/M2 topotecan. Dose 2 was well
tolerated, with one grade 3 neutropenia. The third dose group experienced one grade 4
febrile neutropenia, and thus the second dose group was considered the MTD for this
protocol. The response in this study to the treatment regimen was more positive than that
seen in previous studies, especially for ovarian cancer patients. Two out of three patients
in dose 1 had stable disease, and 8 of 13 at dose two had stable disease, one with a partial
response. This work led to a phase II study of ovarian cancer patients with advanced
disease at the same facility (see phase II section below, Welch et al., 2007).

The topoisomerase inhibitor irinotecan was also evaluated in combination with UCN-01
in a Phase I clinical trial (Jimeno et al., 2008). Sixteen total patients with incurable solid
tumors (four colorectal, three pancreatic, and one each of the following tumor types:
biliary, duodenal, hepatocellular, tongue base, mesothelioima, thyroid, overy, skin
(Merkel), and unknown primary adenocarcinoma) were accrued in the study, fourteen of
which could be evaluated for response. The treatment plan used four dose levels of
irinotecan and UCN-01 (50/60, 70/60, 90/60 and 70/90 mg/M2 of UCN-01/irinotecan
respectively); irinotecan was administered as a one-hour infusion on day one,
immediately followed by UCN-01 over three hours. Irinotecan was given again on day 8,
and the cycle lasted for 21 days. Two of four patients experienced a DLT at the third
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dose level, and two out of five had a DLT at the fourth dose level. One patient had
progressive disease following one cycle, as did seven others when evaluated after two
cycles. The other six patients had stable disease, and four were able to receive ten or
more treatment cycles.

Predinosone was also evaluated in a Phase I trial in concert with UCN-01 in patients with
refractory solid tumors and lymphomas (Kummar et al., 2009). Three dose levels were
used: level 1 used 51 mg/M2 UCN-01 for the initial cycle, level 2 used 72 mg/M2, and
level 3 102 mg/M2. The initial cycle was given over days 3-5. Each additional cycle
used 50% of the initial UCN-01 dose, given over 36 hours. Each cycle was for 28 days,
and prednisone was given orally on days 1-5 at 60 mg/M2daily. Fifteen patients were
enrolled in the study, and a total of 55 treatment courses were undertaken. Two of the six
patients at dose level 3 experienced DLT, including grade 3 hyperglycemia,
hyponatremia, and leucopenia, and were dropped to dose level 2. No tumor response to
treatment was observed. Five patients had stable disease for longer than 2 cycles, and
two patients had stable disease for 8 and 18 months.

A phase I trial of UCN-01 in combination with cytarabine (ara-C) was carried out in
patients with relapsed acute myelogenous leukemia (AML) following some promising
results using this combination in the leukemia cell line ML-1 and primary AML blasts
obtained from patients (Sampath et al., 2006). It was demonstrated that ML-1 cells were
able to survive ara-C treatment by undergoing an S-phase arrest, via activation of Chk1.
Subsequent UCN-01 was able to abrogate this arrest, as well as prevent the activation of
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Akt and its downstream survival pathways (Figure 3). Primary blasts treated with ara-C
followed by UCN-01 also demonstrated reduced survival. A clinical trial was undertaken
to evaluate this treatment scheme, in which patients were first given ara-C over 4 days at
1.0 mg/M2/d followed by 45 mg/M2/d starting on day 2; this was done for 11 patients.
Two additional patients received 1.5 mg/M2/d ara-C, with the same UCN-01 given on
day 2. Blasts were collected from patients during the course of therapy to monitor the
effects on the S-phase checkpoint and the Akt/Jnk survival pathways. Unlike the cell
culture samples examined previously, the pretreatment patient blasts had significant
levels of phospho-Chk1 (Ser345) and also the inhibited form of cdk2 (phospho-Tyr15); as a
result, few of the circulating blasts were actively cycling. Levels of both phosphoproteins were diminished upon both ara-C treatment and also after subsequent UCN-01,
but in a very heterogenous manner; 2 samples showed less than 10% of initial phosphoChk1 after UCN-01, while another sample registered no effect due to UCN-01
administration. The ratios of phospho-Akt to total Akt were similarly varied, and were
unaffected by ara-C, but 7 out of 8 samples exhibited loss of phospho-Ser345 due to UCN01 treatment. The combination treatment resulted in only one complete response out of
the thirteen patients receiving treatment. While this was a disappointing response rate,
the presence of phospho-Akt and inhibited cdk2 in this previously treated and relapsed
patient group does give hope that a naïve population would better respond to this
treatment regimen.

Phase II trials utilizing UCN-01
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A phase II trial of UCN-01 as a single agent was initiated in a population of renal cell
carcinoma (RCC) patients (Rini et al., 2004). Most clear cell renal carcinoma tumors
have mutated von Hippel-Lindau (VHL) genes; the inactive VHL gene is unable to
suppress the expression of the tumor promoter VEGF (vascular endothelial growth
factor), presumably through lack of suppression of PKC (Gnarra et al., 1994; Herman et
al., 1994; Nishizuka, 2001; Pal et al., 1997). As a potent PKC inhibitor, it was hoped that
UCN-01 would help inhibit this process. 21 patients were enrolled in this study. UCN01 was given at an initial dose of 90 mg/M2, and then subsequently 45 mg/M2 every 21
days. Treatment was well tolerated, with hyperglycemia the only grade 3 toxicity
observed. All cases of hyperglycemia were successfully managed. The trial was halted
after four months (6 treatment cycles), as only 7 of the 21 patients exhibited stable
disease. No response was seen, and the authors concluded that this treatment regimen
was not effective in RCC.

Using previous Phase I data (Hotte et al., 2006), a Phase II trial for recurrent ovarian
cancer combining UCN-01 with topotecan was undertaken. Patients were treated with
the dose 2 regimen (1 mg/M2/day topotecan for five days, with 70 mg/M2 UCN-01 on
day 1 for the first cycle; UCN-01 was cut to 35 mg/M2 in subsequent cycles) from the
phase I trial (Welch et al., 2007). The expected toxicities of hyperglycemia and
leucopenia were observed, but none precluded treatment continuation. However, the
results were not encouraging. Of the 19 patients treated in the first stage of the protocol,
only one responder was observed. As the expected response for topotecan as a single
agent in ovarian cancer is 10-15%, the study was halted. While it may be possible that
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the co-administration of the two drugs (rather than topotecan followed by UCN-01) may
interfere with the actions of topotecan, the authors did not feel that this combination
would be appopriate for further study in the ovarian cancer setting.

A current Phase II study on UCN-01 in lymphoma patients is in progress (NCI-04-C0173).

Summary of UCN-01 in clinical trials
With the exception of the initial ovarian cancer study, the clinical data to date utilizing
UCN-01 as a chemosensitizer and/or tumor suppressor has been disappointing. Although
the patient populations used are not ideal (patients with no prior exposure to
chemotherapeutics and presumably harboring less resistant tumors might have better
responses), it was to be expected that a better response would have been observed in
some of the trials. The trials reported are summarized in Table 6 below. For Phase I
trials using UCN-01 alone, 71 patients were treated, leading to 20 cases of stable disease
and 2 partial responders. For Phase I trials using combination therapy, 152 total patients
led to only 46 cases of stable disease (some for as little as 6 weeks) and 3 responders. 40
patients enrolled in the reported Phase II trials had 1 responder and 7 patients with stable
disease. The six responders across theses studies do not share any obvious
commonalities; no overlap in disease types or dosing (UCN-01 levels vary as well across
the responsive patients) exist among them. It may be possible that the course of therapy
received prior to UCN-01 treatment may be similar, but this information is not included
in the reported data. It is also possible the specific malignant alterations in these tumors
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are similar, thus potentiating the ability of UCN-01 to invoke a response. The lack of
molecular characterization of the tumors in most of the clinical work makes this theory
difficult to pursue as well. If the nature of the cell cycle defect(s) in specific tumors were
known prior to treatment, it would likely improve the success of therapy using UCN-01.
Tumors with at least a partial impairment of the DNA damage response would likely be
unable to survive a combination treatment (DNA-damaging agent followed by UCN-01),
while tumors with complete or partial G1 checkpoint integrity would be more likely to
respond to UCN-01 as a single agent.

UCN-01 and Normal Cells
One aspect of the UCN-01 has received little attention, specifically that of its effects on
normal cells. Only one published report focuses on the effects of UCN-01 on the normal
tissues of the mouse, specifically the hyperproliferative bone marrow and gut epithelium
(Redkar et al., 2001). C57BL/6 mice were injected with 0-10 mg/kg UCN-01 for either 3
or 24 hours; 20 mg/kg was lethal in these mice. Analysis of BrdU incorporation in small
intestinal epithelial cells demonstrated a significant inhibition of proliferation at both 3
and 24 hours following the 5 mg/kg UCN-01 dose in all three small bowel tissues,
duodenum, jejunum and ileum; colon was not affected. The 10 mg/kg dose was not able
to inhibit cell proliferation, possibly indicating a pleiotropic, dose-dependent effect of
UCN-01. Flow cytometric analysis of harvested bone marrow cells from these mice
showed a G1 arrest at the 5 mg/kg dose; as before the 10 mg/kg dose did not induce the
same effect. Further work on bone marrow cells recovered from naïve mice also noted an
interesting feature of UCN-01. Simultaneous treatment of these cells with UCN-01and
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the topoisomerase I inhibitor topotecan led to a less-than-additive growth inhibition
compared to either agent used alone. This antagonism between a cytotoxic drug and
UCN-01 is an indicator that UCN-01 may be used in vivo to protect normal dividing cells
from toxicity.

Another in vivo study which examined the effects of UCN-01 in concert with
chemotherapy or fractionated radiation also lends credence to the treatment protocol
proposed below. Implanted murine fibrosarcoma (FSa-II) tumors treated with UCN-01
and γ irradiation were significantly growth-retarded compared to radiation treatment
alone (Tsuchida and Urano, 1997). However, the combination of UCN-01 and cisplatin
was not any more effective than cisplatin alone. Addition of UCN-01 to fluorouracil 5FU) was also had no effect on tumor growth compared to 5-FU alone. Survival analysis
of the FSa-II cells grown in culture also showed no syngerism of UCN-01 and cisplatin,
and 5-FU plus UCN-01 had an effect that was less than additive, suggesting a protective
action of UCN-01 in these cells.

Little else is currently known concerning the actions of UCN-01 on the normal tissues of
any organism, save for the toxicities explored in the clinical trials (see below) and a few
reports which have sought to explore the pharmacokinetics of UCN-01 and the influences
of its binding to AGP. The maximum tolerated dose (MTD) of UCN-01 in mice is 20
mg/kg via intravenous delivery and 10 mg/kg when injected subcutaneously (Hill et al.,
1994). The terminal exponential phase of elimination (t1/2β) following intravenous 10
mg/kg UCN-01 is 85 minutes, and the area under the plasma concentration-time curve

83

(AUC) is 117 µg/minutes/ml; the values for subcutaneous delivery are 130 minutes and
113 µg minutes/ml respectively, indicating that the two routes may have substantially the
same pharmacokinetics. This study also demonstrated that UCN-01 is stable in mouse
serum. A second report sought to examine the altered pharmacokinetics of UCN-01
reported in human trials and attributed to strong binding of the serum protein AGP
(Hedaya and Daoud, 2001). Rats were injected (i.v.) with either UCN-01 or UCN-01
plus 30 mg/kg human AGP, and plasma and tissue concentrations of UCN-01 were
determined from 30 minutes post-injection to 24 hours later. As expected, the presence
of AGP increased the plasma concentrations of UCN-01 by 5- to 7-fold, and reduced the
ratio of drug/tissue for all organs examined (brain, skeletal muscle, heart, liver, kidney,
spleen and lungs). The AGP binding of UCN-01 will be further explored in the
Discussion below. Pertinent to the project discussed in this work, the authors also
evaluated these parameters following intramuscular (i.m.) injection. While the
elimination and distribution kinetics were essentially the same as seen in the intravenous
study, this is the only publication that has detailed them following the i.m. route. The
authors found that UCN-01 delivered intramuscularly had approximately the same initial
plasma concentration as the i.v. delivery (240 ng/ml), and that UNC-01 was not
detectable in plasma by 14 hours post-injection.

Gap in Knowledge; UCN-01 as a protector of normal cells
The clinical studies discussed previously focused primarily on the use of UCN-10 to
enhance the toxicity of chemotherapeutic agents to eradicate tumors. In fact, as UCN-01
has been used in all of the reported clinical cases to either damage or suppress tumors,
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these studies do not exclude the possibility that UCN-01 could act as a protective agent
for normal dividing cells. The effects of UCN-01 seem to be highly dependent upon both
the dose administered and the cell cycle status of a particular cell. The clinical trials use
very high doses of UCN-01 (up to 135 mg/M2), whereas the levels of UCN-01 used as a
protective agent would be much lower. The mouse protection study proposed in this
thesis utilizes a much lower dose range (0.63-5.0 mg/kg, approximately equivalent to
1.26-10 mg/M2). This low dose of UCN-01 would presumably target only normal
proliferating cells. Another concern is the binding of UCN-01 to hAGP and the altered
pharmacokinetics that ensue. While this is not expected to complicate the mouse study,
any clinical translation will have to account for this phenomenon to keep the unbound
fraction of UCN-01 within the effective range for a reversible G1 arrest. One possible
solution would be the use of liposomes to deliver the drug to the target cell populations.
Recent reports indicate some success using these vehicles to prevent hAGP binding in the
bloodstream and to control the release rate of UCN-01 (Yamauchi et al., 2005; Yamauchi
et al., 2008). The plasma protein binding of UCN-01 and the clinical implications of this
property will be further explicated in the discussion section below.

The work described in this thesis explores the use of UCN-01 in protecting normal
dividing cells of the mouse from the toxicity of chemotherapy. The rationale for this
approach is based on the in vitro and in vivo work previously mentioned. It is known that
UCN-01 is able to temporarily arrest the normal dividing tissues (intestinal epithelia and
hematopoietic tissue) of the mouse in G1 (Redkar et al., 2001) and that no adverse effects
accompany this effect. It has also been shown that non-tumorigenic cells in culture
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(wild-type Rb) can be arrested in G1 with UCN-01, and that the cells can return to a
proliferative state once the drug has been removed (Chen et al., 1999). This state of
temporary arrest is protective from drugs (in this case camptothecin) which target
actively dividing cells (Chen et al., 2000). Tumor cells, which are not affected by this
dose of UCN-01, are not similarly protected. The ability of UCN-01-arrested normal
cells to evade the toxicity of chemotherapeutic agents will be evaluated in vivo in a
mouse model system.

The other aspect of UCN-01 which will be examined is the molecular changes in the
normal dividing tissues of the mouse following treatment. UCN-01 is a very
promiscuous compound, and the literature discussed above indicates many targets and
effects due to its use. However, the predominant setting for these studies has been in the
tumor environment, and as a result, there has been quite a variety of molecular changes
and cellular fates described. The focus here will be on normal dividing cells in the
mouse, and to better understand how UCN-01 affects these cells and causes an arrest in
the cell cycle.
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RESULTS Chapter I. Arrest and Recovery of Normal Cells by UCN-01

Introduction: Several studies discussed in the introduction which examined the actions
of UCN-01 in both cell culture and in mice indicate that the drug can arrest proliferating
cells, usually in G0/G1. This project attempts to exploit the arrest of normal cells to
protect them from chemotherapeutics which target dividing cells in an in vivo system
(Chen et al., 2000). In order to demonstrate the ability of UCN-01 to arrest normally
dividing cells in the mouse, we have chosen to examine the epithelium of the small
intestine of nude mice. This is a rapidly dividing tissue, in which cells are continually
replicating in the crypt and to replace the cells at the villus tip as they die and are shed
into the lumen. We have chosen to use the nude mouse in order to facilitate future
studies in which human xenograft tumor-bearing mice are treated with the UCN-01
protection protocol. The hypothesis to be evaluated in this section is: The normal
dividing cells of the mouse small bowel can be reversibly arrested by UCN-01
administration. In order to be able to exploit a cell cycle arrest to protect normally
dividing tissues, we must be able to show that UCN-01-mediated arrest is temporary, and
specifically when the cells enter into arrest and when they recover.
The cell cycle kinetics in the mouse small bowel were analyzed by flow
cytometry to identify changes due to UCN-01 treatment. Cell cycle arrest of the dividing
epithelial cells was demonstrated beginning 24 hours after UCN-01 administration, and
this arrest was shown to reverse two weeks after treatment. Additionally, an antagonistic
effect of the UCN-01 carrier DMSO was observed in the small intestine epithelial cells.
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However, this effect did not prevent the arrest and reversal of UCN-01 mediated cell
cycle arrest.

Material and Methods: Mice: Male and female nude mice from 8-12 weeks of age
(apprpoximately 24-30 grams) were obtained from the Experimental Radiation Oncology
colony at M.D. Anderson Cancer Center. Mice are maintained in the specific pathogen
free barrier facility on sterilized normal chow and water with no restrictions. UCN01/mock treatment: Mice were injected with UCN-01 or carrier (dimethyl sulfoxide,
DMSO, Sigma Aldrich, St. Louis MO) intramuscularly (i.m.) into the right hindlimb.
UCN-01 was obtained from the NCI Chemotherapeutic Agents Repository, and is
resuspended in DMSO at 7.5 mg/ml. Prior to injection, the UCN-01 solution is diluted
2:1 with sterile normal saline for a final concentration of 5 mg/ml. DMSO given as
vehicle control was diluted in the same fashion, and was given as a volume equivalent
dose. To obtain the normal mouse values for flow cytometry, mice either received no
treatment or were given volume equivalent PBS in the right hindlimb.

Bromodeoxyuridine (BrdU) labeling: Mice were sacrificed at one of five timepoints
following UCN-01/mock injection: 24 hours, 48 hours, and 7, 14 or 28 days. On the day
of sacrifice, mice were injected i.p. with 60 mg/kg BrdU (Sigma Aldrich, St. Loius MO)
six hours prior to sacrifice. Mice were staggered in injection and sacrifice times such that
each mouse had exactly six hours of BrdU exposure. Upon sacrifice, the jejunum was
dissected out and flushed with ice-cold ethanol (60% in PBS, both Fisher Scientific,
Pittsburgh, PA). A small piece was fixed in formalin (10%, Fisher Scientific), and the
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remainder fixed overnight in the 60% ethanol/PBS buffer. To prepare the tissues for flow
cytometry, the jejunums were opened longitudinally and placed on a glass microscope
slide. A second slide was dragged across the epithelial surface to dislodge the cells; care
was taken not to apply excess pressure and disrupt the basement membrane. The isolated
cells were placed in a 50 ml glass flask and resuspended in 5 ml of 0.04% pepsin (Fluka
chemical, obtained from Sigma Aldrich) and placed in a shaking water bath at 37ºC and
90 Hz for one hour. The cells were filtered through 35 µm mesh and centrifuged at 1200
RPM for 5 minutes in a swinging bucket centrifuge (Beckman Coulter, Brea CA). Cells
were resuspended in 1.5 ml of 2N HCl (Fisher Scientific) for 20 minutes in a 37ºC
incubator. The acid was neutralized with 3 ml 0.1M sodium borate (Sigma Aldrich) and
the cells were again centrifuged at 1200 RPM for 5 minutes. The cells were washed with
5 ml of PBTB (phosphate-buffered saline plus 0.5% Tween-20 (Sigma Aldrich) and 0.5%
bovine serum albumin (Fisher Scientific)) and centrifuged at 1200 RPM for 5 minutes.
Samples were resuspended in primary anti-BrdU antibody (IU-4, Caltag, Burlingame
CA) diluted 1:100 in PBT (phosphate-buffered saline plus 0.5% Tween-20) for 60
minutes. Samples were washed in 5 ml of PBTB and centrifuged at 1200 RPM for 5
minutes. Samples were resuspended in 0.2 ml of secondary antibody ( goat anti-mouse
fluorescein isothiocyanate (GAM-FITC), Beckman Coulter, Brea CA) diluted 1:100 in
PBTG (PBT with 2% normal goat serum) for 60 minutes, then washed in PBTB and
centrifuged at 1200 RPM for 5 minutes. Samples were then suspended in propidium
iodide solution (1 mg/ml PI (Roche, Branford CT) in 95% ethanol diluted 1:100 in PBT)
and stored at 4ºC overnight.
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Flow Cytometry: Intestinal digests were analyzed using a Beckman Coulter flow
cytometer. An example of the output of the bivariate analysis is shown in Figure 4.
DNA content (PI, x-axis) and BrdU-positive nuclei (log BrdU, y-axis) are both counted
and exported to the ModFit LT program (Verity software, Topsham ME). Labeling index
is calculated by dividing the number of BrdU-positive nuclei by the total number of
nuclei analyzed. The fraction of labeled divided cells (fld) is the number of BrdU-positive
nuclei which are in G1 phase divided by the total number of nuclei counted (upper left
box, Figure 4). The fraction of labeled undivided cells (flu) is the number of BrdUpositive nuclei which correspond to the S and G2/M phases of the cell cycle divided by
the total number of cells analyzed. A complete explication of the flow analysis
parameters and other values which may be calculated can be found in a recent methods
article (Terry and White, 2006)

Immunohistochemistry: Jenunum sections were embedded in paraffin and 5 µM sections
were cut onto superfrost/plus slides (Fisher Scientific). To visualize BrdU in the
sections, slides were processed as for IHC. Slides were hydrated in 3 washes of xylene
(Fisher Scientific) for five minutes each, and then 3 minutes each of 100%, 90% and 70%
ethanol. Slides were washed for five minutes in water, and then digested in 0.1%
protease (Sigma Aldrich) for one hour. Slides were washed twice for five minutes in
PBS and placed into 2 normal hydrochloric acid for fifty minutes. The acid was
neutralized in 0.1 M sodium borate. Slides were washed twice in PBST (PBS plus 0.5%
Tween 20, Sigma Aldrich) for five minutes and then blocked in normal horse serum
(Vector Labs, 3 drops in 10 ml PBST) at 37º for thirty minutes in a humidified chamber.
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Figure 4. Typical output for bivariate analysis of mouse jejunum
after 6 hours of BrdU labeling. The large upper box gates all cells positive
BrdU (y-axis). The x-axis represents propidium iodide (PI), and cells are
sorted by DNA content; the first large population (1) is G1/G0 cells,
the second large population is G2 (2). The cells in between the two are
in S phase. The small box on the upper left (3) delineates the fraction of
labeled, divided cells (fld), which are BrdU positive cells which have gone
through mitosis. The upper left box (4) represents the BrdU positive cells
which have yet to divide (fraction of labeled, undivided cells, flu).
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The slides were incubated with primary IU-4 antibody (1:100 in PBST) for one hour in a
humidified chamber at 37ºC. After two five-minute washes in PBST, the slides were
incubated with secondary GAM-FITC (1:100 in PBST plus 1% normal goat serum) for
one hour at 37ºC in a dark humidified chamber. After two washes of five minutes each in
PBST, the nuclei were stained with 0.1 µg/ml Propidium iodide (Sigma Aldrich) for
fifteen minutes. Slides were mounted in antifade medium (Vectasheild, Vector Labs,
Burlingame CA) and sealed with a glass coverslip.

Microscopy: BrdU was visualized on stained jejunum sections using a Leica DM400B
(Wetzlar, Germany) fluorescent microscope. Images were taken using a Spot digital
camera and Spot Advanced software (Spot Imaging Solutions, Sterling Heights MI).

Statistics: Pairwise comparison of means was performed using Student’s t-test; a
confidence level of 95% was considered to be statistically significant in these studies.
All calculations were performed using the Prism software package (GraphPad Software,
Inc.).

Results:
Initial dose range study for UCN-01 in mouse jejunum:
The results from the study by Redkar et. al. (Redkar et al., 2001) demonstrated that the
proliferating tissues of the mouse (intestinal epithelium and bone marrow) could be
arrested by UCN-01 at doses of 5 and 10 mg/kg. In order to establish the efficacy of this
arrest in our mouse model system, an initial pilot study was performed (Figure 5). Nude
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Figure 5. Flow cytometric analysis of mouse jejunums harvested 48 hours
after treatment with 10 mg/kg UCN-01 (n=6), 0.63 mg/kg UCN-01 (n=5) or
DMSO control (n=5). (A) Fraction of labeled divided cells (fld) was significantly
decreased in the 10 mg/kg UCN-01 group compared to vehicle (*, p<0.05).
The 0.63 mg/kg UCN-01 group was not significantly lower than DMSO
control (p=0.0516). (B) Percentage of all BrdU-labeled cells which have
divided. No change is evident after treatment with UCN-01, suggesting the
decrease in Fld in (A) is not due to a block in G2/M phase, but rather
a decrease in cells entering S phase. [Calculation: (Fld/2)/(Flu+ Fld/2)]
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mice were injected with DMSO control (n=5), 0.63 mg/kg UCN-01 (n=5), or 10 mg/kg
UCN-01 im. 48 hours after treatment, the mice were injected with BrdU and sacrificed
six hours later. Jejunum was harvested and fixed overnight for flow cytometric analysis.
The six-hour BrdU labeling of the mice allows time for some proliferating cells which
incorporate label in S phase and pass the label through G2 phase and mitosis. This
population of cells is termed the fraction of labeled, divided cells (fld). The visual
representation of this population is shown in Figure 4 by arrow 3. A complete
description of the parameters measured by the flow analysis is described in the Materials
and Methods section above. A decrease in fld cells is indicative of a decrease in cells
progressing through the cell cycle. As shown in Figure 5, the 10 mg/kg UCN-01 treated
mice had a significantly lower fld value than the DMSO vehicle control group. The 0.63
mg/kg UCN-01 mice also had a lower fld compared to controls, but the difference was not
statistically significant (p=0.0516). Our results are in agreement with the previous report
(Redkar et al., 2001), and it appears that UCN-01 at either concentration used in this
experiment is able to arrest the proliferating cells of the nude mouse small intestine.

Baseline fld for untreated mice:
While it is clear from the study in Figure 5 that DMSO is not causing the decrease in cell
proliferation seen in the jejunum of UCN-01 treated mice, we felt it was important to
establish a baseline fld value for untreated mice. To this end, mice were either injected im
with PBS (n=7) or left untreated (n=9). 48 hours later, BrdU was injected and mice
sacrificed six hours later. Flow cytometric analysis (Figure 6) demonstrated no
significant difference between the two groups. However, the combined values for the
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Figure 6. Flow cytometric analysis of mouse jejunums 48 hours after
im injection of PBS (volume equivalent to 5 mg/kg UCN-01 treatment,
n=7) or null (no treatment, n=9). The two groups were not significantly
different (p=0.378), and the mean fld for all control mice is 0.99%.
The pooled values of fld for the null and PBS treated mice are
significantly different from the DMSO treated mice (p=.0073)
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“untreated” mice in this experiment are significantly different from the value of the
DMSO mice (Figure 5), which is also included in Figure 6 for comparative purposes.
The mean fld value for all mice in this experiment was 0.99%. This will be used as the
baseline untreated value for the rest of the studies in this section. It is also important to
note that DMSO appears to stimulate proliferation in the mouse intestinal epithelium.
However, the combined values for the “untreated” mice in this experiment are
significantly different from the value of the DMSO mice (Figure 5), which is also
included in Figure 6 for comparative purposes. The fld value in the previous experiment
(Figure 5) for the DMSO control group is 1.729%, a significant increase over the
untreated value of 0.99% obtained in this group of “untreated” mice. The antagonism
between the effects of UCN-01 and its carrier is not particularly a desirable feature, and
will be addressed in future studies. However, as the DMSO values may skew future
analyses of UCN-01 activity in the mouse epithelial cells, we will use the control value
for normal mice from Figure 6.

UCN-01 arrest and time to recovery:
While our work to this point and the previous study by Redkar et. al. demonstrated that
UCN-01 can arrest the proliferating cells in the mouse small bowel, the time course of
this effect is not known (Redkar et al., 2001). In order to take advantage of any arrest to
prevent chemotherapy-induced toxicity, it is crucial to know when the UCN-01-mediated
arrest commences and also how long it takes for cells to return to normal levels of
proliferation. To this end, we conducted a time course study in the UCN-01 treated mice
to examine the reversibility of arrest following treatment. A mouse study was designed
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to analyze the time course of UCN-01 effect. Nude mice were treated with 5 mg/kg
UCN-01 or DMSO control, 30 mice per group. 10 mice from each group were BrdUlabeled and sacrificed each at one, two and four weeks post-treatment. Shown in Figure
7a (experiment A), the fld values for the UCN-01 treated mice are lower than the baseline
level (blue bar, results of experiment in Figure 6) at one week post-treatment, suggesting
that UCN-01 treatment has inhibited proliferation of the jejunum epithelial cells. By the
two-week time point, the proliferation of the gut epithelial cells increases to
approximately the baseline value established in Figure 5 (0.99%, indicated by the blue
bar). At four weeks post-UCN-01, the mouse jejunum has a slightly higher than normal
proliferative level. It is likely that this response is a reaction to the lack of proliferation
caused earlier by UCN-01, in which greater cell proliferation is intended to repopulate the
villi; this is similar to the response seen when mice are treated with γ-irradiation (Farrell
et al., 1998). Figure 7b displays the fld values obtained by mice treated with DMSO for
one, two and four weeks. As seen previously in Figure 5, DMSO treatment appears to
stimulate cell proliferation in the jejunum, as fld levels are elevated above baseline
(0.99%, blue bar) at one week. By two weeks, the intestinal epithelial cells have returned
to normal levels of proliferation, and the four-week samples remain at this level. This
experiment provides us with the time course for UCN-01 effects on the small bowel
proliferating cells; it also corroborates the previous data (Figure 5) which shows an
antagonistic effect of the carrier DMSO. This information is crucial to planning future
protection experiments using UCN-01 prior to a chemotherapeutic agent. Additionally,
these results show that the antagonistic action of DMSO (i.e the stimulation of cell
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Figure 7a. Flow cytometric analysis of mouse jejunums at one, two, and
four weeks after 5 mg/kg UCN-01 (n=10 for each group). Cell cycle arrest
persists through one week, recovers to approximately normal levels (figure
202, 0.99% indicated by blue line) by week 2, and gives way to a slight
increase in proliferation by week 4. The second set of mice was evaluated at
1 and 4 weeks post-UCN-01 (B), confirming the results of the first experiment.

Figure 7b. Flow cytometric analysis of mouse jejunums at one, two, and
four weeks after DMSO treatment (n=10 for each group). DMSO causes
increased cell proliferation at one week, and this effect diminishes to normal
levels by week 2. This indicates an antagonism between UCN-01 and DMSO.
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proliferation) on the gut epithelium does not inhibit the UCN-01 mediated inhibition
cellular proliferation or the subsequent recovery from this arrsest.
A section of jejunum for each mouse from this experiment was also fixed in
formalin and embedded in paraffin for histological analysis. Sections from each time
point were probed by anti-BrdU antibodies and visualized by fluorescent microscopy. In
this analysis, BrdU positive cells are labeled with fluorescein and appear as green signals.
A green cell indicates that BrdU was successfully incorporated into the cell, which is an
indicator of active cell proliferation. In addition, the nuclei have been stained with
Propidium iodide, and appear as red signals. In Figure 8, the sample from the one week
time point has fewer BrdU positive cells compared to the two and four week time point
samples. This indicates that gut epithelial cells are in a less proliferative state than the
two and four week samples, as less BrdU has been incoporated during S phase. This
staining provides visual evidence confirming the flow data shown in Figure 7.

Repeat analysis of UCN-01 time course:
To examine the reproducibility of UCN-01 mediated arrest and subsequent reversibility
of this arrest over time, a new experiment repeating the one and four week time points for
UCN-01 at 5 mg/kg was planned to both validate the results in Figure 7 and to verify that
a new batch of UCN-01 (from a different source) was similarly effective in affecting the
small bowel epithelial cells. For this experiment, 20 mice were injected with 5 mg/kg of
the new batch of UCN-01 10 mice were BrdU-labeled and sacrificed one week after
UCN-01 treatment, and the remaining 10 mice labeled and sacrificed at week four.
Similar to the results shown in Figure 7, the one-week mice had a lowered fld value,
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1 week

2 weeks

4 weeks

Figure 8. Anti-Brdu immunohistochemistry of mouse jejunums harvested
at one, two and four weeks after treatment with 5 mg/kg UCN-01. Mice were
sacrificed six hours after BrdU injection. The qualitative levels of BrdU
incorporation appear lowest in the one week sample, and increase as UCN-01
inhibition recedes over two and four weeks. White arrows indicate crpyt to villus
orientation. Green signal indicates BrdU incorporation, and nuclei are
stained in red with proidium iodide. Quantitave analysis of BrdU IHC is shown in
Figure 9.
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indicative of cell cycle arrest in the repeat experiment (Figure 7, experiment B). This
value increased to a slightly higher than normal value at week four, also in agreement
with our previous results. This experiment demonstrates both that our previous results
are reproducible, and that the new batch of UCN-01 is effective in causing a cell cycle
arrest in the proliferating tissues of the mouse. Both experiments clearly show that not
only is UCN-01 able to inhibit cell proliferation in the epithelial tissue of the jejunum, but
that the arrested cells can resume normal proliferative activity within two weeks of UCN01 treatment. Hence, UCN-01 causes a reversible inhibition of cell proliferation in vivo.

Solving the solvent problem – reducing the effect of DMSO:
UCN-01 is able to arrest the proliferating cells of the mouse small bowel, and does this
despite an apparent stimulatory effect of its solvent DMSO. The results in Figures 5 and
7b indicate that DMSO causes an undesirable increase in cell cycle proliferation in the
jejunum, in opposition to the arresting effect of UCN-01. To mitigate this conflict, an
alternative solvent for UCN-01 was sought. UCN-01 poorly soluble in most buffers, but
some previous studies have used sodium citrate as a solvent (3% w/v, pH 3.5) both in
vitro (Hamed et al., 2008) and in vivo (Patel et al., 2002). An experiment to evaluate
both UCN-01 in the citrate buffer as well as a higher concentration UCN-01 solution was
planned (10 mg/ml UCN-01 versus 4.8 mg/ml in all previous studies; the higher
concentration reduces the volume of DMSO injected by more than 50%). 10 mice each
would be injected with (a) 5 mg/kg UCN-01 in sodium citrate, (b) sodium citrate control,
(c) 5 mg/kg UCN-01 (at 10 mg/m in DMSO), or (d) DMSO control (volume equivalent to
the 10 mg/ml UCN-01 solution). 24 hours later, the mice were injected with BrdU and

101

Figure 9. Quantiative analysis of anti-BrdU IHC on jejunum sections of mice
treated for 48 hours with 5 mg/kg UCN-01 or DMSO control. The results mirror
the analysis by flow, demonstrating a drop in DNA synthesis due to UCN-01
treatment, suggesting a block before S phase. An image of this analysis is
shown in Figure 48.

102

sacrificed, and the jejunum processed for flow cytometry. In Figure 10a, it can be seen
that both methods attempting to reduce the solvent effect of DMSO were ineffective.
UCN-01 dissolved in the citrate buffer was unable to produce any cell cycle arrest, with a
fld value above the baseline (blue bar). The higher concentration UCN-01 in DMSO has
a significant arrest (mean fld 0.615%), but the volume equivalent DMSO control group
had elevated levels of cellular proliferation. The fld value for DMSO in this study
(2.269%) is very close to the 2.048% value obtained previously using the more dilute 4.8
mg/ml UCN-01 solution (Figure 7b). However, neither the approach of a higher
concentration of UCN-01 in DMSO nor the switch to sodium citrate as a solvent for
UCN-01 were effective methods to minimize the unwanted solvent effects of DMSO.
Another attempt to minimize the DMSO effect used an even higher concentration
of UCN-01 in DMSO, this time 60 mg/ml (versus 10 mg/ml used in Figure 10a). At this
concentration, a 30 gram mouse would only receive 2.5 µl of DMSO, compared to 15 µl
at the 10 mg/ml concentration. However, this volume is too small to be reliably injected,
and the UCN-01 solution was brought up to 15 µl total for each mouse immediately prior
to injection with warm (37ºC) saline. 10 mice were injected with the high concentration
UCN-01/saline mixture, and 10 mice received the volume equivalent of DMSO/saline.
However, this method also failed to alleviate the DMSO effect. Seen in Figure 10b, the
DMSO group had an observed fld of 2.154%, similar to the elevated values for DMSO in
both 10a and 7b. Additionally, the UCN-01-treated mice did not undergo an arrest of the
small bowel epithelial cells. It is possible that the mixing of UCN-01/DMSO with saline
prior to injection caused a significant amount of drug to come out of suspension; this may
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Figure 10a. Flow cytometric analysis of mice 24 hours after treatment
with 5 mg/kg UCN-01 dissolved in 3% sodium citrate, pH 3.5 or higher
concentration UCN-01 in DMSO (10 mg/ml versus 4.8 mg/ml in figures
7 and 8) and vehicle controls, injected im (n=10 for each group).
No arresting effect was observed in the mice receiving citrate/UCN-01,
and the diminished DMSO still caused an increase in fld.

Figure10b. Flow cytometric analysis of mice 24 hours after treatment
with 5 mg/kg UCN-01 dissolved at a higher concentration in DMSO (60
mg/ml versus 10 mg/ml in figure 10a). DMSO stimulation of cell
proliferation was still present, but the UCN-01 at this concentration
was unable to effect a cell cycle arrest.
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in turn have prevented proper absorption of UCN-01 and resulted in the ineffectiveness
of this treatment.
None of the attempts made to minimize the cellular proliferation stimulated by
DMSO (i.e. UCN-01 antagonism) were successful. This solvent antagonism is an
undesirable feature of our treatment plan, it does not appear to have any effect of the
UCN-01 mediated arrest of cell proliferation and release from arrest over time. All future
experiments in this study will use DMSO and the solvent for UCN-01.

Effect of dosing schedule on effectiveness of UCN-01-mediated arrest:
While UCN-01 treatment can significantly arrest the normal proliferating cells of the
small bowel (Figures 5, 7a, and 9), it was questioned whether a single treatment with
UCN-01 was the most effective way to bring about this arrest. Figure 11 shows antiBrdU staining of jejunum sections of mice treated with either 5 mg/kg UCN-01 or PBS
for 24 hours. The bright green signals indicate incorporation of BrdU, a marker of
cellular proliferation. While the degree of BrdU incorporation (bright green signals,
marked with white arrows) is much lower in the UCN-01 treated samples (indicative of
reduced cellular proliferation) compared to the PBS controls, there is still a significant
number of cells in the UCN-01 mice which are continuing to cycle and incorporate the
BrdU label. As the half-life of UCN-01 in mice is approximately 4 hours, we questioned
whether a different treatment plan would capture more cells in an arrested state.
Specifically, if we were to administer UCN-01 in two half doses separated by 12 hours, it
might be possible to affect cells with the second dose which were not in the correct phase
for UCN-01’s action during the first dose. To test this hypothesis, 10 mice were treated
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Figure 11. Anti-BrdU immunohistochemical analysis of jejunum sections of
mice treated with either 5 mg/kg UCN-01 or PBS im for 48 hours. The UCN01 treated mice have qualitatively lower levels of incorporated BrdU compared
to PBS (this has been confirmed by flow analysis, Figure 7) controls, but some
cells are still actively cycling even after UCN-01 treatment.
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with a single 5 mg/kg dose of UCN-01, and then injected with BrdU 24 hours later and
sacrificed. Another 10 mice were injected with 2.5 mg/kg at the same time, and then
again with an additional 2.5 mg/kg UCN-01 12 hours later. These mice were also labeled
with BrdU 24 hours following the initial injection and sacrificed for flow cytometric
analysis. Shown in Figure 12, the two half-dose treatment group had lower levels of
BrdU incorporation than the single full dose of UCN-01. However, the difference was
not statistically significant (p=0.0944). While this experiment did not show a significant
improvement in cell cycle arrest when UCN-01 was administered over a greater time
frame, it is possible that a treatment schedule that is even more spread out could result in
greater cell cycle arrest.

Discussion:
The main purpose of the studies in this section was to demonstrate that UCN-01 could
cause a reversible cell cycle arrest in our model system, the small bowel of the nude
mouse. Our results indicate that 5 mg/kg UCN-01 can cause a significant arrest of the
gut epithelial cells as early as 24 hours after treatment. This arrest persists through day 7
post-UCN-01 treatment, and the intestinal epithelia return to the normal level of
proliferation by two weeks post-UCN-01 treatment. This information is critical in
planning the experiments for protection against chemotherapeutics for normal cells,
which is the goal of the next chapter. In order to take advantage of cell cycle arrest to
evade the toxicity of agents targeting dividing cells, we will need to time the exposure of
the cytotoxic agents to occur during the period of cell cycle arrest. As some
chemotherapeutic agents are only able to target dividing cells, protection will only be
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Figure 12. Comparison of the arresting effects of a single dose of
5 mg/kg UCN-01 versus two 2.5 mg/kg doses injected 12 hours apart.
The level of BrdU positive nuclei is lower in the two-dose method, but
the difference is not significant (p=.0944).
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afforded to the normal dividing cells if the cytotoxic agent is administered while they are
in an arrested state. The exact timing of this treatment scheme will be examined in the
next chapter.

The antagonism of UCN-01 by its solvent DMSO was also demonstrated. Neither
alternative solvents nor minimal use of DMSO (via high concentration UCN-01) were
able to alleviate this effect. While the DMSO mediated antagonism is not desirable, the
use of DMSO as a solvent does not affect the inhibition of cellular proliferation by UCN01 or this subsequent release from arrest. In our experiments, DMSO is the most
effective solvent for delivering UCN-01 in vivo. As such, DMSO will be used for all
subsequent experiments in this thesis.
The idea of separating UCN-01 doses over a 12 hour period to induce a greater
level of cell cycle arrest was also found to be not statistically significant. However, the
two-dose treatment plan did result in a somewhat lower level of BrdU incorporation. It
may be possible that a continuous infusion of 5-10 mg/kg of UCN-01 over a 24 hour
period could more effectively capture a greater percentage of dividing cells into a state of
arrest. This method might also allow for an alternative solvent to be used, alleviating the
DMSO complication. However, the effects of UCN-01 are dose dependent. A 5 mg/kg
dose spread over time may never reach a concentration sufficient to cause a significant
level of cell cycle arrest. Alternatively, a constant exposure to UCN-01 could also lead to
induction of other unwanted effects of UCN-01 (see Introduction), especially those
leading to apoptosis or prevention of DNA damage repair. The possible complications of
this treatment plan render it beyond the scope of this investigation.
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II. Improved Tolerance of Fluorouracil following UCN-01 Administration

Introduction: The study by Chen et al. demonstrated that UCN-01 is able to specifically
arrest normal cells in culture, while tumor cell lines are unaffected and continue to
proliferate (Chen et al., 1999). In another study examining the effects of the UCN-01
parent analog staurosporine, normal mammary epithelial cell lines 70N and 81N and Rb
wild-type 76NE6 cells entered into a G0/G1 arrest after 48 hours of treatment with 0.5
nM of staurosporine; the tumor cell lines MDA-MB157 and MDA-MB436 as well as the
Rb-deleted 76NE7 were resistant to this arrest (Chen et al., 2000). Subsequent treatment
with doxorubicin or camptothecin was tolerated in the arrested lines, while the tumor cell
lines were susceptible apoptosis induced by the chemotherapeutic drugs. The temporary
arrest increased the MTD for the normal cell lines by two orders of magnitude for
camptothecin.
In the previous chapter, UCN-01 was demonstrated to cause a significant cell
cycle arrest in the small bowel epithelium of the nude mouse as early as 24 hours
followng a single administration at 5 mg/kg im. This arrest persisted through day 7, and
the cells returned to normal proliferative levels by day 14. These results indicate that the
first requirement for the protection strategy (UCN-01-mediated arrest of normal cells in
the mouse) has been met. The next part of this in vivo strategy is to demonstrate a
protective arrest persists in the mouse while undergoing treatment with chemotherapeutic
agents. In order to evaluate any potential protective effect of this arrest, mice pretreated
with either UCN-01 or DMSO control will be subsequently treated with fluorouracil (5FU). 5-FU was chosen as an agent which targets dividing cells and has been show to
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cause significant toxicity to the gut epithelium system, especially when administered in a
bolus fashion (Sobrero et al., 1997). 5-FU is able to kill cells in at least three ways, by
thymidylate synthase inhibition (when metabolized into FdUMP), misincorporation into
DNA (when metabolized into FdUTP), and prevention of rRNA maturation (Longley et
al., 2003). Cell death following 5-FU treatment is concomitant with an increased
bax/bcl-2 ratio (Inomata et al., 2002) or induction of apoptosis or permanent quiescence
through the p53/p21 pathway (Pritchard et al., 1998), although the exact cause of cell
death is still under investigation. In patients treated with 5-FU (370-400 mg/M2), both
oral and gastrointestinal mucositis can be limiting side effects, along with neutropenia
and myelosuppression (Schwab et al., 2008). The ability of the mice to tolerate 5-FU
following UCN-01 will be evaluated by examining alterations in weight, blood markers
and survival. The hypothesis for this section is that the temporary arrest of the normal
dividing tissues of the nude mouse by UCN-01 pretreatment will improve tolerance
of the toxicity caused by 5-FU administration.
Mice were treated with UCN-01 to cause a cell cycle arrest (as demonstrated
chapter 1), followed by administration of the chemotherapeutic agent fluorouracil (5-FU).
5-FU was injected at time points from one to seven days post-UCN-01, and the tolerance
of this treatment was evaluated by measuring weight, blood markers and survival. We
show here that UCN-01 pretreated mice had significant improvements in all these facets
after 5-FU treatment when compared to DMSO pretreated control mice. However, this
improvement is only observed when 5-FU is administered during a window of efficacy,
approximately three to five days post-UCN-01 treatment.
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Materials and Methods: Mice: Female nude mice from 8-12 weeks of age
(apprpoximately 24-30 grams) were obtained from the Experimental Radiation Oncology
colony at M.D. Anderson Cancer Center. Mice are maintained in the specific pathogen
free barrier facility on sterilized normal chow and water with no restrictions. UCN-01
treatment: Mice were injected with 5 mg/kg UCN-01 (or volume equivalent DMSO for
controls) im in the right hindlimb via a 0.5 ml insulin syringe with a 32 gauge needle.
Fluorouracil treatment: Mice were given 5-FU (50 mg/ml, Abraxis Pharmaceuticals,
Schaumburg IL) ip via a 0.5 ml insulin syringe with a 32 gauge needle. Mice were
treated with either a single bolus dose or 5 daily injections, depending on the
experimental protocol (see below). For doses below 80 mg/kg, normal saline was added
to 5-FU to increase volumes to 50 µl. Mice were weighed using a Scout Pro balance
(Ohaus, Pine Brook NJ).

Blood collection: Mice were anesthetized by inhalation of isoflurane (Baxter Healthcare,
Deerfield IL). Once sedated, the mice were bled via retro-orbital puncture of the sinus
with a sterile capillary tube. For liver chemistry (aspartate aminotransferase (AST),
alanine aminotransferase (ALT), and alkaline phosphatase) 50µl of blood was sampled
and placed into a microtainer with a clotting activator (Becton Dickinson, Franklin Lakes
NJ) and cenrifuged at 1100 X g. Serum supernatant was collected and stored at -80º until
analyzed. Enzyme levels were detected using a Roche Integra 400 Plus analyzer with
liver panel cassettes (both from Roche Diagnostics, Branchburg NJ). For complete blood
counts (CBC), 200µl of blood was collected using heparinized capillary tubes (Fisher
Scientific) and placed into EDTA-coated microtainer (Becton Dickinson); these samples
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were rotated at 8 RPM on a Labquake tube rotator (Barnstead, from Fisher Scientific) to
prevent clotting prior to analysis. Blood counts were determined using an Advia 120
hematology analyzer (Siemens Diagnostic, Deerfield IL); results were confirmed by
microscope analysis of blood smear. All samples were analyzed by the Hematology Core
in the Department of Veterinary Medicine at M.D. Anderson Cancer Center.

Tissue collection: Mice were sacrificed by cervical dislocation. Sternums were
harvested and preserved in 10% formalin prior to embedding in paraffin. Small bowel
sections (jejunum) were dissected from the abdomen, flushed with PBS and then
preserved in 10% formalin.

Hematoxylin and eosin (H&E) staining: Sternum sections were hydrated by placing
slides into Histoclear (National Diagnostics, Atlanta GA) three times for five minutes
each. This was followed by 100% ethanol (twice for three minutes), 95% ethanol (twice
for three minutes) and 70% ethanol for three minutes. Slides were rinsed in distilled
water for five minutes. Slides were stained in Gill’s hematoxylin (Vector Labs) for 6
minutes and then rinsed in running tap water for 20 minutes. Slides were decolorized for
two seconds in acid alcohol (1% hydrochloric acid in 70% ethanol) and rinsed in water
for five minutes. Slides were next immersed in ammonia water (0.1 ammonia in distilled
water) five times and were rinsed in water for five minutes. Counterstaining in eosin was
done for fifteen seconds, and the slides were washed in water for five minutes.
Dehydration was accomplished by immersion in 95% ethanol twice for five minutes
followed by 100% ethanol twice for five minutes. Slides were washed twice in
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Histoclear for five minutes each, and samples were mounted behind a coverslip using
Permount (Sigma Aldrich).

Microscopy: Mouse sternum H&E sections were visualized using a Leica DM400B
(Wetzlar, Germany) microscope. Images were taken using a Spot digital camera and
Spot Advanced software (Spot Imaging Solutions, Sterling Heights MI). The total area
of the blood precursor cells was determined using the histogram analysis function in
Photoshop (Adobe Systems, San Jose CA). This area was normalized to the total stained
area of each section analyzed. Five sections were analyzed per mouse, and five mice per
treatment group (UCN-01 or DMSO pretreated mice) were examined.

Statistics: Pairwise comparison of means was performed using Student’s t-test; a
confidence level of 95% was considered to be statistically significant in these studies.
Survival analysis was interpreted using the Kaplan-Meier method and significance for
comparing treatment outcomes was performed using the Mantel-Cox Log Rank test. All
calculations were performed using the Prism software package (GraphPad Software,
Inc.).

Results:
Serial injection of 5-FU beginning day 7 post-UCN-01/DMSO:
The BrdU incorporation results presented in chapter 1 indicate that the arresting effect of
UCN-01 in the small bowel was present through seven days, and that the proliferative
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rate of these cells had returned to normal levels by two weeks. These results pose the
question as to whether UCN-01 can be used to protect normally proliferating tissues
against the toxic effects of 5-FU during this period of arrest. The ability of UCN-01 to
protect mice against the toxic effects of 5-FU during this period was examined in an
experiment using six groups of mice, five mice per group; the treatment protocol is
shown in Figure 13. The groups were as follows:

• 1: 5 mg/kg UCN-01, followed in 7 days with 5 X daily PBS ip
• 2: 5 mg/kg UCN-01, followed in 7 days with 5 X daily 25 mg/kg 5-FU ip
• 3: 5 mg/kg UCN-01, followed in 7 days with 5 X daily 35 mg/kg 5-FU ip
• 4: DMSO, followed in 7 days with 5 X daily 25 mg/kg 5-FU ip
• 5: DMSO, followed in 7 days with 5 X daily 35 mg/kg 5-FU ip
• 6: DMSO, followed in 7 days with 5 X daily PBS ip

The levels of 5-FU administered in this experiment were chosen for their ability to induce
sub-lethal enzymatic and structural damage in the mouse small bowel (Kaufmann et al.,
1967). The hypothesis for this experiment is that the temporary arrest of the proliferating
cells of the mouse will allow better tolerance of subsequent 5-FU treatment. It was
expected that the UCN-01-treated groups would have less weight loss following 5-FU
compared to DMSO controls, an indication of improved gastrointestinal health. The mice
were weighed daily and sacrificed one day following the final 5-FU/PBS treatment. The
percent change in weight is shown in Figure 14. The weights of mice pretreated with
UCN-01 and then injected with 25 mg/kg/day 5-FU were almost identical to those of
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Figure 13. Treatment protocol for first mouse
protection experiment. 5 mg/kg UCN-01 or DMSO
injected on Day 0 (15 mice each), and then 5 mice per
group injected daily with 25 or 35 mg/kg/day or PBS
daily for days 7 through 11. Weight was measured daily
during 5-FU treatment.

Figure 14. Percent change in daily weights for mice treated
with 5-FU or PBS daily for days 7 through 11 (treatment
protocol in shown in figure 13).
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mice pretreated with vehicle (DMSO) and prior to 25 mg/kg/day 5-FU. Mice injected
with 35 mg/kg/day 5-FU had slightly improved weight status if pretreated with vehicle as
opposed to UCN-01, although this difference is not significant (p=0.435, Student’s t-test).
As such, the hypothesis for the concentrations and timing of 5-FU administered was
tested and found to be incorrect. It is possible that the seven-day gap between UCN-01
treatment and 5-FU treatment is too long for optimal protection, especially with a daily
injection of chemotherapy (the last injection would be on day 12, very close to the time at
which normal proliferation returns). The arrested cells of the mouse will be resuming
cell cycle activities at this point, and may be susceptible to 5-FU toxicity. While this
protocol failed to demonstrate any protective effect of UCN-01, perhaps a different
treatment schedule would be more successful. It was also noted that the doses of 5-FU
(25 mg/kg/day and 35 mg/kg/day) were very well tolerated in the mice (greatest weight
loss was just over 5%, Figure 14); further experiments will use the 35 mg/kg/day as a
starting dose.

Serial injections of 5-FU beginning day 3 post-UCN-01/DMSO:
The previous experiment failed to demonstrate in improvement in the tolerance to 5-FU
toxicity in mice pretreated with UCN-01. These results raised the question as to whether
a shorter interval between the two drugs would better exploit the arresting effect caused
by UCN-01. The hypothesis for this new protocol is that earlier 5-FU administration
would be better tolerated in UCN-01 pretreated mice compared to vehicle control. In
order to evaluate this idea, the timing of 5-FU administration was moved from seven days
post-UCN-01 to 3 days following UCN-01. The ability of UCN-01 to protect mice
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against the toxic effects of 5-FU using this altered timing scheme was examined in an
experiment using four groups of mice, five mice per group (Figure 15). The groups were
as follows:

• 1: 5 mg/kg UCN-01, followed in 3 days with 5 X daily PBS ip
• 2: 5 mg/kg UCN-01, followed in 3 days with 5 X daily 35 mg/kg 5-FU ip
• 3: DMSO i.m. followed in 3 days with 5 X daily 35 mg/kg 5-FU ip
• 4: DMSO i.m., followed in 3 days with 5 X daily PBS ip

As before, it was expected that the UCN-01 pretreated mice would have improved weight
status compared to control mice after subsequent exposure to 5-FU. The mice were
weighed daily and sacrificed one day following the final 5-FU/PBS treatment. To
evaluate hepatotoxic effects of this treatment and the status of the hematopoietic system,
blood was collected upon sacrifice for both complete blood counts (CBC) and liver
enzyme analysis. The percent change in daily weight is shown in Figure 16. Unlike the
previous experiment, pretreatment with UCN-01 was able to improve the weight status of
the mice receiving 35 mg/kg/day 5-FU when administered 3 days post-UCN-01 (Figure
16). The difference was significant at day 6 (p = 0.0131). The liver enzymes measured
in the blood (AST, ALT and alkaline phosphatase) were not significantly elevated by the
treatments, and no difference between UCN-0/ 5-FU and DMSO/5-FU were observed
(Figure 17 a-c). 5-FU is primarily metabolized in the liver, while UCN-01 is mostly
excreted. As such, it was possible that the two groups receiving 5-FU would have
elevated liver enzymes in the blood. However, as can be seen in Figures 17a and 17b,
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Figure 15. Treatment protocol for the second mouse
protection experiment. 5 mg/kg UCN-01 or DMSO
injected on Day 0 (10 mice each), and then 5 mice per
group injected daily with 35 mg/kg/day or PBS
daily for days 3 through 7. Weight was measured daily
during 5-FU treatment. Mice were bled and sacrificed
on day 8.

Figure 16. Percent change in daily weights for mice treated
with 5-FU or PBS daily for days 3 through 7 (treatment
protocol in shown in figure 15). The difference in weights
between the DMSO/5-FU mice and the UCN-01/5-FU mice
was significant on day 8 (p<0.05).
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Figure 17a. ALT levels in serum for mice treated with protocol
shown in figure 15. No elevation consistent with hepatic
damage was seen in the mice treated with either UCN-01 or 5-FU.

Figure 17b. AST levels in serum for mice treated with protocol
shown in figure 15. No elevation consistent with hepatic
damage was seen in the mice treated with either UCN-01 or 5-FU.
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Figure 17c. Alkaline phosphatase levels in serum for mice treated
with protocol shown in figure 15. Some elevation consistent with hepatic
damage was seen in the mice treated with either UCN-01 or 5-FU.

Figure 17d. Platelet counts in whole blood for mice treated with the
protocol in figure 15. The difference in platelets between the UCN-01
pretreated mice receiving 5-FU and the DMSO pretreated mice receiving
5-FU was significant at day 8 (*, p<0.05)
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Figure 17e. White blood cell counts in whole blood for mice treated with the
protocol in figure 15. No significant difference between the 5-FU mice
pretreated with either DMSO or UCN-01 was seen at day 8.

Figure 17f. Hemoglobin counts in whole blood for mice treated with the
protocol in figure 15. No significant difference between the 5-FU mice
pretreated with either DMSO or UCN-01 was seen at day 8.
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ALT and AST levels were actually reduced in all treated groups compared to PBS
control. Alkaline phosphatase levels were higher in all treated groups (Figure 17c), but
overall no evidence for either UCN-01 or 5-FU related liver toxicity seems to be present
at these doses. Whole blood counts demonstrated a significant improvement in platelets
(Figure 17d) for the UCN-01 pretreated 5-FU group in comparison to the 5-FU/DMSO
group (p = 0.043). Hemoglobin and white blood cells were not significantly different
between the UCN-01/5-FU and DMSO/5-FU (Figures 17e and 17f), although a later time
point would be more appropriate to measure these parameters. This will be addressed in
a later experiment (see below). In summary, this experiment did show tangible
improvements in weight status (a marker for intestinal health) and platelets, which
indicates an improvement in the hematopoietic system. The cause for this improvement,
in comparison to the initial study, is likely the shortened time frame between UCN-01
and 5-FU treatments. The arrested status of the dividing tissues in the UCN-01 pretreated
mice throughout the five-day 5-FU treatment can afford protection to these cells, and may
explain the improvements observed.

High dose 5-FU administered 24 hours after UCN-01/DMSO:
The results thus far suggest that cytotoxic treatment is better tolerated in the UCN-01
pretreated mice when 5-FU is administered when the UCN-01-mediated arrest is at a high
level (days 3-7 post-UCN-01); the improvement in tolerance is not observed if 5-FU is
administered later in the post-UCN-01 recovery period (days 7-11 post UCN-01). These
results raised the question as to the best timing of 5-FU treatment relative to UCN-01
administration. To determine the optimal dosing schedule for UCN-01 and 5-FU, it was

123

decided to evaluate the protective effect of UCN-01 at 24 hours post-administration, the
time of the greatest measured cell cycle arrest (see chapter 1). The hypothesis for this
experiment is that UCN-01 pretreated mice would best tolerate 5-FU during the period of
greatest UCN-01-mediated arrest (24 hours following UCN-01 treatment). For this
experiment, two groups of 15 mice were analyzed, one treated with two doses of UCN-01
separated by 12 hours, and the other naïve (treatment and bleeding schedule shown in
Figure 18). The two UCN-01 doses separated by 12 hours were shown to decrease the
fraction of labeled, divided cells compared to a single dose treatment (chapter 1). To
clarify the effect of timing, a single bolus dose of 5-FU was given, rather than a 5-day
serial injection; the effects of UCN-01 in the gut epithelium may undergo daily changes
as the cells move towards recovery from arrest. A single dose administration of 5-FU
would limit the effects of this process from affecting our results. 24 hours after the
second administration of UCN-01, all mice were given a single ip dose of 450 mg/kg 5FU. Blood was collected weekly, including a pretreatment measurement, and weight was
recorded daily. Unlike the experiment with a 3 day separation of UCN-01 and 5-FU, the
bolus dose of 5-FU given 24 hours after UCN-01 was more detrimental than in the mice
pretreated with vehicle control in terms of weight status, survival and blood markers. As
seen in Figure 19, weight loss is significantly greater in the UCN-01 pretreated group,
both in the initial weight loss period (through day 8) and also in the second period, from
day 11 until day 15 (* indicates p <0.05). The numbers in days 8-15 are somewhat
skewed, due to the diminishing survival of the UCN-01 pretreated mice. Shown in
Figure 20, survival of UCN-01 pretreated mice is diminished (23% versus 60% for the
untreated mice) compared to DMSO pretreated mice, although the difference was not
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Figure 18. Treatment plan for the third mouse experiment. 15 mice
each were treated with either 2.5 mg/kg UCN-01 or DMSO on Day 0
and then again 12 hours later. 450 mg/kg 5-FU was given to both
groups 24 hours after the last UCN-01/DMSO treatment. Mice were
bled one week prior to treatment, and then weekly beginning on Day 0.

Figure 19. Percent change in weight from Day 0 for mice after 450
mg/kg 5-FU. The weight change was significantly worse in the UCN01 pretreated mice on days marked with * (p<0.05).
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Figure 20. Survival of mice receiving 450 mg/kg 5-FU 24 hours after
pretreatment with either 2 X 2.5 mg/kg UCN-01 or DMSO (15 mice per
group), as shown in figure 18. Mice pretreated with UCN-01 had
diminished survival compared to DMSO control mice.

Figure 21a. Weekly platelet counts for mice before and after 450 mg/kg
5-FU (protocol in figure 18). No significant differences were observed
in mice pretreated with UCN-01 versus DMSO. Poor survival of UCN-01
mice prevented collection of blood at the 3 week time point.
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Figure 21b. Weekly white blood cell counts for mice before and after
450 mg/kg 5-FU (protocol in figure 18). No significant differences were
observed in mice pretreated with UCN-01 versus DMSO. Poor survival
of UCN-01 mice prevented collection of blood at the 3 week time point.

*

Figure 21c. Weekly red blood cell counts for mice before and after
450 mg/kg 5-FU (protocol in figure 18). Counts were significantly diminished
at 2 weeks in the UCN-01 pretreated mice (*, p<0.05). Poor survival
of UCN-01 mice prevented collection of blood at the 3 week time point.

127

significant (p=0.0714). Platelets, white blood cells and red blood cells were also lower in
the UCN-01 pretreated group two weeks following 5-FU administration, although not
significantly so (Figure 21a-c). Insufficient UCN-01 mice survived to obtain CBC values
for the three week time period, so any comparison at this time point is not possible. A
possibility raised by this data is that the decreased survival of the UCN-01 pretreated
mice is due to the early administration of 5-FU; perhaps a time closer to the recovery of
the normal dividing cells would be more appropriate. Mice treated with serial 5-FU
treatment from days 3 until 7 post-UCN-01 (previous experiment, Figure 15) seem to
obtain some benefit due to cell cycle arrest. However, when given only 24 hours after
UCN-01, 5-FU seems to be more toxic than 5-FU in mice pretreated with vehicle control.
These results strongly suggest that the timing of 5-FU administration after UCN-01 is a
critical parameter in providing protection for the normal dividing tissues of the mouse,
which requires further refinement. It may be most beneficial if the cytotoxic treatment
occurs during the period of UCN-01 arrest (thus protecting some dividing cells), but very
close to the recovery time from that arrest, such that the protected cells are quickly able
to resume proliferation and repopulate the gastrointestinal and hematopoietic tissues after
the toxic agent has been eliminated.

High dose 5-FU administered on day 5 post-UCN-01/DMSO:
The results of the different treatment strategies thus far place the optimal protective
window for UCN-01 protection against 5-FU somewhere between three and seven days
following UCN-01 administration. A new experiment was designed to more closely
investigate this effect, using a bolus dose of 5-FU in the center of this window (day 5
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post-UCN-01). As shown in the treatment scheme in Figure 22, mice were injected with
either UCN-01 (7 mice) or DMSO (5 mice), both groups im as before. Five days
following treatment, 400 mg/kg 5-FU was injected, and the mice were weighed daily, and
blood was drawn for CBCs once a week. The lower 5-FU bolus dose (400 mg/kg vs. 450
mg/kg in the previous experiment) was chosen to increase the survival of both groups, in
hopes of having sufficient blood samples for each group for comparative purposes. In
contrast to the previous experiment (24 hour separation between UCN-01/DMSO and 5FU), the UCN-01 pretreated mice in this treatment protocol had improved weight status
and survival compared to the DMSO/5-FU control mice. Shown in Figure 23, the UCN01 pretreated mice had significantly improved weight status on days 13 and 14 (p<0.05),
although the diminished survival of the DMSO group prevented any meaningful analysis
beyond that time. As seen in Figure 24, no DMSO mouse survived beyond 14 days post5-FU, while 43% of the UCN-01 pretreated mice survived until day 28; at this point the
surviving mice were bled and sacrificed. Blood was collected for comparative CBC
analysis, but the poor survival once again prevented any meaningful differences to be
measured, as no DMSO pretreated mice survived beyond two weeks. For the earlier time
points, no significant differences in any blood markers were noted, although these were
likely collected too soon following 5-FU to reflect the damage done to the hematopoietic
system. The results from the surviving UCN-01 mice seem to indicate that the platelets
decrease within about one week following 5-FU administration and then recover by two
weeks (Figure 25c) while the red and white blood cells decrease at two weeks post-5-FU
and then recover at 3 weeks (Figures 25a & 25b). While the protocol for this experiment
(5-FU at 5 days post-UCN-01) seemed to demonstrate a protective effect of UCN-01, the
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Figure 22. Treatment plan for the fourth mouse experiment. Mice
were treated with either 5 mg/kg UCN-01 (n=7) or DMSO (n=5) on
Day 0. 400 mg/kg was administered to both groups on Day 5. Mice
were weighed daily following 5-FU treatment, and bled weekly.

**

Figure 23. Daily weight changes for mice treated with 400 mg/kg 5-FU
five days after 5 mg/kg UCN-01 (n=7) or DMSO (n=5) treatment. Weight
loss was significantly greater in the DMSO mice on days 13 and 14
(*, p<0.05), and no DMSO mice survived beyond day 14.

130

Figure 24. Survival of mice treated with 400 mg/kg 5-FU five days after
administration of either 5 mg/kg UCN-01 (n=7) or DMSO (n=5).

Figure 25a. Weekly red blood cell counts in mice treated with 400 mg/kg
5-FU five days after 5 mg/kg UCN-01 (n=7) or DMSO (n=5). Lack of
surviving DMSO mice prevented collection of data for weeks 3 and 4.
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Figure 25b. Weekly white blood cell counts in mice treated with 400 mg/kg
5-FU five days after 5 mg/kg UCN-01 (n=7) or DMSO (n=5). Lack of
surviving DMSO mice prevented collection of data for weeks 3 and 4.

Figure 25c. Weekly platelet counts in mice treated with 400 mg/kg
5-FU five days after 5 mg/kg UCN-01 (n=7) or DMSO (n=5). Lack of
surviving DMSO mice prevented collection of data for weeks 3 and 4.
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low numbers of mice in both groups and the lack of control mice surviving for
comparison of blood markers prevented a statistical interpretation of the results. Even
though the dose of 5-FU was decreased in this experimental protocol (400 mg/kg instead
of 450 mg/kg), the poor survival of the control mice is problematic and will be addressed
in future experiments to ensure sufficient numbers of mice for comparison of blood
markers. It is likely that weekly bleeds for CBCs are too harsh for mice which are
already suffering 5-FU-induced damage to the hematopoietic system.

Repeat high dose 5-FU on day 5 post-UCN-01/DMSO (no CBCs):
The diminished survival of control (DMSO) mice given a bolus dose of 5-FU in the
previous experiment prevented a meaningful analysis of changes in weight status
(Figures 23 and 24) and blood markers (Figure 25). It is possible that the pre-bleed and
weekly bleeds are too deleterious to the mice when being treated with high levels of 5FU, so the protocol was altered in hopes of improving the survival of the control mice; no
blood was collected in this experiment. To evaluate the tolerance of mice receiving a
bolus dose of 5-FU, two groups of fifteen mice each were treated with either 5/mg/kg
UCN-01 or volume equivalent DMSO (see Figure 26). As in the last experiment (Figure
22), five days post-UCN-01 treatment both groups were injected with 400 mg/kg 5-FU.
Weight was measured daily (Figure 27). The weight status of the UCN-01-pretreated
mice was significantly improved compared to DMSO control from days thirteen until
twenty-two, with the exception of day twenty-one (p < 0.05, day 21 p=0.16). One UCN01 mouse died at day 13, and two DMSO mice died at day 10, but there were no
statistical differences in survival. While this level of 5-FU (400 mg/kg) does lead to
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Figure 26. Treatment plan for the fifth mouse experiment. Mice were
treated with either 5 mg/kg UCN-01 or DMSO on Day 0 (n=15 for each).
400 mg/kg was administered to both groups on Day 5. Mice were
weighed daily following 5-FU treatment.

**

* **
*

**

*

Figure 27. Daily change in weight for mice following 400 mg/kg 5-FU
given 5 days post-UCN-01 or DMSO (n=15 for each group). Weight
loss was significantly greater for the DMSO groups on days marked
with an asterisk (p<0.05).
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some significant loss of weight, the dose will have to be increased slightly to obtain any
possibly differences in the survival rates of mice protected by UCN-01 pretreatment
versus controls.

Serial injections of 5-FU beginning on day 3 post-UCN-01/DMSO:
The results of the previous two studies (Figure 23, 24 and 27) reveal that the ability of
UCN-01 to protect mice from the toxicity of a bolus dose of 5-FU appears to be effective
at five days post-UCN-01 administration. Weight loss and survival are both improved in
the mice pretreated with UCN-01 using this treatment scheme. The initial experiments
with serial dosing demonstrate that UCN-01 given three days prior to 5-FU is protective
(Figure 16) and that waiting until seven days post-UCN-01 treatment before commencing
serial 5-FU administration can nullify this protective effect (Figure 14). The previous
results (Figure 17d) also demonstrated that platelets are significantly elevated one week
after 5-FU injection in mice pretreated with UCN-01 in comparison to DMSO pretreated
mice. However, the doses used (25 and 35 mg/kg/day for five days) were not very toxic
in either the UCN-01 or DMSO pretreated groups. The ability of UCN-01 to protect
mice from a higher dose of serial injections of 5-FU was evaluated, to determine if a
more potent dose would increase the separation in the tolerance of the UCN-01 versus
DMSO pretreated mice. This experiment (serial 5-FU beginning day 3 post-UCN01/DMSO) was repeated with a greater number of mice per group (ten versus five) and a
slightly higher serial dose of 5-FU (40 mg/kg/day versus 35 mg/kg/day, see Figure 28).
The higher dose was chosen to better demonstrate the ability of UCN-01 to protect
against increased levels of a toxic agent. Mice were weighed daily and blood was
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collected prior to 5-FU and weekly for three weeks to evaluate the effects on the
hematopoietic system (Figure 28). Similar to the previous experiments in which 5-FU
was given three days after UCN-01 (Figure 15), the weight status of the mice pretreated
with UCN-01 was improved significantly (p < 0.05) from day 2 until the end of the
experiment compared to the DMSO pretreated mice (Figure 29). The platelet counts of
the UCN-01 pretreated mice were significantly (p < 0.05) improved at 2 weeks (Figure
30a). Red blood cell counts were similarly improved at the three week time point for the
UCN-01 group, but were lower than the DMSO mice at weeks one and two (Figure 30b).
This may be due to the temporary arrest caused by UCN-01. The white blood cells
counts were significantly lower in the UCN-01 pretreated group compared to DMSO at
week one (Figure 30c), likely due to the same cause. While arrested hematopoietic cells
may indeed evade 5-FU mediated toxicity, the cell cycle arrest caused by UCN-01 can
also prevent those cells from dividing and contributing to maturing blood cell counts, at
least initially. Even though the red and white cell counts do not unequivocally
demonstrate a protective effect of UCN-01, his experiment both corroborates the previous
(35 mg/kg/day X 5 days 5-FU, Figures 16 and 17) experimental results and gives a more
complete picture of the changes in the hematopoietic system in the mice after 5-FU
administration, both with UCN-01 pretreatment and without. The lack of surviving
control mice in the previous experiment prevented the collection of this data (Figures 24
and 25). Future experiments will also examine bone marrow to provide a visual analysis
of the health of the blood-forming tissues of the mice after 5-FU treatment. As the CBC
numbers indicate improved platelets and red blood cells in the UCN-01 pretreated mice,
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Figure 28. Treatment plan for the sixth mouse experiment. Mice were
treated with either 5 mg/kg UCN-01 or DMSO on Day 0 (n=10 pre group).
40 mg/kg/day was administered to both groups daily on days 3-7. Mice were
weighed daily following 5-FU treatment. Mice were bled on day 2 (prior to
5-FU) and then every seven days for a total of five bleeds.

Figure 29. Percent change in weight following 40 mg/kg/day 5-FU for 5
days begun 3 days post UCN-01/DMSO (protocol in figure 28). Weight
loss for the DMSO group was significantly greater than the UCN-01 group
for all days marked with an asterisk (*, p<0.05).
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Figure 30a. Weekly platelet counts in mice treated with five daily doses of
40 mg/kg/day 5-FU beginning on day 3 post UCN-01 or DMSO (n=10
for each group). Counts were significantly higher in the UCN-01 pretreated
group at week 2 (*, p<0.05); however, when using the adjusted p-value
for multiple comparisons (α = 0.0125) the difference is not significant.

*
*

*

Figure 30b. Weekly red blood cell counts in mice treated with five daily
doses of 40 mg/kg/day 5-FU beginning on day 3 post UCN-01 or DMSO
(n=10 for each group). Counts were significantly higher in the UCN-01
pretreated group at week 3, and significantly lower at weeks 1 and 2
(*, p<0.05) ; however, when using the adjusted p-value for multiple
comparisons (α = 0.0125) the difference is not significant.

138

Figure 30c. Weekly white blood cell counts in mice treated with five daily
doses of 40 mg/kg/day 5-FU beginning on day 3 post UCN-01 or DMSO
(n=10 for each group). Counts were significantly lower in the UCN-01
pretreated group at week 1 (*, p<0.05); ; however, when using the adjusted
p-value for multiple comparisons (α = 0.0125) the difference is not significant.
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the hematopoietic tissues of these mice (i.e. bone marrow) should have increased
numbers of blood precursors compared to the control mice after 5-FU treatment.

High dose bolus 5-FU administered on day 5-post UCN-01/DMSO (survival study):
The ability of UCN-01 to improve the blood counts and weight status of mice exposed to
5-FU has been shown both in bolus (Figures 22, 23, and 27) and daily serial injections
(Figures 16, 17, 29, and 30) of 5-FU. These studies clearly show that we can achieve the
goal of protection of the normal proliferating cells of the mouse against high levels of 5FU. The next study was designed to obtain robust numbers examining survival of mice
given high dose 5-FU (Figure 31). Two treatment groups of twenty-two mice each were
pretreated with either two doses of 5 mg/kg UCN-01 or volume equivalent DMSO
(carrier control) separated by 12 hours. Five days after the second injection, mice were
injected with 450 mg/kg 5-FU. Mice were monitored for survival and weighed daily. As
in the last bolus 5-FU experiment, no blood was collected in order to prevent deaths due
to exsanguination. Mice were also given moistened food in the bottom of cages if needed
(upon signs of dehydration or the inability to feed from suspended pellets). As can be
seen in Figure 32, the weight status of the UCN-01 pretreated mice was significantly
improved from days eleven through twenty-one, with the exception of day fourteen. Also
significantly improved was the survival of the UCN-01 pretreated group (Figure 33).
Mice pretreated with UCN-01 had a survival rate of 91%, while the DMSO pretreated
group had a survival rate of only 50%. This is similar to the rate seen in the 24 hour
UCN-01 treatment experiment for “unprotected” mice (Figure 20). Sternums were also
harvested from surviving mice at day 21 and paraffin embedded sections visualized via
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Figure 31. Treatment protocol for the seventh mouse experiment.
Mice were treated with 5 mg/kg UCN-01(n=22) or DMSO (n=22) on
day 0 and then again 12 hours later. On day 5, all mice were injected
with 450 mg/kg 5-FU. Weights were recorded daily, and all surviving
mice were sacrificed on day 21.

*
*** * *** * *

Figure 32. Percent change in weight after 450 mg/kg 5-FU, given 5 days
after UCN-01 or DMSO (n=22 for each group). UCN-01 pretreated mice
had significantly lower weight loss for days 11 through 21, with the
exception of day fourteen (*, p<0.05).
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Figure 33. Kaplan-Meier survival analysis of mice treated with a
bolus dose of 450 mg/kg 5-FU on day 5 following UCN-01 or DMSO
pretreatment (n=22 for each group). Survival for the UCN-01 pretreated
group was significantly higher (p=0.0025). Error bars are 95%
confidence intervals.
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H&E staining. Shown in Figure 34, the blood precursors (small purple cells) in the
UCN-01 pretreated mice are more abundant than in the DMSO pretreated mice. The area
of blood precursors in the sections was quantified as a ratio of the total stained area, and
the UCN-01 pretreated mice had significantly more blood precursors than the DMSO
mice (Figure 35).

Discussion: The ability of UCN-01 to improve the tolerance of 5-FU in the mouse
appears to depend critically on the dosing schedule of the two compounds. The arrest of
the small bowel epithelium occurs within 24 hours of UCN-01 administration and this
suppression is in effect for at least seven days (the peak is at 24 hours and decreases with
time). In order for the normal proliferating tissues to take advantage of this arrest, 5-FU
must be administered during this time period. However, as the major toxicity due to
bolus 5-FU treatment is observed in the gut, and is also due in part to permanent
suppression of cell cycling via p53 and p21 (Pritchard 1998), it is likely that 5-FU given
too early is even more toxic than 5-FU alone. The cells arrested by UCN-01 will take
better than seven days to recover, and the cells which evade UCN-01 arrest continue to
cycle are then susceptible to 5-FU toxicity. As seen in the experiment dosing UCN-01
and 5-FU separated by 24 hours (Figure 18), this combination increases mortality; the gut
cannot replenish the required enterocytes (and presumably the bone marrow cannot form
sufficient blood cells) while still under arrest; unarrested cells can be killed by 5-FU, and
the mouse succumbs to this combined pressure. However, when 5-FU is given closer to
the time of recovery (3-5 days post-UCN-01, Figures 22, 26, 28 and 31), the mouse can
evade the damage to the temporarily arrested cells, and those cells can begin cycling
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DMSO

UCN-01
Figure 34. Sternum H&E samples of mice given 450 mg/kg 5-FU on day
five post DMSO (top row) or UCN-01 (bottom row). Mice were sacrificed
on day 21. The UCN-01 mice appear to have more abundant levels of
blood precursors compared to the DMSO mice. This is quantified in figure
35.
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Figure 35. Quantification of blood precursors cell in mouse sternums
after treatment with 450 mg/kg 5-FU. The area of blood precursor cells
was normalized to the total stained area of a 40X section. Five fields were
quantified per mouse, and five mice for each group were evaluated.
The UCN-01 pretreated mice have significantly greater levels of blood
precursors than the DMSO pretreated mice (*, p<0.05).
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anew within 2-3 days after 5-FU treatment ceases. This likely explains the improved
tolerance and survival seen in the final two experimental protocols. Given the sum of the
results of all seven mouse studies, it appears that the optimal time for protection from the
toxicity of a bolus dose of 5-FU is five days post-UCN-01. For a series of 5 daily
injections, beginning 5-FU administration on day 3 post-UCN-01 appears to be the
optimal schedule. This treatment protocol allows the last dose to be given while some of
the arresting effect of UCN-01 still persists, but also very close to the time of recovery
from arrest. Based on the results of all the mouse studies, the best chance for protection
against toxicity during treatment to kill tumors is the scheme shown in Figure 31.
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III. Mechanism of UCN-01 Cell Cycle Arrest in Mouse Small Bowel

Introduction: The analysis of BrdU incorporation into the cells in the jejunum of mice
treated with UCN-01 demonstrates a slowdown in the proliferation of gut epithelium as
early as 24 hours following treatment; this arrest persists through day seven post-UCN01, and is eliminated by two weeks (Figures 5 and 7). While UCN-01 has many targets,
both direct and indirect (see Introduction), the exact mechanism by which it arrests the
crypt cells of the small bowel is unknown. It is the aim of this portion of the project to
determine what changes in proteins governing the cell cycle are affected by UCN-01 and
can contribute to the arrest seen. Previous work in our laboratory has indicated that the
UCN-01 analog staurosporine causes a G1 arrest in cultured epithelial cells by
downregulating the kinase cdk4 and causing subsequent hypophosphorylation of Rb
(McGahren-Murray et al., 2006). The hypothesis for this section of the project is: UCN01 causes a decrease in cdk4 levels in the jejunum of the mouse, leading to the cell
cycle arrest demonstrated in chapter 1. Our analysis of mouse small bowel epithelium
treated with UCN-01 revealed modulation of some key cell cycle proteins, including
cdk4 and p27. However, unlike the in vitro studies, we have shown that level of cdk4 are
increased following UCN-01 administration. In addition, the inhibitor p27 was increased
by UCN-01. No changes in the activities of G1 phase cyclin dependent kinases (cdk2
and cdk4) were observed, and the levels of cdk2, cyclin E and active cdk2 were unaltered
as well. UCN-01 had no effect on the levels of Rb or p53. Interestingly, the levels of
phospho-Rb were increased in the UCN-01 treated mice. However, analysis of BrdU
incorporation demonstrates that the UCN-01 treated mice have reduced cellular
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proliferation, so the increase in phospho-Rb is unexpected. It is thought that UCN-01 is
preventing the arrested cells from traversing the restriction point, but may not be
inhibiting the early G1 phase phosphorylation of Rb by cdk4.

Materials and Methods: Mice: Nude mice (see Chapter 1) were injected with 5 mg/ml
UCN-01 in the right hindlimb muscle. 24 hours later, the mice were sacrificed by
cervical dislocation. For studies using whole epithelial tissue, the jejunum was dissected
from the abdomen and flushed with 10 ml of ice-cold PBS. A small section (~1 cm) was
removed and fixed in 10% formalin for histology. The tissue was then opened
longitudinally and placed on a glass microscope slide. A second glass slide was dragged
across the surface of the tissue to dislodge the epithelium. The cells were suspended in
ice-cold PBS and spun down at 1100RPM for 5 minutes at 4ºC. The cells were then
resuspended in a minimum (40-50 µl) of protease/phosphatase inhibition (PPI) buffer:
25µg/ml leupeptin, 25µg/ml aprotinin, 10µg/ml pepstatin, 1 mM benzamidine, 10µg/ml
soybean trypsin inhibitor, 0.5mM PMSF (Phenyl methyl sulfonyl fluoride), 50mM
sodium fluoride, 0.5 mM sodium orthovanadate. Cells are lysed by 2 rounds of
sonication (one round = 3 minutes sonication, 1 minute rest, 3 minutes sonication) and
are vortexed between rounds. Sonication is performed in a ice/water bath by a Sonicator
XL (Misonix, Inc., Farmingdale, NY). The protein suspension is then separated by
centrifugation at 125000 x g for 45 minutes at 4º. The protein suspension is stored at 80ºC. In order to minimize the background of nondividing villus cells, serial
fractionation to enrich for cypt cells was performed. For the serial fractionation of the
gut epithelium, the jejunum is dissected out of the abdomen and flushed with 10 ml ice-
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cold PBS, followed by 10 ml ice-cold PBS plus 1 mM dithiothreitol (DTT). The tissue is
then tied closed on one end with 3-0 silk suture (Ethicon/Johnson & Johnson, Warsaw
IN) and then everted. The everted tissue is filled with ice-cold PBS to distension and
then tied closed. The tissue is incubated in a citrate buffer (96 mM NaCl, 1.5 mM KCl,
27 mM Na citrate, 8 mM KH2PO4, and 5.6 mM Na2HPO4, pH 7.3) for 15 minutes at
37ºC. The tissue was then placed in a 50 ml glass flask in 15 ml of a PBS buffer with
1.5 mM EDTA, 0.5 mM DTT and 1 mg/ml bovine serum albumin (BSA). The flask is
placed in a 37ºC water bath shaking at 90Hz for 25 minutes. The buffer with dislodged
cells is collected and spun down at 1100 RPM for 5 minutes at 4ºC; the cell pellet is
washed with 10 ml ice-cold PBS, spun down again, and resuspended in PPI and
processed as above. This is designated as fraction 1. The tissue is placed in a new flask
and shaken at 37ºC for an additional 35 minutes; the cells are processed as before and
comprise fraction 2. A third incubation for 60 minutes is collected and processed as
fraction 3. All fractions are processed using the sonication/centrifugation procedure
shown above.

Western analysis: Samples are separated on a either a 10% or 7% (for Rb blots) SDSPAGE vertical denaturing gel. Concentration matched extracts are boiled in denaturing
sample buffer: 1.4M β-mercaptoethanol (Samples are run at 150 volts for 90-120
minutes, depending on the location of the proteins of interest. After running, the gels are
transferred to polyvinylidene fluoride (PVDF) membranes (Immobilon-P, Millipore,
Billerica, MA) using a BioRad (Hercules, CA) transfer cell. Transfer buffer is: 57.6g
glycine, 12g Tris base, 800ml methanol; bring up to 4l with H2O. Transfer in overnight
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at 35 volts or for 90 minutes at 85 volts (quick transfer requires ice block in the transfer
cell). Following transfer, membranes are blocked at 4º overnight in TBS/Tween Blotto:
20mM Tris base, 500mM sodium chloride, 0.05% Tween 20 with 5% nonfat dry milk.
Blots are incubated in primary antibody for one hour, are washed for 6 x 10 minutes in
TBS/Tween, and are placed in secondary antibody (Immunopure HRP, diluted 1:25,000
in Blotto) for one hour. Membranes are again washed 6 x 10 minutes in TBS/Tween.
Membranes are developed with “Western Lightning” chemiluminescense reagent
(PerkinElmer, Wellesley, MA) and exposed on Blue x-ray film (Phenix, Hayward, CA).
The primary antibodies used in this aim are: anti-cyclin E (0.3 µg/ml), anti-CDK2 (1.0
µg/ml) – both from SantaCruz. Anti-p21 is 1.0 µg/ml from Calbiochem. Anti-p27 (1.0
µg/ml) is from BD TransLab. Anti-Rb is from Millipore.

Immunoprecipitation assays: Protein samples are collected as above. For
immunoprecipitation, protein g sepharose beads (GE HealthCare, ? ) are washed in a
lysis/protease/phosphatase buffer (0.5M tris, pH 7.5, 2.5M sodium chloride, 1% NP-40
(Igepal), 25µg/ml leupeptin, 25µg/ml aprotinin, 10µg/ml pepstatin, 1 mM benzamidine,
10µg/ml soybean trypsin inhibitor, 0.5mM PMSF (Phenyl methyl sulfonyl fluoride),
50mM sodium fluoride, 0.5 mM sodium orthovanadate. The buffer is added to the beads
at a 2:1 ratio, mixed, and then centrifuged at 4º for 5 minutes at 1000 x g. This wash is
carried out 3 times. After the wash buffer is removed, the beads (30 µl/sample) are added
to a 10mM DTT/lysis buffer (36 µl/sample). Anti-FLAG antibody (1 µl/sample) is added
to the mixture, and the beads plus antibody are left to rotate slowly at 4º overnight. The
following day, 150 µg of protein sample is added to each mixture, and allowed to mix at
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4º for one hour. The beads are then washed in 250 µl of the lysis/protease/phosphatase
buffer 4 times. For a Western analysis of the immunoprecipitated samples, 3 further
washes are carried out, and then the beads are centrifuged for 5 minutes at 1200 x g.

Kinase assays: Immunoprecipitation for kinase assays was carried out as above.
Following the final wash, four additional washes in H1 buffer (10mM MgCl2, 1mM
DTT, 0.1 mg/ml BSA, 25mM Tris HCL pH 7.5, 125mM NaCl) are done. Following the
washes, the wash solution is removed as for the IP Western. Beads are then resuspended
in the kinase reaction buffer: 10mM magnesium chloride, 1mM dithiothreitol, 0.1 mg/ml
bovine serum album, 25mM Tris hydrochloride pH 7.5, 125mM sodium chloride, along
with 60mM ATP, 5µCi of γ-32P ATP and 5µg of histone H1 substrate (for cdk2 kinase
assay, Roche Diagnostics) or GST-Rb substrate (for cyclin D kinase assay, Santa Cruz
Biotechnology). The reaction proceeds for 30 minutes at 37ºC, and is then inactivated by
addition of 15µl of sample buffer. The samples are separated on a 13% SDS-PAGE gel.
The gel is stained in Brilliant Blue (Sigma, St. Louis, MO) overnight. The following day,
the gel is destained and dried onto Whatman filter paper. The dried gel is exposed to a
phosphorimager screen for one hour and analyzed for quantiation by a Typhoon scanner
(Molecular Dynamics).

Immunohistochemistry: Sections of jejunum were embedded in paraffin, sectioned onto
slides and processed for immunohistochemical analysis. Deparaffination was done with
three washes in Histoclear for five minutes each. Samples were rehydrated by washing in
100%. 90% and 70% ethanol for five minutes each, and then washed in PBS for five
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minutes. Antigen retrieval was performed in antigen unmasking solution (Vector Labs)
heated in a steam chamber for 20 minutes. Slides were allowed to cool for 20 minutes in
the unmasking buffer, and were washed twice in distilled water and twice with PBS for
three minutes each. Endogenous peroxidase was blocked by incubation in 90 %
ethanol/3% hydrogen peroxide for ten minutes. After three washes in PBS for five
minutes each, excess buffer was removed around the samples and 50-100 µl of blocking
buffer (5% BSA/0.5% Tween-20 in PBS) was applied to the tissue sections. Blocking
was accomplished by overnight incubation in a humidified chamber at room temperature
for one hour. Blocking solution was drained from the slides, and 50-100 µl of primary
antibody (diluted blocking buffer) was applied to the sections. Primary antibody was
incubated overnight in a humidified chamber at 4ºC. After incubation, slides were
washed three times for ten minutes each in PBS. Secondary antibody (diluted in blocking
buffer) was applied to the sections and incubated for one hour in a humidified chamber at
room temperature. Slides were washed in PBS (three times for ten minutes) and then
dried to remove excess solution around samples. Avidin-biotin complex (ABC, Vector
Labs) was applied to the sections and incubated for 30 minutes at room temperature.
Slides were washed in PBS for five minutes. Staining with daiminobenzidine (DAB
peroxidase substrate kit, Vector Labs) was performed for two to ten seconds under a
microscope; slides were washed in water once desired levels of staining were attained.
Counterstaining in hematoxylin (DAKO) for 10 seconds was followed by two washes in
tap water for 5 minutes. Slides were dehydrated in 70, 90 and 100% ethanol for five
minutes each. Slides were washed with Histoclear twice for five minutes, and then
mounted behind a glass coverslip using Permount. Primary antibodies used for IHC:
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anti-phospho T160 cdk2, Cell Signaling, used at 1:100. Anti-phospho S807/811 Rb,
from Cell Signaling, was used at 1:500. Both of these rabbit primary antibodies were
used with the secondary anti-rabbit ABC elite kit from Vector for development. For the
BrdU staining, the primary antibody (rat anti-BrdU) from GeneTex was used at a 1:500
dilution, and the secondary anti-rat biotin antibody (Vector) was used at a 1:200 dilution.
For quantification of IHC results, ten crypts of complete integrity (both sides of the crypt
visibly transitioning to villi) were counted for both positive cells and total crypt cells;
results were reported as a percentage of positive crypt cells.

Densitometry: Films produced in the western analyses above were scanned using a
Microtek 9800TM scanner and saved in the TIFF format. Signals were quantified using
IP Lab Gel H software (Signal Analytics, Vienna, VA).

Statistics: Pairwise comparison of means was performed using Student’s t-test; a
confidence level of 95% was considered to be statistically significant in these studies.
All calculations were performed using the Prism software package (GraphPad Software,
Inc.).

Results:
This chapter focuses on identifying the molecular changes which accompany the UCN01-mediated arrest in the dividing small bowel epithelial cells. One complication in this
endeavor is the makeup of the crypt/villus architecture in the gut. The area of interest is
the small proliferating region of the crypt, approximately cell positions 4-8 upward from
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the crypt base. However, the majority of the epithelial cells in the small bowel are
differentiated enterocytes, which exist in a quiescent state. This is a very large
background of nondividing cells, against which changes in the small region of
proliferation will likely be dwarfed. To help alleviate this problem, we have adapted a
method of isolating cells along the crypt-villus axis in fractions. This method, detailed in
the Material and Methods above, was first described by Weiser (Weiser, 1973) for use in
rats, and was further refined for use in the mouse small bowel (Ferraris et al., 1992).
This method uses heat and shaking of everted intestinal sections to detach “fractions” of
gut epithelial cells into a buffered PBS solution over a 2-hour period. The early fractions
contain cells near the villus tip, while the late fractions are enriched for cells from the
crypt region. This separation method has been validated by immunohistochemistry and
gene array analysis (Mariadason et al., 2005; Smartt et al., 2007). Protein isolated using
the fractionation method was first evaluated for efficacy of this process. 10 mice were
injected with either 5 mg/kg UCN-01 or DMSO. 24 hours later, the mice were sacrificed
and the jejunum harvested and serially digested. The fractions from the villus to the crypt
(1 -> 3) were analyzed for PCNA via Western blotting. As seen in Figure 36, the levels
of PCNA were lowest in the outermost villus tip fraction (#1), and highest in the
proliferating crypt (fraction 3). Analysis by densitometry indicates a 2-fold increase in
PCNA levels from fraction 1 to fraction 2, and a 2.5 fold increase to fraction 3. In
addition, H&E sections taken after each incubation are shown in Figure 37,
demonstrating visually the digestive process in the tissue from the villus tip inward. As
proliferation in the jejunum occurs exclusively in the crypt region, all subsequent analysis
will focus on fraction 3 of the mouse gut samples.

154

DMSO

UCN-01

3 2 1 3 2 1 3 2 1 3 2

1

Figure 36. Serial fractions of jejunum epithelium separated using the
Weiser method (see Material and Methods). The image represents
protein from four mice, each divided into three fractions. The three mice
on the right side were treated with UCN-01; the mouse on the left side is
a DMSO control. The first fraction, taken after 24 minutes of incubation,
is low in PCNA (a proliferative marker) and high in the structural β-actin.
The second fraction (taken after an additional 36 minute incubation) has
increased levels of PCNA, and the third fraction (final 60 minute incubation)
contains the highest levels of PCNA, indicative of the proliferating cells
found in the crypt. The control DMSO mouse, which should have a greater
level of proliferation than the UCN-01 mice, has a greater amount of PCNA
at all three fractions; this indicates that the UCN-01 treatment was
effective in causing a cell cycle arrest. Densitometry of UCN-01 fractions
Indicates increased levels of PCNA in the crypt fraction (3).
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Figure 37. H&E stained sections of everted small bowel at the 4 stages
of the serial fractionation procedure. Samples were processed to display the
tissue at time zero (A), and after incubation times of 24 minutes (fraction 1
cells removed), (B) 60 minutes (fraction 2 cells removed) and (C) 120
minutes (fraction 3 cells removed). The images demonstrate the continual
digestion of the epithelial cells from the villus tip downwards into the crypt.
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Examination of early G1 cell cycle proteins:
The work with cultured cells arrested by the UCN-01 analog staurosporine (McGahrenMurray et al., 2006) demonstrated that cell cycle arrest was dependent on wild-type Rb
and that staurosporine treatment caused a decrease in cdk4 levels and its kinase activity.
To determine if UCN-01 will have a similar effect on proliferation in vivo, fraction 3
samples from UCN-01 treated mice and DMSO controls were analyzed by western
blotting for cdk4 expression. For each biochemical analysis performed (western blot,
immunoprecipitation, and kinase assays), we used the fraction 3 material from five
different mice per treatment group, loaded into five different lanes. Densitometry was
performed on each lane, and values for each treatment group averaged. This method was
chosen to reduce the variability naturally seen among mice. As shown in Figure 38a, the
levels of cdk4 in the UCN-01 treated mice are higher than the levels in the DMSO mice.
Densitometric analysis (Figure 38b) confirms that the levels of cdk4 are significantly
higher in the UCN-01 treated mice compared to the DMSO control mice.

As UCN-01 treatment causes an increase in the levels of cdk4, the mechanism of UCN01-induced arrest likely differs from that of staurosporine. This led us to examine the
other proteins controlling the early events of the G1 phase. The first candidate was the
cyclin binding partner for cdk4, cyclin D. In Figure 39a, the western analysis for cyclin
D shows a higher level in the UCN-01 treated mice compared to DMSO control, although
the difference is not statistically significant when the results of all five mice are averaged
(densitometry in Figure 39b). Also analyzed were the levels of the cyclin dependent
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Figure 38. (A) Western analysis of mouse jejunum crypt fractions for
levels of cdk4. β-actin is used as a loading control. (B) Densitometry
of western shown in (A). Levels of cdk4 are significantly elevated in
the UCN-01 treated mice in comparison to DMSO controls (*, p<0.05).
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Figure 39. (A) Western analysis of mouse jejunum crypt fractions for
levels of cyclin D. β-actin is used as a loading control. (B) Densitometry
of western shown in (A). Levels of cyclin D are not significantly altered
in the UCN-01 treated mice compared to DMSO control mice.
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kinase inhibitors p21 and p27. The levels of p21, shown in Figure 40, did not differ
between the mice treated with UCN-01 and the DMSO control mice. Levels of p27,
however, were altered by UCN-01 treatment. Shown in Figure 41, p27 was significantly
higher in the UCN-01 treated mice compared to the DMSO control mice. These results
both agree and conflict with the data from A549 cells (which were analyzed ini vitro), in
which UCN-01 treatment significantly increased both p21 and p27 levels (Akiyama et al.,
1999).

To assess any change in the kinase activity due to UCN-01 treatment, cyclin D was
immunoprecipitated from both sets of lysates (from UCN-01 and DMSO treated mice).
The immunoprecipitated complexes were incubated with 32P (gamma) and the substrate
GST-Rb to determine the cyclin D associated kinase activity of both groups of samples.
Figure 42a is the phosphor screen image of the kinase reactions. Lysate incubated with
beads only (no cyclin D antibody) was used as a negative control, and MCF-7 cell lysate
was the positive control. The cyclin D associated kinase activity of the UCN-01 treated
group samples appears to be slightly higher than the activity of samples from the DMSO
control mice; however, the difference is not significant (densitometry in Figure 42b).
The results of this experiment can be reconciled with the previous data demonstrating the
altered levels of cyclin D and p27 in the UCN-01 treated group. It is possible that any
increase in cdk4 activity that could result from an abundance of cyclin D is being blunted
by the increased levels of the kinase inhibitor p27.

Examination of late G1 cell cycle proteins:
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Figure 40. (A) Western analysis of mouse jejunum crypt fractions for
levels of p21. β-actin is used as a loading control. (B) Densitometry
of western shown in (A). Levels of p21 are not significantly altered
in the UCN-01 treated mice compared to DMSO control mice.
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Figure 41. (A) Western analysis of mouse jejunum crypt fractions for
levels of p27. β-actin is used as a loading control. (B) Densitometry
of western shown in (A). Levels of p27 are significantly higher in
the UCN-01 treated mice compared to DMSO control mice (*, p<0.05).
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Figure 42. (A) Kinase assay of cyclin D immunoprecipitated complexes
from the jejunums of mice treated with 5 mg/kg UCN-01 or DMSO control.
GST-Rb peptide is used as the substrate. Positive control is lysate from
MCF-7 cells. (B) Densitometry of the results shown in (A). The cyclin D
associated kinase activity does not differ significantly between the
UCN-01 treated mice and the DMSO control mice.
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The results of the analysis of early G1 cell cycle proteins are both in agreement and in
conflict with previous reports; the increased level of p27 after UCN-01 treatment had
been demonstrated by Akiyama et al, but the same report showed a decrease in cdk4
levels and kinase activity, which is differs from our results here (Akiyama et al., 1997).
This unique response to UCN-01 in the mouse gut epithelial cells persuaded us to look
elsewhere for other possible molecular changes, since it is likely that proliferating tumor
cells in culture respond differently to UCN-01 than normal proliferative mouse
epithelium. The next logical step was to examine the late G1 cell cycle protein cyclin E
and its kinase binding partner cdk2. Western analysis for both proteins is shown in
Figure 43; UCN-01 did not alter the levels of either protein. Although the levels of both
cdk2 and cyclin E were unaffected by UCN-01, it is possible that the increased levels of
the inhibitor p27 (Figure 41) have an effect on the kinase activity of cdk2. To examine
this possibility, cdk2 was immunoprecipitated from jejunum lysates from both UCN-01
treated mice and DMSO treated controls and incubated with 32P (gamma) and the
substrate histone H1. Jejunum lysate incubated with naked beads (no antibody) was used
as a negative control, and MCF-7 cell lysate was used as a positive control. The
phosphor screen image of the kinase assay is shown in Figure 44a. Similar to the results
of the cyclin D associated kinase assay (Figure 42a), treatment with UCN-01 did not
significantly alter the kinase activity of cdk2 in comparison to DMSO control treatment
(densitometry in Figure 44b). This lack of change in cdk2 kinase activity following
UCN-01 differs from other reports in which UCN-01-mediated cell cycle arrest is
accompanied by a decrease in cdk2 activity and subsequent lack of Rb phosphorylation,
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Figure 43. Western analysis of mouse jejunum crypt fractions for
levels of cdk2 and cyclin E. β-actin is used as a loading control.
Levels of each protein were not significantly different in the UCN-01
samples compared to the DMSO samples.
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Figure 44. (A) Kinase assay of cdk2 immunoprecipitated complexes
from the jejunums of mice treated with 5 mg/kg UCN-01 or DMSO control.
Histone H1 used as the substrate. Positive control is lysate from MCF-7
cells. (B) Densitometry of the results shown in (A). The cdk2 kinase activity
does not differ significantly between the UCN-01 treated mice and the
DMSO control mice.
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although these studies were all done on cells in culture rather than in an animal model
system (Akiyama et al., 1999b; Chen et al., 1999; Facchinetti et al., 2004).

UCN-01 and the phosphoproteins p53 and pRb:
The reported data on the necessity vs. dispensability of p53 for cellular response to UCN01 was a feature of many UCN-01 studies presented in the Introduction. Some studies
indicated that active, wild-type p53 was required for UCN-01-mediated cell cycle arrest
(Byrd et al., 2001; Facchinetti et al., 2004; Husain et al., 1997), while others
demonstrated that the absence or presence of p53 did not modulate the cellular response
to UCN-01 (Chen et al., 1999; Shao et al., 1997c; Wang et al., 1996). The
hypophosphorylation of Rb accompanying UCN-01-mediated cell cycle arrest was also
shown in previous work (Chen et al., 1999; Courage et al., 1996; Kawakami et al., 1996).
Even though the kinase assays for this study did not demonstrate any change in cdk2
(Figure 44) or cyclin D-associated (Figure 42) kinase activities following UCN-01
treatment in the mice, it was possible that modulation of either p53 or Rb was occurring
in the mouse gut epithelium. Western analysis of the crypt fractions (Figure 45),
however, showed no significant alterations in the levels of Rb or p53 in the mice treated
with UCN-01 compared to the DMSO controls. While total Rb levels did vary somewhat
within each treatment group, no consistent pattern of change is present when the results
of five mice were averaged. Also of note is the fact that no shift due to phosphorylation
is present in the Rb western analysis. As hypophosphorylation has been shown in some
studies to accompany UCN-01-mediated arrest, this result provided little insight into this
mechanism. The samples were also probed with anti-phospho Rb antibodies (S780,
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Figure 45. (A) Western analysis of mouse jejunum crypt fractions for
levels of Rb and p53. β-actin is used as a loading control. No shifts
in Rb migration due to phosphorylation are evident. (B) Densitometry
of Rb levels shown in (A). Levels of Rb do not differ significantly
between UCN-01 treated mice and DMSO control mice.
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S795, and S807/811) but unfortunately no signal was observed in these analyses (data not
shown).

The data collected to this point do not give a clear indication of how UCN-01 is able to
arrest the proliferating cells in the mouse small bowel. One concern with the serial
fractionation method is that the long incubation (up to 2 hours) in heated (37ºC) buffer
may negatively affect the proteins harvested. While no sample degradation was observed
in the western analyses shown in this study, it may be possible that the activities of
certain proteins are affected by the separation process. To address this concern, we
decided to directly assess kinase activity via immunohistochemistry. For these analyses,
the jejunum samples taken for IHC are harvested immediately after sacrifice, flushed and
placed into formalin. The remainder of the tissue is then processed for serial fractions.
As such, the proteins in the fixed tissue should be unaltered. We decided to assess the
levels of active cdk2 in the crypts of the mice by IHC. The levels of cdk2 kinase activity
measured in the UCN-01 treated mice were similar to the levels seen in the DMSO
control mice. If the process of fractionation does not affect the integrity of cdk2 activity,
it should then be true that levels of active (phospho Thr 160) cdk2 are similar in the two
groups when the tissue sections (which do not undergo fractionation) are analyzed. IHC
using anti-phospho-Thr 160 cdk2 is shown in Figure 46a (UCN-01) and 46b (DMSO).
Positive cells were specific to the crypt region, and no difference was observed in the
levels of active cdk2 in the UCN-01 mice versus the DMSO control mice. This result is
in agreement with the cdk2 kinase activity levels shown in Figure 44, and indicates that
cdk2 has not been altered by the serial fractionation process. It should also be noted that
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Figure 46: IHC analysis of active (phospho-Thr160) cdk2 in
jejunum of mice treated with DMSO (A) or 5 mg/kg UCN-01 (B) for
24 hours. 10 crypts per mouse were analyzed, with 5 mice per
treatment group. Results of the quantification of positive cells (C)
indicates no difference in the levels of active cdk2 between the two
treatment groups.
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the serial digestion method has been successfully used to assess cdk2 kinase activity in a
recent publication (Smartt et al., 2007). The authors of this study were able to
demonstrate an increase in cdk2 kinase activity in the crypt fraction of transgenic mice
harboring defective p27 compared to cdk2 from wild-type mice. It therefore seems
probable that the proteins isolated using the serial fractionation method are not altered by
the process.

UCN-01 and Rb phosphorylation:
While the assessment of active cdk2 by IHC (Figure 46) does indicate that our
methodology for examining changes in the crypt cells of the mouse gut is sound, the
results to this point do not give a clear indication of how UCN-01 is able to arrest these
cells. One piece of information of great interest in this process is the phosphorylation
status of Rb. Attempts utilizing phospho-specific antibodies for Rb (S708, S795 and
S807/811) in western analyses were unsuccessful, even when Rb was first isolated from
whole lysates via immunoprecipitation and then examined (data not shown). The
positive staining of active cdk2 via IHC was encouraging, so we applied the same battery
of phopho-specific anti-Rb antibodies to sections of mouse jejunum. While the phosphoS780 and phospho-S795 antibodies failed to display a specific signal, the phosphoS807/S811 antibody resulted in specific staining of cells in the crypts. Shown in Figure
47a, this staining shows that phospho-Rb is significantly increased in the UCN-01
samples compared to DMSO controls. These results were quantified, with 10 crypts per
mouse analyzed, five mice per treatment group. The results indicate that UCN-01 treated
mice have a significantly increased level of phospho-Rb compared to the DMSO control
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Figure 47a. IHC analysis of phospho-Ser 807/811 Rb on jejunums
from mice treated with either DMSO control (top panel) or 5 mg/kg
UCN-01 (bottom panel) for 24 hours.
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Figure 47b. Quantification of IHC analysis of phospho-Ser 807/811
Rb positive crypt cells. 10 crypts per mouse were analyzed, with 5
mice per treatment group. Statistical analysis indicates a significant
increase in phospho-Rb cells in the UCN-01 treated mice in
comparison to DMSO treated mice.
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mice. While the results clearly show a difference in Rb phosphorylation, the increase in
phospho-Rb was not expected, as cell culture results using UCN-01 have shown a
decresase in Rb phosphorylation in cells arrested by UCN-01 treatment (Chen et al.,
1999; Courage et al., 1996; Kawakami et al., 1996). While the results of animal studies
can often depart somewhat from findings in cultured cells, this alteration in phospho-Rb
was a very intriguing result. The preponderance of phospho-Rb in cells arrested in G1 is
perplexing, as Rb phosphorylation is a hallmark of progress through G1 phase and into S
phase. To ensure that this result truly reflected the arresting action of UCN-01 that was
demonstrated in chapter 2, the proliferative status of the crypt cells in these mice were
analyzed. Six hours prior to sacrifice, both the UCN-01 treated mice and the DMSO
control mice had been injected with BrdU. Sections of jejunum were stained with antiBrdU and analyzed for incorporation via IHC. In Figure 48, it can be seen that the UCN01 treated mice had fewer BrdU positive crypt cells than the DMSO control mice. The
percent of BrdU-positive crypt cells was significantly lower in the UCN-01 treated mice
versus the DMSO control mice (Figure 48c), indicating a decreased level of DNA
synthesis in the UCN-01 mice. The combination of low levels of DNA synthesis
(indicative of cell cycle arrest) and high levels of phospho-Rb seems to indicate that the
cells exposed to UCN-01 are traversing the post-mitotic portion of G1 (thus
phosphorylating Rb) but are not crossing the restriction point into S phase (leading to the
diminished levels of BrdU incorporation). Further investigation will be required to better
understand how UCN-01 is causing this block, although the exact mechanism governing
passage through the restriction point is not completely understood (Ekholm et al., 2001).
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Figure 48: IHC analysis of BrdU incorporation into nuclei of the
jejunum of mice treated with DMSO (A) or 5 mg/kg UCN-01 (B) for 24
hours. 10 crypts per mouse were analyzed, with 5 mice per treatment
group. Results of the quantification of positive cells (C) indicates a
significant decrease in the level of BrdU incorporation in the mice treated
with UCN-01
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Conclusions:
The data presented in this chapter sought to uncover the mechanism responsible for the
UCN-01-mediated cell cycle arrest in the mouse small bowel epithelium. Some of the
results, such as the increased levels of p27 following UCN-01 treatment (Figure 41), are
in agreement with previous reports on cultured cells treated with UCN-01. However, the
increases in cdk4 (Figure 38), cyclin D (Figure 39), and phospho-Rb (Figure 47) are a
departure from the effects of UCN-01 observed in cell culture. A common motif of cells
arrested in G1 is lack of Rb phosphorylation, due to decreased cyclin levels (D and/or E),
increased inhibitor levels (p21, p27, p16), and the concomitant suppression of E2Fgoverned transcription of genes required for entrance into S phase. The greatly increased
levels of phospho-Rb and the increases in cdk4 and cyclin D were unexpected, but might
simply be a consequence of increased numbers of cells arrested in late G1; a greater
proportion of cells in late G1 phase would lead to increased levels of early G1 proteins.
High levels of cyclin D and cdk4 could then increase the levels of phospho-Rb. The lack
of an increase in cyclin E (Figure 43) and the drop in BrdU incorporation (Figure 48) in
the UCN-01 treated mice indicate that the crypt cells are unable to cross the restriction
point into S phase. It has been demonstrated that accumulation of cyclin E occurs after
passage through the restriction point (Ekholm et al., 2001), so it is likely that the UCN-01
treated cells are arrested at this point. The lack of increased cdk2 kinase activity in the
UCN-01 treated mice (Figure 44) supports this conclusion as well.

The mechanism by which UCN-01 is able to arrest the normal proliferating cells of the
mouse small intestine will require further investigation. The results reported here show
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some unexpected consequences of UCN-01 treatment, especially the increased levels of
phospho-Rb. An understanding of the in vivo mechanism of UCN-01 is important not
only in the setting of normal proliferating cells, but may also be important in identifying
appropriate tumor tissues for treatment with the UCN-01 protection protocol. Successful
treatment would require that a tumor not respond to UCN-01-mediated arrest, leaving it
vulnerable to chemotherapeutic treatment, while the normal dividing tissues are spared
this toxicity due to temporary arrest. Possible future directions to further uncover the
mechanism of UCN-01 cell cycle arrest are presented in the Discussion below.
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Discussion:

Our findings indicate that UCN-01 is able to reversibly arrest the normal dividing tissues
of the nude mouse, and that this arrest commences 24 hours following treatment and
persists for seven days. Two weeks following UCN-01 treatment, the proliferation rate
returns to normal levels. This arrest can provide protection from the toxicity of 5-FU if
administered during a specific window of efficacy. Mice treated with 5-FU between
three and five days post-UCN-01 administration demonstrate improvements in weight
status, survival and blood markers. However, if 5-FU is given either too early or too late
following UCN-01, no protective effect is realized. 5-FU administered 24 hours
following UCN-01 is actually more toxic than in control mice treated with 5-FU, likely
due to the combined toxicity of 5-FU and the length of time until cessation of the UCN01 mediated arrest. Mice treated with 5-FU at one week following UCN-01
administration also failed to benefit from pretreatment, perhaps due to the initiation of
recovery from UCN-01 mediated arrest. The mechanism of this arrest was also examined
in the mouse small bowel. Treatment with UCN-01 caused an increase in the early G1
phase cell cycle proteins cdk4 and cyclin D, as well as the inhibitor p27. However, no
increase in cdk4 kinase activity was measured. Late G1 phase proteins cyclin E and cdk2
were also unaltered by UCN-01 treatment, and the level of cdk2 activity was unchanged
as well. Interestingly, the levels of phosphorylated Rb in the UCN-01 treated samples
were significantly higher than in control mice. While BrdU analysis demonstrates that
the UCN-01 treated mice had reduced levels of proliferation in the gut epithelium, the
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increase in Rb phosphorylation was unexpected. The mechanism of UCN-01 arrest in
normal tissues will require further investigation.

The work presented in this thesis has been divided into three parts. The initial work was
done to assess the ability of UCN-01 to arrest the dividing cells of the small bowel and
the time frame for commencement and release of this arrest. While the arrest of the
dividing tissues of the mouse had already been demonstrated (Redkar et al., 2001), it was
important to identify both the commencement and the cessation times for UCN-01mediated cell cycle arrest in these tissues. If this cell cycle arrest is to be properly
exploited to minimize damage to dividing cells, it is critical to understand when the arrest
is in effect. Our results indicate that UCN-01 is able to arrest the gut epithelial cells as
early as 24 hours following treatment, and that this arrest persists through day 7 posttreatment. The arrest ceases by week two, and week four samples displayed a slightly
hyperproliferative state, likely the result of increased epithelial cell division to repopulate
the villi after the arrest. An interesting finding was the antagonistic effect of the solvent
DMSO. Attempts to mollify this effect by decreasing the volume of DMSO injected or
by using an alternative solvent (sodium citrate) were unsuccessful. UCN-01 was also
administered in a fractionated fashion (2 doses separated by 12 hours) in hopes of
increasing the number of cells susceptible to UCN-01-mediated arrest. While it is likely
that some cells which escaped the effects of the first injection of UCN-01 were affected
by the second dose, the increase in arrest measured was not significant. While the
DMSO antagonism is undesirable, the goal of this part of the study was to understand the
time frame of UCN-01-mediated arrest, which was accomplished.
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The timing of UCN-01-mediated arrest was crucial knowledge for designing experiments
to evaluate the protective ability of UCN-01 in mice receiving 5-FU, the aim of the
second part of this thesis. Our results demonstrate that treatment with 5-FU either too
early after cell cycle arrest (24 hours, Figure 18) or too close to recovery from arrest
(days 7-11, Figure 13) did not benefit from UCN-01 pretreatment. Only when cytotoxic
treatment was given during the period of arrest but proximal to the time of recovery from
arrest was a protective effect of UCN-01 pretreatment realized (figures 15, 22, 26, 28 and
31). Pretreatment with UCN-01 three to five days prior to high dose 5-FU led to
improvements in weight status, blood cell counts (platelets and red and white blood cells)
and overall survival compared to control mice. While protection from apoptosis has been
shown to be responsible for the enhanced survival of arrested normal cells in culture after
cytotoxic treatment (Chen et al., 2000), this type of protection may only be part of the
effect in vivo. The toxicity to gut epithelial cells following high dose 5-FU treatment is
not solely apoptosis, but also conversion of proliferating cells to a permanent state of
quiescence (Pritchard et al., 1998). Mice treated with 400 mg/kg 5-FU displayed similar
levels of apoptosis to mice treated with only 40 mg/kg at both 24 and 48 hours after
treatment. The large difference observed between the two treatment groups was the
induction of p21 through p53. After treatment with 400 mg/kg 5-FU, cells in the
proliferating region of the crypt displayed a significant and prolonged increase in the
levels of p21, leading to a permanent decrease in cellular proliferation and breakdown of
the crypt-villus architecture by 96 hours. Mice null for p53 had significantly less
inhibition of cell proliferation and displayed improved numbers of crypt cells and total
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villus area after 5-FU treatment. The permanent arrest caused by p21 after high dose 5FU treatment was also demonstrated in a different study (Inomata et al., 2002). The fate
of cells in the crypt hinged upon the comparative levels of p21 and bax after 5-FU
treatment. High levels of bax led to apoptosis, while high p21 led to a permanent state of
arrest. Our treatment plan may help avoid both of these fates. Arrested cells should be
spared some toxicity of 5-FU if they are unable to enter S phase. In addition, the cells
pretreated with UCN-01 might also evade the p53/p21 mediated permanent arrest
pathway; in a fashion, activating one type of cell cycle arrest may prevent the cells from
entering into the permanent p21-mediated arrest seen in these two studies. An interesting
future experiment would be to examine the levels of p53 and p21 in the mouse small
bowel after treatment with 5-FU following UCN-01 pretreatment. A lack of increase of
these proteins in the UCN-01 pretreated mice would indicate that UCN-01 is able to
prevent the p21 increase and subsequent quiescence caused by high dose 5-FU.

An alternative possibility to explain the protection afforded by UCN-01 is to think of the
arrested population of cells as similar to a potential energy source. Villus structure is
maintained by balancing the loss of apoptotic cells at the villus tip with proliferation of
cells in the crypt. The newly divided cells differentiate into mature enterocytes and
migrate upwards along the crypt-villus axis as more cells continue to be produced in the
proliferative zone of the crypt. This balance is maintained by signaling through at least
two zinc-finger transcription factors, Kruppel-like factors 9 (Klf9) and 5 (Klf5) (Shindo
et al., 2002; Simmen et al., 2007). This homeostasis has also been linked to the Wnt
pathway through c-Myc (Pinto et al., 2003), although later work has demonstrated that
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mice lacking c-Myc in the intestine were able to maintain normal epithelial turnover and
maintenance (Bettess et al., 2005). A lack of cellular proliferation due to UCN-01
treatment may activate one or more of these control pathways, leading to initiation of
signaling to increase proliferation. If UCN-01 continues to block cells in G1, this could
lead to a feedback loop in which the Klf5/9 pathway attempts to further stimulate cellular
proliferation in the crypt. When the arrest caused by UCN-01 treatment recedes, the
buildup of cells stimulated to proliferate could quickly repopulate the villi. If this release
occurs very soon after cytotoxic treatment, this repopulation could ameliorate the effects
of cell death due to treatment. This seems similar in principle to the palifermin protocol
discussed in the introduction, in which stimulation of cellular proliferation is used to
improve patient tolerance of chemotherapeutics. Transcriptional activation of targets of
Klf5 and Klf9 would demonstrate that this hypothesis is responsible for at least some of
the protection afforded by UCN-01.

A third possibility for the response to UCN-01 pretreatment may also account for the
increased levels of phospho-S708/811 Rb shown in chapter three (Figure 47). One
notable feature of the phospho-Rb staining is that the positive cells in the UCN-01 treated
groups are not only in the proliferative region of the crypt (approximately positions 4 – 8
from the base of the crypt), but in cells above and below this range as well. These Paneth
cells and maturing enterocytes are largely quiescent or are terminally differentiated and
are in G0. Cell cycle arrest due to UCN-01 treatment may stimulate these cells to reenter the G1 phase of the cell cycle to help repopulate the villus. It has been shown that
inactivation (phosphorylation) of Rb can force G0 cells to enter G1 (Sage et al., 2003). It
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has also been shown that cyclin C can bind to cdk3 in G0 cells and phosphorylate Rb on
serines 807 and 811, and that this phosphorylation is required for entry into G1 (Ren and
Rollins, 2004). The increase in phospho S/870/811 Rb observed in the UCN-01 treated
cells may not be due to cdk4 kinase activity, but rather a consequence of cyclin C/cdk3
activity attempting to stimulate G0 cells to re-enter the cell cycle. As with the previous
“potential energy” theory, this increase in cells which can quickly repopulate the gut after
cytotoxic treatment could account for the protective benefit observed with UCN-01
treatment. Future examination of cyclin C and cdk3 activity could determine whether
this mechanism is responsible for the increased phospo-Rb seen in the UCN-01 treated
mice.

The unexpected increases in the G1 phase proteins cdk4, cyclin D and phosphorylated Rb
may also be a consequence of comparison with DMSO as the control group. As shown in
the first results section, DMSO appears to increase the proliferative rate of gut epithelial
cells. The increase in proliferation may cause alterations in cell cycle proteins; it is
possible that some of these changes occur even when UCN-01 is administered, as DMSO
is required as the solvent. Further investigation of this mechanism will require an
assessment of the actions of DMSO as well as UCN-01 versus untreated mice to help
distinguish the actions of these two agents.

The most common criticism of the protection protocol has been the failure of UCN-01 in
clinical trials to produce improvement in patient response or survival. A second concern
has been the pharmacologic problems associated with the strong binding of UCN-01 to

183

hAGP in the blood. This indeed is a problem, and will be discussed below. However,
the initial concern (the disappointing clinical trials reports) is more a product of faulty
comparison than truly a robust criticism of the concept of protection via cell cycle arrest.
The UCN-01 clinical trials (see Introduction above) have either sought to prevent tumor
growth/induce apoptosis (single agent trials) or to enhance the toxicity in tumors by
treating patients with a primary cytotoxic agent and then a simultaneous or subsequent
dose of UCN-01 to prevent a G2/M arrest and enhance cell killing. There is a fair
argument that neither of these treatment protocols has been successful, and in some
settings the UCN-01 treatments have performed worse than the standard of care.
However, the protection of normal cells afforded by a temporary cell cycle arrest by
UNC-01 pretreatment prior to administration of a cytotoxic agent (5-FU) has not been
addressed by any of the clinical protocols. An important feature of this proposed
treatment scheme is that UCN-01 does not arrest the growth of some tumor types, while
causing a G1/S arrest in normal proliferating tissues (Chen et al., 2000). It could be
argued that any tumors which did respond to the UCN-01 single agent protocols should
be excluded from evaluation of the protection protocol, as the tumor might benefit from
protection due to cell cycle arrest; only tumors which can divide in the presence of UCN01 would be appropriate for this scheme. The double agent (UCN-01 following cytotoxic
agent) protocols would be less relevant to evaluating the work presented in this thesis.
The protective effect of cell cycle arrest necessitates that the arresting agent (UCN-01) be
administered prior to any cytotoxic treatment. The temporary arrest allows the normal
cells to evade toxicity of a subsequent chemotherapeutic drug. However, when UCN-01
is given after chemotherapy, it may actually be more damaging to these tissues. Some
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damaged cells which had arrested in the G2/M phase would be unable to complete DNA
repair and could be forced instead into mitotic catastrophe. Other cells could be
potentially arrested in G1; this arrest can last more than one week, preventing
repopulation of damaged tissues and further increasing the toxicity borne by the patient.
This effect can be seen in the protection experiment in which mice were treated with 5FU only 24 hours after UCN-01 treatment. While some of the intestinal and
hematopoietic cells were potentially spared from 5-FU toxicity, the combined loss of
some “unprotected” cells to apoptosis plus the weeklong arrest of the “protected” cells
culminated in worse survival for the UCN-01 pretreated mice than DMSO control mice
after 5-FU treatment. Only when 5-FU was administered closer to the release of UCN01-induced arrest was a protective effect demonstrated.

The second concern with UCN-01 use in humans is the strong binding of the drug to the
plasma protein hAGP, which maintains UCN-01 at a high concentration in the blood
while greatly diminishing the distribution volume and clearance. Initial UCN-01 studies
in mice demonstrated a half-life of 3-4 hours, and greater distribution to implanted PSN-1
tumors than in plasma (Kurata et al., 1999). However, initial data from Phase I clinical
trials in the United States (Sausville et al., 2001) and in Japan demonstrated a different
behavior of UCN-01 in humans (Fuse et al., 1998). The elimination half-life in patients
was between 253 and 1660 hours, and the distribution volume was extremely low. This
altered behavior was attributed to extremely tight, specific binding to the serum protein
hAGP. Rats infused with 150 nmol/h/kg of hAGP prior to injection of UCN-01 had
significantly reduced distribution volumes (1/250) and clearance (1/700) of UCN-01
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compared to control rats (Fuse et al., 2000). The pharmacokinetics of UCN-01 in
humans is responsible for the altered dosing in clinical trials, in which subsequent doses
of UCN-01 are typically half that of the initial dose (see Table 3).

This aspect of UCN-01 in humans is problematic in the context of our protection
protocol. As demonstrated in chapter 3, the protective effect of UCN-01 is limited to a
narrow window of efficacy, approximately 3 -5 days after UCN-01 treatment. Cytotoxic
treatment (5-FU) outside this period is at best unaffected (later) and can be even more
detrimental than 5-FU alone (earlier). As the half-life for UCN-01 in humans can be
greater than two months, coordinating the administration of a chemotherapeutic agent
during the period of UCN-01-mediated arrest would likely be impossible. Moreover, it is
possible that constant exposure to UCN-01 alone would be detrimental to normal
proliferative tissues; a semi-permanent arrest would prevent the replenishment of tissues
which undergo frequent turnover.

Some effort has been made to address this concern. Liposomes (capsules of polyethylene
glycol (PEG)) have been used as carriers for drugs such as cisplatin and topotecan to
increase delivery to tumor sites and reduce interaction with blood components (Burke and
Gao, 1994; Newman et al., 1999). Initial studies using liposomes to encapsulate UCN-01
showed some efficacy in shielding the drug from hAGP when coadministered in rats
(Yamauchi et al., 2005). Six hours after administration, almost 18% of the UCN-01
injected was still present in the liposomes, shielded away from the coadministered hAGP.
However, by 24 hours very little protected UCN-01 remained. Refinement of this
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method focused on increasing the size of the liposomes, with the hope that a greater lipid
shield would enhance the protection of UCN-01 from serum interaction (Yamauchi et al.,
2008). The results were somewhat promising, with almost 25% of the injected UCN-01
remaining encapsulated in the liposome at 24 hours when the size was increased from
112 nm to 155 nm.

The use of UCN-01 to protect normal dividing cells from the toxicity of 5-FU in this
study was successful when employed during a limited window of efficacy. Weight loss,
blood markers and survival were all significantly improved, proving the validity of this
model of protection. The ability of UCN-01 to place normal dividing cells into a
reversible state of arrest and the length of this arrest have also been determined. The
exact mechanism behind this arrest remains largely unknown, and the pharmacokinetics
of UCN-01 further complicate any potential use in humans. The idea of protecting
normal cells from chemotherapeutic damage is an attractive one, but its implementation
may require identification of other agents which mimic the differential arresting effects of
UCN-01 without the complications associated with its use.

An optimal agent to protect normal cells by inhibiting proliferation would need three
features. First, it must have a very specific rate of clearance, and preferably one short in
duration. The results with UCN-01 pretreatment clearly indicate that protection is
available only in a short time period. This time frame would be easier to evaluate for a
drug which had a short, defined period of bioavailability. A prolonged clearance process
would make this definition less clear, especially when taken in context of the cell cycle.
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If a candidate compound took longer than 24 hours to clear from the system, it could
affect more than one cycle, so having a truly uniformly affected cell population would be
difficult, and again a window of efficacy difficult to predict. Unlike UCN-01, an ideal
compound would also have a much shorter duration of effect. The effect(s) of UCN-01
take longer than 7 days to recede; this is a very long time for cells to be held from
dividing, and is not ideal for the host. Replenishment of rapidly dividing tissues is
essential for maintenance of homeostasis, and a prolonged interruption plus a second
toxic insult is not an ideal situation. It would be preferred that the reduction in cell
proliferation last no more than 48 hours; this would allow protection from toxic agents
targeting the cell cycle, but then allow for a rapid return to cell division and maintenance
of the bone marrow and intestinal epithelium. This would be preferable to the situation
with UCN-01, in which proliferation is impaired for more than seven days. There are
few side effects of UCN-01 at the doses used in this study, but the prolonged inhibition of
cycling cells is undesirable, and any alternative compound would hopefully have a much
shorter period of action.

Screening for potential protective compounds can be initially done in cultured primary
cells, and any candidate drugs could subsequently be evaluated as UCN-01 has been in
this dissertation. It is essential that any new potential agents cause a reversible cell cycle
arrest in only normal cells, and that tumor cells derive little or no protection. If animal
studies are successful, the screening in a Phase I toxicity trial would require not only
assessment of dosing and side effects, but also a way to measure proliferation of normal
dividing tissues. DNA labeling methods would likely not be appropriate; in this case,
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profiling of blood markers (red & white blood cells and platelets) would be less invasive
and still powerful method to determine the period of attenuation of normal cycling cells.
Once the times of cell cycle inhibition and return to proliferation are understood,
treatment with a toxic chemotherapeutic compound can be scheduled during the period of
inhibition. Successful protection would be measured in terms of both intestinal health
(weight, appetite, nausea, and diarrhea) and the blood markers previously mentioned.
Hair loss could also be assessed, although this would be difficult to quantify and would
be a qualitative indicator. Successful protection would improve most or all of these
parameters compared to patients without the protective regimen.

The results of this study indicate that temporary cell cycle inhibition can be exploited to
improve the survival and health of mice receiving high dose chemotherapy. While the
pharmacokinetic issues of UCN-01 in humans will likely prevent this protocol from being
taken into a clinical setting, the work discussed here provides a framework for developing
alternative agents which could also provide this protection. It is hoped that other
compounds will be identified to carry the protection protocol successfully into a clinical
trial setting.
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